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Abstract
Biopolymer-based hydrogels have emerged as promising platforms for drug
delivery systems (DDSs) due to their inherent biocompatibility, tunable physical
properties and controllable degradability. Yet, drug release in majority of these
systems is solely contingent on diffusion of drug molecules through the hydrogel,
which often leads to burst release of drugs from these systems. As a result, the main
aim of this thesis was to develop suitable hydrogel platforms that allow sustained
release of anti-cancer drugs, to be ultimately used as implants for local delivery of
drugs to tumors. To this end, inspired by the chemistry of mussel adhesive proteins,
a new generation of coaxial hydrogel structures were developed that could
simultaneously exert both affinity and diffusion control over the release of
chemotherapeutic drugs. Specifically, dopamine-modified hydrogel along with
chemotherapeutic drugs was used as the main core component to confer affinitycontrolled release, while a methacrylated hydrogel was used as the shell
composition to provide the controlled diffusion barrier. Initially a well-recognized
wet-spinning technique was employed to fabricate coaxial fibers with the given
composition, mainly because this fabrication method allows high throughput and
continuous production of coaxial structures. Accordingly, it was shown that the
fabricated coaxial fibers were robust in both dry and wet conditions, and most
importantly they were capable of exerting a controlled release of Doxorubicin (a
chemotherapeutic drug) over a span of 3 weeks. Also, in vitro and in vivo
evaluations showed that drug loaded coaxial fibers had optimal anticancer activity
against pancreatic cancer cells.
Given the obtained results from the coaxial fibers in delivering chemotherapeutics,
they were next used for a combinational chemo-photothermal therapy. This
x

treatment requires that not only the system allowed sustained release of the drug,
but also it could generate heat instigated by an external stimuli. Consequently,
nanoparticles with photo-thermal properties (copper selenide nanoparticles;
Cu2−xSe) were added into shell compartment of the coaxial fibers, while the core
compartment contained a chemotherapeutic drug (Doxorubicin). The obtained
results showed that addition of nanoparticles to the coaxial fibers further enhanced
their mechanical properties in both dry and wet conditions, and it also endowed
photo-thermal capabilities to the fibers instigated by near infra-red (NIR) laser
irradiation. Remarkably, combination of chemo-photothermal modalities in these
fibers allowed optimal anticancer activity both in vitro and in vivo when tested
against breast cancer cells.

Lastly, with the aim of fabricating drug-loaded implantable patches, a 3D printing
technique was employed to produce novel coaxial hydrogel patches. Similar to
previously fabricated coaxial fibers, the core-section of these patches contained a
dopamine-modified methacrylated hydrogel loaded with a chemotherapeutic drug
(Gemcitabine), while their shell section was solely comprised of a methacrylated
hydrogel. Subsequently, these patches were further modified with CaCO3 cross
linker and a polylactic acid (PLA) coating to facilitate prolonged release of the
drug. Consequently, the results showed that addition of CaCO3 to the formula
enhanced the mechanical properties of the patches and significantly reduced their
swelling ratio as compared to that for patches without CaCO3. Furthermore,
addition of PLA coating to CaCO3-containing patches has further reduced their
swelling ratio, which then significantly slowed down the release of Gemcitabine,
to a point where 4 layers patches were capable of releasing the drug over a period
xi

of 7 days in vitro. Remarkably, it was shown that 3 layers- and 4 layers Gemcitabine
loaded patches were successful in inhibiting pancreatic cancer cell growth for a
period of 14 days when tested in vitro.
In conclusion, a range of coaxial hydrogel structures were developed either through
wet-spinning or 3D-printing techniques, with the purpose of building suitable
therapeutic platforms for sustained and local release of anti-cancer drugs to tumors.
Based on the obtained results in this thesis, these drug-loaded coaxial hydrogel
structures were successful in releasing Gemcitabine and Doxorubicin in a sustained
manner, which in turn prevented cancer cell growth as indicated from both in vitro
and in vivo experiments. The drug-loaded coaxial hydrogel structures produced in
this work may find application as neoadjuvant or adjuvant therapies for controlled
delivery of therapeutics locally to the tumor site with the aim of suppressing cancer
growth, with reduced side effects.
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Chapter 1
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1. Introduction and Literature review

1.1.

Motivation

In spite of remarkable improvements in cancer treatments and survivorship, cancer still
remains as one of the major causes of death worldwide. Although current standards of
care provide encouraging results, they still cause severe systemic toxicity and also fail in
preventing recurrence of the disease. In order to address these issues, biomaterial‐based
implantable drug delivery systems (DDSs) have emerged as promising therapeutic
platforms, which allow local administration of drugs directly to the tumor site. Owing to
the unique properties of biopolymers, they have been used in a variety of ways to institute
biodegradable implantable DDSs that exert precise spatiotemporal control over the
release of therapeutic drug. Of the many biopolymers currently utilized for drug delivery
applications, hydrogels are among the most promising ones. Hydrogels are comprised of
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polymeric networks that are capable of absorbing and retaining high amounts of water.
Hydrogels are also tunable (both physically and chemically), are injectable, and have been
used over the years for various drug delivery applications. Controlled drug release profiles
attainable with these systems are dictated by factors such as porosity, network
swelling/degradation, the size of the molecule to be released, and drug-polymer
interactions. So far, various fabrication technologies have been utilized to institute
hydrogel implants for drug delivery purposes, this included methods such as casting,
electrospinning, 3D printing, and injectable gels. Among different structures that have
been fabricated from hydrogels, coaxial structures offer specific advantages that are
befitting for drug delivery applications. These advantages include: (i) the bioactive drug
can be incorporated into the core while being safely protected by a shell, which protects
the drug from loss of bioactivity, (ii) by choosing suitable components sustained release
of a drug can be realized.
This thesis presents a novel composition of coaxial hydrogel structures that were
fabricated either through wet-spinning or 3D printing, and were aimed for sustained
release of anti-cancer drugs to be ultimately used as implants for local delivery of
chemotherapeutics to tumors.

1.2.

Thesis outline

Methods for incorporation of drugs into hydrogels generally fall into three categories: (i)
physical encapsulation, where drugs are simply entrapped within the cross-linked
polymer network; (ii) covalent conjugation, where drugs are covalently bound to the
polymer network; and (iii) affinity binding, where hydrophobic, ionic, or hydrogen
bonding are utilized to retain drugs within the hydrogel network. Though, physical
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encapsulation renders a simplistic approach for designing drug loaded hydrogels, these
systems often face uncontrolled drug diffusion out of the bulk hydrogel immediately after
formation (burst release). On the other hand, covalent conjugation of drugs to the
hydrogel network yields a much slower drug release profile, where release is facilitated
by cleavage of the covalent linkage or by complete hydrogel degradation. However, this
strategy often involves chemical modification of drugs which not only can impact their
FDA approval but could also alter their biological activity. Along those lines, affinitybased drug delivery has emerged as an alternative to achieve controlled release of smallmolecule drugs, without compromising their activity. Affinity-controlled release is
usually achieved by immobilizing a drug-binding ligand within a hydrogel matrix. Based
on the type of drug molecule, a variety of ligands have been explored for affinitycontrolled release, this includes heparin-like moieties, binding peptides, cyclodextrins,
and thiols. Recently, inspired by marine mussels, researchers have utilized 3, 4dihydroxyphenylalanine (DOPA) to confer affinity-controlled release to hydrogels. The
catechol group of dopamine is shown to be capable of adhering to drug molecules by
using a variety of mechanisms including hydrogen bonds, π-π interactions, cation-π
interactions and dynamic covalent bonds. Nevertheless, controlled release of drugs from
hydrogels is also affected by tortuosity of the release path, which is determined by factors
such as porosity and network swelling/degradation. In line with this, modification of
biopolymers with methacrylate groups and their subsequent photo-crosslinking has been
proven as an effective way to control physical properties of the hydrogels including their
mechanical properties, porosity, swelling behaviours, and degradation rate.

This thesis describes the development of novel coaxial hydrogel structures using either
wet-spinning or 3D-printing approach to be utilized for cancer drug delivery. More
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specifically, the core section of these structures was comprised of dopamine-modified
alginate along with chemotherapeutic drugs to confer affinity-controlled release, while a
methacrylated-alginate was used as the shell composition to provide the controlled
diffusion barrier. For one, coaxial hydrogel fibers were made via wet-spinning technique
and they were subsequently used for delivery of two chemotherapeutic drugs
(Gemcitabine and Doxorubicin). Then, incporation of nanoparticles with photothermal
properties into these drug-loaded coaxial hydrogel fibers were assessed to allow chemophotothermal combinational cancer therapy. Lastly, a 3D-printing technique was utilized
to develop coaxial hydrogel patches for prolonged release of chemotherapeutic drugs.
This work is summarized in the chapters as follows:

In Chapter 1, the significance of local delivery of chemotherapeutic drugs for cancer
therapy is highlighted. Secondly, a brief description of the novel aspects of this work is
highlighted, which is followed by a blueprint into contents of every chapters.
Subsequently, this is followed by a comprehensive review of the current state and future
outlook of biopolymers for Antitumor Implantable Drug Delivery Systems, including the
various implemented biopolymers as well as their corresponding fabrication techniques.
Lastly, based on the conducted literature review the thesis objectives were stated.

In Chapter 2, a new generation of coaxial hydrogel fibers was developed using wetspinning technique, that could simultaneously exert both affinity and diffusion control
over the release of chemotherapeutic drugs. Specifically, dopamine-modified alginate
hydrogel along with chemotherapeutic drugs (Doxorubicin or Gemcitabine) was used as
the main core component to confer affinity-controlled release, while a methacrylatedalginate hydrogel was used as the shell composition to provide the controlled diffusion
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barrier. It was shown that our coaxial mussel-inspired biofibers yielded biocompatible
hydrogel fibers (as indicated by comprehensive in vitro and in vivo experiments) with
favourable properties including controlled swelling, and enhanced mechanical properties,
when compared against single fibers made from unmodified alginate. Notably, it was
observed that these coaxial fibers were capable of releasing the two drugs in a slower
manner, when compared to single fibers made from pure alginate, which was partly
attributed to stronger interactions of drugs with dopamine-modified alginate (the core
element of coaxial fibers) as observed from zeta-potential measurements. It was further
shown that these drug-loaded coaxial fibers had optimal anticancer activity both in vitro
and in vivo using various pancreatic cancer cell lines. Most remarkably, drug loaded
coaxial fibers, particularly Doxorubicin-containing fibers, had higher anticancer effect in
vivo compared to systemic injection of equivalent dosage of the drugs.

In Chapter 3, with the aim of establishing a suitable implantable platform for multimodal
chemo-photothermal cancer therapy, we have fabricated for the first time a coaxial
composite hydrogel fiber using a wet-spinning method established in our laboratory.
Particularly, the core-section of these fibers (Chemo-compartment) contained dopaminemodified alginate along with a chemotherapeutic drug (Doxorubicin), while their shell
section (Phothothermal compartment) was composed of UV-crosslinkable methacrylatemodified algine together with Cu2−xSe Nanoparticles. It was hypothesized that specific
biopolymeric composition of these fibres along with their corresponding core-shell
geometry would allow controlled release of Doxorubicin (loaded in the core), while the
Cu2−xSe nanoparticles (loaded in the shell) would facilitate heat generation upon near
infra-red (NIR) laser irradiation. The results suggested that the fibres possessed a coreshell morphology where nanoparticles were dominantly distributed in the shell section.
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Furthermore, it was shown that addition of Doxorubicin and Cu2−xSe Nanoparticles to the
coaxial fibres led to an increase in their corresponding tensile properties (when compared
to unloaded coaxial fibres), an effect which was more prominently observed for fibres in
their wet state. In addition, not only the coaxial composite fibres allowed controlled
released of Doxorubicin in vitro over a span of 3 weeks, but they were also capable of
generating heat in a tuneable manner (based on the length of the fibre) upon NIR
irradiation, in both in vitro and in vivo conditions. Most remarkably, the coaxial drugloaded composite fibres in the presence of NIR radiation showed superior anti-cancer
effect (both in vitro and in vivo) when tested against breast cancer cell lines, a
phenomenon attributed to their synergistic chemo-photothermal effect.

In chapter 4, with the purpose of fabricating a suitable platform for prolonged delivery
of Gemcitabine (a chemotherapeutic drug), we have 3D printed a novel coaxial hydrogel
patch. Particularly, the core-section of these patches contained dopamine-modified
alginate methacrylate loaded with Gemcitabine, while their shell section was solely
comprised of alginate methacrylate. Subsequently, these patches were further modified
with CaCO3 cross linker and a PLA coating to facilitate prolonged release of the drug.
The results showed that addition of CaCO3 to the formula enhanced the mechanical
properties of the patches and significantly reduced their swelling ratio as compared to that
for patches without CaCO3. Furthermore, addition of PLA coating to CaCO3-containing
patches has further reduced their swelling ratio, which then significantly slowed down the
release of Gemcitabine, to a point where 4 layered patches were capable of releasing
Gemcitabine over a period of 7 days in vitro. Moreover, PLA coated CaCO3-containing
patches showed a good level of biocompatibility when tested in vitro against pancreatic
cancer cell lines. Remarkably, in vitro long term therapeutic effect of these GEM-loaded
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patches were assessed, and the results showed that 3 layers- and 4 layers structures were
successful in inhibiting the cancer cell growth for 14 days.

Chapter 5 concludes the body of work that has been done in this thesis and provides
recommendations for future works based on the obtained results. Of note, every chapter
contains its own introduction, experimental chapter, results and discussion, conclusion,
and a final supporting information.
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1.3.

Introduction and Literature review

Cancer is a disease that arises from mutated cells that have acquired the capacity to
proliferate indefinitely and evade apoptosis which eventually leads to tumor formation
and subsequent invasion to surrounding tissues (also known as metastasis).1-2
Accordingly, advanced cancer is viewed as a “systemic” disease that requires systemic
treatment and on account of such notion systemic administration (administered by
intravenous injections) of chemotherapeutic drugs has been established as one of the
standard methods to treat cancer.

3-5

Traditional systemic chemotherapy has many

limitations in treating the disease including: low efficiency of delivering the drugs
specifically to the tumor site at therapeutic concentrations, and the ensuing toxicity to
healthy tissues.6-8 Consequently, local delivery systems have entered the fray to address
the shortcomings of systemic delivery, by delivering the drug directly to the tumor site
using an implantable system (Figure 1-1). 9-10 The implantable drug delivery system
(DDS) contains one or more therapeutic agents while being placed around or inside the
tumor to facilitate targeted delivery.11-12 These DDSs are intended to enhance drug uptake
and efficacy since they (I) are delivered locally (directly at the site of the tumor) and
therefore offer strategic and precise spatial control that significantly reduces the required
drug dosage and often the side/off-target effects, (II) present temporal control over release
profile of chemotherapeutic agents to maintain therapeutic concentrations over a longer
duration of time and (III) protect the loaded drugs from degradation or clearance until
they are released.4, 6, 13-16 In the past decade, a wide variety of biomaterials have been
exploited to institute anti-cancer implantable DDSs, and the properties afforded by
biopolymers (such as biocompatibility, biodegradability, and ease of processing), has led
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to recent increased attention.9, 17-19 A significant advantage of biopolymeric implantable
DDSs is that they do not demand surgical extraction after use, as they can be cleared
naturally by the body.20

Figure 1-1. Schematic of systemic drug delivery versus local drug delivery for treatment of
malignant tumors, including various types of bio-polymeric implantable systems used for local drug
delivery and different anti-cancer therapeutic modalities employed based on these implantable
systems.

Biopolymeric implantable DDSs are classified under two distinct categories, pre-formed
systems or systems that are formed after the injection into the tumor site.21 Pre-formed
implants have been made from commercially available and FDA (U.S. Food and Drug
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Administration) approved synthetic biopolymers such as polycaprolactone (PCL),
polylactic acid (PLA) and poly(lactic-co-glycolic) (PLGA) - or naturally occurring
polymers including alginate, gelatin, silk and dextran. Pre-formed systems were typically
fabricated through well-established fabrication methods such as casting, electrospinning
and 3D printing.22-41 On the other hand, in-situ formed implants are realized by direct
injection into the tumor site, typically using gels that solidify in response to either
temperature or pH (Figure 1-1).42-57 Biopolymeric implantable DDSs have shown to be
capable of releasing the therapeutic agents either actively (stimuli-responsive systems) or
passively (non-stimuli responsive systems). Accordingly, stimuli-responsive systems
showed a rapid change in dimension or physical properties, instigated by either internal
stimuli within the body, such as temperature or pH, or external stimuli such as
electromagnetic waves, ultrasound, visible-, infrared (IR)- and near infrared (NIR)-light
(Figure 1-2).58-62

Figure 1-2. Schematic showing different mechanisms of drug release from bio-polymeric
implantable drug delivery systems (DDSs).
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With non-stimuli responsive systems release is passive and controlled by diffusion, drugcarrier affinity, degradation of polymer, and/or any combination of these

13, 63-64

.

Therefore, in these systems factors such as tortuosity of pores, steric interactions between
drug and matrix, reversible chemical interaction of drug and matrix, and molecular weight
of polymeric matrix determine the release profile of the therapeutic agent in question.13,
65

Overall, application of the biopolymeric implantable DDSs for cancer therapy goes

beyond delivery of anti-neoplastic agents (e.g. chemotherapeutic drugs), as recently they
have been successfully applied to other cancer therapeutic modalities (Figure 1-1)
including hyperthermia: local heating of tumors to a very high temperature using
electromagnetic waves or NIR radiation;50 photo-dynamic therapy: utilization of
photosensitizing agent and a particular type of light that produce reactive oxygen species
to induce cancer cell death;56 gene therapy: treating the disease using small interfering
RNAs (siRNA) and microRNAs (miRNA);66 and immunotherapy: aiding the immune
system to eradicate the malignancy.67 Interestingly, these DDSs were also shown to be
capable of taking on a combination of multiple therapeutic modalities such as
chemotherapeutic drugs and gene therapy, to synergistically treat malignant tumors.68-69
Nonetheless, implantable biopolymeric DDSs have been commonly used in two different
ways to aid in the treatment of various cancers: they can either be used as neoadjuvant or
adjuvant therapies, in which the tumor itself can be treated (neoadjuvant) or the site where
the tumor was removed can be treated to prevent cancer reoccurrence (adjuvant).21

In this section, we will review the most recent progress in biopolymer-based DDSs for
abrogating various tumors. We will specifically focus on studies with preclinical in vivo
evidences or those with clinical evaluations, as we believe these studies are of higher
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value for transition of DDSs from concept to clinical application. We will further
highlight various fabrication methods commonly deployed for making these DDSs and
review the anti-tumor performance of some recent impressive examples.

1.3.1.

Implantable anti-tumor DDSs

1.3.1.1.

Preformed Implants

Owing to specific features of preformed implants, such as their structural integrity and
defined geometric shapes, these implants endow predictable and adjustable long-term
release and degradation profiles. In vivo implantation of these systems typically entails
an invasive surgery.12, 17

1.3.1.1.1. Cast implants
Casting is considered one of the oldest fabrication methods and it can be further divided
into different subcategories such as solvent casting/particulate leaching, gel casting or
melt casting. Regardless of the sub category it involves pouring the polymer solution/melt
into a cast and subsequently solidifying the precursor through heat/chemical or physical
cross-linking/recrystallization.70-72 One of the main perks of casting is the flexibility in
choice of material as it can be easily applied to thermoplastic biopolymers (such as PLA,
PLGA or PCL) as well as natural/synthetic hydrogels. Moreover, it can be utilized for
fabrication of either 2D films or 3D delivery systems. 22-24, 31, 73-75 However, casting comes
up short in producing structures wherein porosity, mechanical properties and/or
composition as well as the distribution of these is controllable. Nevertheless, on account
of its simplicity it has been widely employed for fabrication of anti-cancer DDSs from
various biopolymers. 24, 73, 76
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Silk
Silk fibroin, a protein based material, has been gaining a foothold in biomaterials science
and oncology therapeutics.77-78 In addition to the use of silk materials for disease therapy
for centuries, they are FDA approved for implantation as a bioresorbable scaffold.79
Moreover, biodegradable materials based on silk fibroin isolated from Bombyx mori
silkworm cocoons have been shown to induce minimal immune response in vivo.80-81
Consequently, it was observed that this type of protein can be combined with various anticancer drugs to bring about anti-tumor activity. For instance, recently, delivery of
vincristine and Doxorubicin (DOX) from silk foams, for treatment of neuroblastoma in a
mouse model, has been investigated.26 These implants were fabricated by lyophilization
of silk solution inside a mold and subsequent thermal cross-linking at 121 ºC. The silk
implants were placed intratumorally and the in vivo results revealed that silk foams loaded
with vincristine, with and without DOX, significantly decreased neuroblastoma tumor
growth, increased tumor drug availability and decreased ultimate plasma concentration
compared to intravenous (IV) drug treatment. In another study, silk films loaded with
DOX were used to suppress primary tumor growth as well as metastasis in breast cancer
mice model (Figure 1-3).

24

The in vitro results revealed a direct correlation between

absorption of DOX on silk films and silk crystallinity (beta-sheet content) that enabled
controlled release of drug. The in vivo findings ensuing implantation of films at the
primary tumor site indicated that silk films loaded with DOX had greater primary tumor
response when compared to equivalent dosage of drug administered intravenously. In
addition, drug loaded stabilized films showed reduction in metastatic dissemination as a
result of locoregional control of the disease.
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Figure 1-3. Preparation and in vivo anti-tumor performance of DOX loaded films. A) Strategies to
generate Doxorubicin-loaded films that are water-insoluble with variable β-sheet content. B) Freestanding Doxorubicin-loaded silk films in the dry state. C) Weight of primary tumours at the end of
the study (week 6). D) In vivo tumor cell-specific bioluminescence of representative mice from each
treatment group at week 6. Plot symbols are defined in panel (C). E) Metastatic spread of cancer
cells to organs at week 6. Plot symbols are defined in panel (C), Reprinted from 24, Copyright
(2012), with permission from Elsevier.

Gelatin
Gelatin a natural protein derived from hydrolytic degradation of collagen, has attracted
much attention in the biomedical field owing to its biocompatibility and biodegradation
in physiological environments.82-84 However, gelatin has a sol-gel transition temperature
around 30 ºC, and so needs to be cross-linked to avoid dissolution at body temperature.85
Yet, in the context of cancer drug delivery this property can be leveraged to allow
controlled release of the drug in a temperature-dependent manner. For example, Zhang et
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al., made a physically cross-linked gelatin hydrogel that was embedded with
poly(ethylene glycol)-block-poly(caprolactone) (PEG-b-PCL) nanoparticles ,which were
co-loaded with tetrandrine (Tet) and paclitaxel (PTX), and evaluated the performance of
this implant (P/T-NPs-Gelatin) for treatment of gastric cancer in mice model.22 These
hydrogel implants underwent a gradual gel-sol phase transformation at 37 ºC, which
resulted in controlled release of drug loaded nanoparticles. In vivo results showed that
P/T-NPs-Gelatin implants had the greatest inhibitory growth effect when compared to
either intraperitoneal delivered P/T-NPs or free combinations of PTX and Tet. Similarly,
a gelatin hydrogel loaded with gelatin/poly(acrylic acid) nanoparticles containing
cisplatin (CDDP) was used for treatment of liver cancer in a murine hepatoma cancer
model.28 It was found that implantation of the gelatin hydrogel containing CDDP-loaded
nanoparticles on tumor tissue led to a remarkably higher efficacy in preventing tumor
growth as well as prolonged lifetime of the mice compared to that of IV injected CDDPloaded nanoparticles. More importantly, bio-distribution results revealed that these
gelatin hydrogel implants yielded a much higher drug concentration in tumor and far less
accumulation in non-target organs when compared to that in the group which received
systemic administered CDDP-loaded nanoparticles. Since gelatin has a variety of
functional groups on its side chains, they can be exploited in various ways to crosslink
the hydrogel either chemically or physically.85 Accordingly, Jaiswal et al., developed a
hydrogel implant by in-situ polymerization and cross-linking of acrylic acid with
polycaprolactone diacrylate in the presence of gelatin.27 It was shown that an increase in
crosslinker concentration led to a slower degradation rate as well as drug release.
Additionally, the semi-interpenetrating network of gelatin and poly-(acrylic acid) loaded
with DOX was implemented as an adjuvant therapy by implanting it into the tumor cavity
post tumor resection to prevent recurrence of breast tumors in mice models. It was
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observed that use of this drug-loaded implant led to prevention of tumor recurrence after
resection until day 25 as opposed to implants with no drugs which showed tumor relapse
on day 18.

Dextran
Dextran is a polysaccharide of microbial origin consists of glucose molecules connected
via a 1-6 glucosidic linkage while side chains are connected in a 1-4 linkage.86 Aside from
its biocompatibility and biodegradability, this polymer is resistant to protein adsorption
and consequently it was deployed as drug delivery vehicles.87 Owing to abundance of
hydroxyl groups in this polymer, one can partially oxidize them to produce aldehyde
groups that can be crosslinked by addition of amine-containing polymers.88 For instance,
based on a schiff-base interaction between dextran-aldehyde and polyamidoamine
(PAMAM) dendrimers, an implantable hydrogel was made, which was embedded with
poly(β-aminoester) nanoparticles containing anti-luciferase siRNA.23 This composite
hydrogel was tested in vivo in a xenograft mouse model for human breast cancer, and
showed no sign of inflammation after implantation. All mice subjected to these implants
maintained healthy conditions indicating implant biocompatibility. Furthermore,
nanoparticle loaded hydrogels promoted efficient luciferase silencing, with up to 70%
reduction in luciferase expression after day 6, which was significant when compared to
20% reduction of luciferase expression achieved by intratumoral injection of
nanoparticles after the same period of time. Conde et al., loaded the same hydrogel with
dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-intercalated nanobeacons,
which acted as an on/off switch activated by the increase of multidrug resistance protein
1 (MPR1) within the tumor microenvironment.68 These nanoparticles were specifically
designed to detect and target MPR1 genes, a process that triggered concomitant 5-FU
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release following nanobeacon opening. Consequently, in vivo implantation of these
nanoparticle loaded hydrogels resulted in over 90% tumor reduction in a triple-negative
breast cancer (TNBC) mice model as a consequence of 80% MPR1 silencing.
In other work by this group, the same hydrogels were simultaneously loaded with gold
nanospheres decorated with siRNAs and gold nanorods containing the anti-cancer drug
bevacizumab(Avastin®), to bring about a “combinatorial” triple-combination therapy for
tumor regression as well as recurrence prevention in a colon cancer mice model (Figure
1-4).69

Figure 1-4. Dextran-based hydrogel scaffold as prophylactic agent for in vivo local gene/drug
delivery combined with phototherapy, before and after tumor resection in mice model of colorectal
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cancer. A) Development of smart hydrogel-nanoparticle patch and subsequent implantation in mice
model. B) Tumor burden following treatment as measured by luciferase activity, without tumor
resection, C) and after tumor resection. D) Survival plot analysis of mice treated with hydrogel
scaffolds for single therapies or triple therapy. Reprinted by permission from Macmillan Publishers
Ltd: Nature Materials 69, Copyright (2016).

The gold nanospheres were designed to specifically silent a major oncogene driver (Kras)
in colorectal cancer (CRC) progression, while the gold nanorods had the capacity to
convert NIR radiation into heat causing release of the drug as well as photothermal
therapy to ablate tumors. Accordingly, this triple therapy hydrogel (gene therapy,
chemotherapy and phototherapy combination) synergistically abrogated the tumor, and
following resection it completely prevented colon cancer recurrence. Furthermore,
animals which received triple therapy have shown 100% survival for at least 170 days
which was significantly higher compared to control groups that received monotherapies.
Conde et al., also established a self-assembled hydrogel containing RNA-triple-helix to
modulate miRNA in the tumor microenvironment.66 This system was comprised of RNAtriple-helix conjugated in PAMAM G5 dendrimers (triplex nanoparticles) which formed
the hydrogel upon mixing with dextran aldehyde. The RNA-triple-helix was formed by
self-assembly of two miRNA oligonucleotides, an antagomiRNA used to inhibit an
oncomiRNA and a miRNA mimic used as tumor suppressor. This nanoparticle loaded
hydrogel were subsequently implanted in TNBC mouse models, which led to almost 90%
tumor size reduction 13 days after hydrogel disk implantation, as well as a significant
survival advantage in comparison to drug-loaded hydrogels. The highly selective and
specific treatment of tumor cells has been shown to be the main advantage of this system
over traditional chemotherapeutic drugs.
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PLA and PLGA
PLA is an FDA approved synthetic biocompatible polymer, belonging to poly (α-hydroxy
acid) class and undergoes in vivo hydrolytic degradation through de-esterification.89
However, long degradation times along with high crystallinity causing fragmentation can
result in inflammatory reactions in vivo. Numerous methods have been used to decrease
crystallinity and subsequently hasten biodegradation.90 For instance, copolymerization of
lactic acid and glycolic acid has produced PLGA with tunable degradation based on the
ratio of lactic acid to glycolic acid.91-92 Hence, on account of desirable properties of PLGA
this copolymer was extensively used in variety of clinical applications including drug
delivery systems for cancer therapy.93 For instance, Wang et al., incorporated
nanoparticles of RGD-modified PEGlated PAMAM dendrimer loaded with DOX (RGDPPCD) into PLGA/PLA solution containing PEG (polyethylene glycol; as drug release
modifier) and then casted them into a cylindrical die.75 In vitro release studies revealed
that the ratio of PLGA/PLA had an impact on the release of DOX, with an increase in
PLA content decreasing the drug release rate. It was also observed that different amounts
of PEG can influence the DOX release, as an increase in PEG led to significant increase
in release rate of DOX. Furthermore, in vivo results indicated that PLG/PLA scaffolds
containing RGD-PPCD nanoparticles could significantly reduce glioma tumor size in
mice as opposed to their counterparts including PPCD implant, DOX implants and blank
implants. These findings were assumed to be result of better penetration of RGD-PPCD
nanoparticles into the tumor which highlighted beneficial role of RGD sequence in tumor
retention of nanoparticles. PLGA was also utilized to fabricate a biopolymeric cylindrical
implant, known as local drug eluter (LODER), that contained an siG12D (an siRNA
against the mutated KRAS oncogene) for growth inhibition of pancreatic tumors in a
mouse model.94 It was found that encapsulated siG12D in LODER was active and stable
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for 155 days in vivo. Further, it was shown that these implants were capable of impeding
the tumor growth and prolonging mouse survival time. This group also conducted a phase
I and a phase II clinical trials for patients with unresectable locally advanced pancreatic
cancer (LAPC). The siG12D LODER implant (implanted into the tumor using an
endoscopic EUS biopsy needle) was combined with chemotherapy and the results showed
that from twelve patients analyzed by CT scans, none showed tumor progression and most
of them (10/12) demonstrated stable disease. Tumor marker CA19-9 was observed to
decrease in 70% of patients and 18 month survival rate was 38.5%.95
Recently, in a ground breaking study, researchers have tried to treat the pancreatic ductal
adenocarcinoma (PDAC) by developing a tunable PLGA-based platform that enabled
local delivery of anticancer drugs to the targeted tumor tissue (Figure 1-5).31
Accordingly, a PLGA solution mixed with PTX was cast on top of a stainless steel disc
containing a suture hole. The resulting PTX eluting device (PED) was sutured onto the
tumor surface in mouse xenograft model (different PDAC cell lines with different
sensitivity to PTX). The results suggested that thickness of the PLGA layer had a direct
impact on PTX released, in that thicker layers yielded higher and longer release when
compared against thinner layers. In vivo this implant showed up to 12-fold increase in
suppression of tumor growth (PDAC-3 tumors with highest sensitivity to PTX), caused
longer survival of mice and reduced retention in non-target organs in comparison with the
group that received IV PTX. Finally, in another study, researchers have fabricated DOX
loaded PLGA cylindrical millirods by casting the polymer and drug mixture into a Teflon
tube via deploying heat/compression.96 The millirods were implanted in the center of VX2
liver tumors in rabbits and the results showed that these implants were capable of
significantly reducing the tumor size when compared to untreated controls. Furthermore,
histological examinations revealed that necrosis happened throughout the tumor,
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however, some viable tumor cells were observed advancing beyond the main front of the
tumor due to their lack of exposure to therapeutic drug concentration.

Figure 1-5. Design, characterization and in vivo anti-tumor performance of implantable paclitaxel
eluting device (PED). A) Schematic of localized therapeutic approach with PED. B) Macroscopic
visualizations of the local delivery device. C) Scanning electron microscopy images of PLGA
coating on top of steel (“C” = coating and “S” = steel). D) Relative tumor growth curves of PDAC-3
mouse xenografts after treatment with either paclitaxel intravenous or PED treatment. E) Survival
plot showing longer median overall survival (28 day increase) for mice treated with PED compared
to mice treated with I.V. injection of paclitaxel. F) Histological analysis of PDAC-3 tumors after
treatment with PED showing higher areas of necrosis (N) compared to preserved tumor structure
(T) in group treated with I.V. paclitaxel. Reprinted from 31, Copyright (2016), with permission from
Elsevier.
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PCL
PCL is yet another biocompatible polyester that has semicrystalline structure with a glass
transition temperature (Tg) of -60 ºC. Therefore it has highly flexible mechanical
properties at room temperature which is the reason it was extensively exploited in various
biomedical applications.97 This polymer has even slower degradation rate than PLA, due
to presence of five hydrophobic –CH2 moieties in its repeating unit.98-99 Nevertheless,
owing to its slow degradation as well as its compatibility with a wide range of drugs, it
was shown to facilitate drug release up to several months and it was used to fabricated
anti-cancer implantable DDSs.99For example, injection molding was used to fabricate
PCL made needle-shaped conical implants that were loaded with 5-FU to abrogate breast
tumors in a mouse model.100 Owing to the specific design of these implants they were
capable of being injected directly into the tumor using a puncture needle that eliminated
the need for invasive surgery. Moreover, in vivo tests revealed that these implants were
capable of significantly preventing tumor growth as they could provide higher regional
drug concentration compared with those in mice that did not receive any treatment or only
received intravenous injections of the drug.

Poly(1,3-bis-(p-carboxyphenoxy propane)-co-(sebacicanhydride))(PCPP-SA)
PCPP-SA (20:80 molar ratio) is an extremely hydrophobic copolymer that possesses
surface-controlled erosion and hence it was used to fabricate Gliadel wafers for treatment
of brain tumors in several clinical studies.101-102 These wafers were fabricated in a twostep process, where initially they were dissolved in an organic solvent along with
carmustine (BCNU) and subsequently spray-dried into microparticles that were
eventually made into wafers using compression molding.4 So far several preclinical in
vivo studies were performed by loading these wafers with carmustine,103 or other anti22 | P a g e

cancer agents such as PTX,104 4-Hydroperoxycyclophosphamide (4-HC) 105, DOX,106 3bromopyruvate (3-BrPA) and dichloracetate (DCA),107 and subsequently implanting
them intracranially against malignant glioma. For instance, one study in rat brain revealed
that carmustine loaded wafers were capable of releasing carmustine over a time span of
five days and they were ultimately fully degraded 6-8 weeks after implantation

103

. In

another study PTX-loaded wafers were used for treatment of malignant glioma in rat brain
and it was observed that PTX-loaded wafers improved the median survival of rats to
different degrees depending on concentration of loaded PTX.104 Further, it was found that
these wafers provided a much higher PTX concentration in the brain tissue proximal to
the implant (75-125 ng taxol/mg brain tissue) than more distant sites (4 ng taxol/mg brain
tissue). Fung et al., also carried out a pharmacokinetic study on interstitial delivery of
carmustine, 4-HC, and PTX from the wafers in the monkey brain which showed high drug
concentration (0.5-3.5 mM for carmustine, 0.3-0.4 mM for 4-HC, and 0.2-1.0 mM for
PTX) within first 3 mm from the implant and fairly lower concentration at 5 cm from the
implant (0.4 µM for carmustine, 3 µM for 4-HC, and 0.6 µM for PTX) after 30 days from
implantation.105 Using area under concentration-time curve (AUC), it was also found that
tissue exposure to carmustine by using implants were 4-1200 times higher than that
achieved by IV administration of a higher dose. Lastly, another group of researchers
investigated delivery of 3-BrPA and DCA using the wafers (both a as monotherapy or in
combination with oral administration of temozolomide (TMZ) and radiation therapy
(XRT)), in rat models with gliosarcoma.107 The results showed that intracranial
implantation of 5% 3-BrPA wafers and 50% DCA wafers led to significant improvement
in median survival of animals, 18 days for 5% 3-BrPA wafers and 17 days for 50% DCA
wafers, when compared to the control group that did not receive any treatment (13 days).
Furthermore, combination of 5% 3-BrPA wafers and TMZ markedly improved the
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survival when compared to either therapy alone. Though triple combination therapy of
wafers with TMZ and XRT did not show any statistical advantages in survival, however,
5% 3-BrPA wafers given on day 0 in combination with TMZ and XRT resulted in longterm survivorship of 30%.
In addition, numerous clinical studies for treatment of malignant glioma with gliadel
wafers (as adjunct to surgery and irradiation) showed notable increase in median survival
time for patients with both primary and recurrent disease 108-111, which ultimately gained
these wafers FDA approval in 1997 for the treatment of recurrent malignant glioma.
However, complications still remain, some of the most common side effects of these
wafers in clinical trials included: seizures, intracranial hypertension, impaired
neurosurgical wound healing, meningitis, wafer migration and poor drug penetration .112113

Poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18)
PGC-C18 is a super-hydrophobic, biocompatible copolymer of caproic acid and glycerol
functionalized with stearic acid.114 Conjugation of hydrophobic side chains (stearic acid)
imparts a large amount of hydrophobicity into this copolymer which makes it a suitable
candidate for fabricating DDSs capable of delivery of anti-cancer drugs over an extended
period of time.115 Consequently, Liu et al., fabricated PTX loaded PGC-C18 polymeric
films for prevention of local tumor recurrence after resection in a mouse model with lewis
lung carcinoma (LLC) tumor.74 In vitro drug release evaluation showed that the drug
loaded film released the PTX over several weeks and in vivo results revealed that PTX
loaded films prevented local tumor recurrence in 83.3 % of animals compared with 22.2
% for systemically administered drug. Additionally, after 10 days, drug loaded films
demonstrated a significantly greater PTX concentration (3000-fold) at the site of resection
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when compared to that for systemic injection of PTX with equal concentration. The same
group used these PTX loaded films to reduce locoregional recurrence of chondrosarcoma,
in mice xenograft model, following macroscopically complete tumor resection.73 Based
on in vivo observations, it was found that in mice treated with PTX-loaded films
locoregional recurrence was 17 % which was much lower than this value for PTX IV
treated mice (89 %). Furthermore, animals treated with PTX-loaded films showed longer
median overall survival (81 days) compared to PTX IV treated animals (48 days), which
was due to higher concentration of PTX in the local tissue. In another study, PGC-C18
films loaded with anti-cancer agent 10-hydroxycamptothecin (HCPT) were used to
prevent local growth and proliferation of LLC tumor in mice model.116 Drug-loaded films
were applied to a collagen-based scaffold to form a flexible composite that can be
administered to resection margins of soft tissue via application of a surgical stapler. In
vitro, HCPT-loaded composites released the drug over a period of seven weeks and in
vivo observations revealed that animals treated with HCPT-loaded composites had much
higher freedom from tumor growth (86 %) compared to animals that received larger
intravenous dose of HCPT (0 %). Moreover, histological analysis of tissues at the surgical
site showed normal wound healing process indicating the nontoxic nature of this
composite.

1.3.1.1.2. Electrospun implants
Electrospinning involves the usage of a strong electric field to create fibers (with diameter
ranging from micrometers down to tens of nanometers) by extruding a polymer solution
from an injection needle and depositing them on a collector plate.117-120 The electrospun
fibers can vary in size and orientation (randomly distributed or aligned) based on the
deployed processing parameters such as polymer solution flow rate, applied electric
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voltage, collector configuration (stationary or rotary), needle-tip-to-collector distance and
needle size.121-122 As a consequence of the many interesting properties of electrospun
fibers, including high specific surface area and tunable porosity, they have been
frequently utilized as implantable depots for drug delivery.117,

123-124

One of the

outstanding features of electrospinning is its ability to create multiaxial fibers comprised
of a core, which can be drug loaded, and a sheath, that can retard the release of drug from
the core, and as a result these multiaxial fibers have recently gained attention for
controlled drug delivery.125-131 Despite these properties, the use of electrospinning is
limited in terms of fabrication of 3D implants with complex shapes and geometries, and
not all biopolymers are spinnable with this technique.121, 132 Nevertheless, over the past
decade electrospun fibrous mats, fabricated from a variety of biopolymers, have been
largely used as DDSs for abrogation of malignant tumors or preventing their reoccurrence
in numerous studies.133

PLA and PLGA
PLA and PLGA were shown to be ideal choices of polymers for fabrication of electrospun
fibers, mainly due to their solubility in volatile chlorinated and fluorinated solvents as
well as their availability in a wide range of molecular weights, which allowed ease of
electrospinning of these polymers.134-135 Electrospun PLA and PLGA mats have been
frequently used as DDSs for cancer therapy.136 For example, electrospun PLA nanofibers
that were loaded with DOX and used as local delivery systems against two types of
secondary hepatic carcinoma (SHCC), namely nodular and diffuse SHCC (NSHCC and
DSHCC), in mice.33 The in vivo results showed that targeting NSHCC tumors with DOX
loaded fibers led to significant suppression of NSHCC growth and increased the median
survival time of mice with DSHCC from 14 days to 38 days. In another study, Ding et
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al., Loaded the poly-D,L-lactide (PDLLA) nanofibers with docetaxel (DTX) to prevent
breast cancer reoccurrence in mouse model.36 It was shown that animals treated with drug
loaded membranes had significant decrease in locoregional reoccurrence after primary
tumor resection (16.7%) when compared to systemic administered DTX (75.0%) or local
administered DTX (77.8%). Additionally these drug loaded membranes showed minimal
signs of inflammation in the surrounding tissue indicating a high level of
biocompatibility. Similarly, other researchers investigated the inhibitory effect of
released DCA from PLA electrospun mats to suppress cervical carcinoma in tumorbearing mice.137 In vivo observations after 19 days showed a significant suppression of
tumor growth in animals treated with drug loaded fibers as well as substantial reduction
of tumor weight. This was assumed to be a result of synergistic necrosis of tumor cells by
two different necroptosis mechanisms that were caused by high dosage of DCA. In a
different study, (5-FU)-loaded PLLA nanofibrous membranes were developed for
suppressing colorectal cancer in xenografted mice.138 In vivo it was shown that these
membranes were more capable of supressing tumor growth than an intraperitoneal
injection of 5-FU (at median lethal dose (LD50) concentration) due to prolonged and
continuous release of 5-FU from the membranes. PLA fibers can also be loaded with
multiple chemotherapeutic agents to treat cancer in a combinatorial manner. For instance,
Zhang et al., evaluated the in vivo activity of PLA fibers containing 5-FU and oxaliplatin
(Oxa) against colorectal cancer (CRC) in tumor-bearing mice.139 As a result, it was shown
that drug loaded fibers can significantly inhibit tumor growth due to higher local drug
dose, caused by a sustained drug release from the fibers. Additionally, histopathological
studies of the excised tumor tissue showed large areas of necrotic regions in the tumors
after treatment with drug loaded fibers which was in great correspondence with
immunohistochemistry results of apoptosis related proteins (namely Bax and Bcl-2).
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PLA fibers could also be arranged in a multilayer structure to bring about controlled
release of the drugs. As an example, Liu et al., fabricated asymmetric multilayer PLA
nanofibers (AMPN) loaded with Oxa or a combination of Oxa and cyclophosphamide
monohydrate (OxCy) to prevent liver cancer recurrence in mice models with either
subcutaneous or orthotopic hepatocellular carcinoma (HCC).41 Three different types of
multi-layered electrospun mats were fabricated, two layered (M2), three layered (M3) and
five layered (M5) (Figure 1-6).

Figure 1-6. Drug loaded asymmetric multilayer PLA nanofibers (AMPN) for preventing liver
cancer recurrence. A) Graphical presentation of multilayer nanofibers and scanning electron
microscopy image of five layered (M5) nanofibrous mat. The top layer (i) in M5 and M3 mats
contained PLA films to allow one sided release of drugs. B) Schematic illustration of performance
of drug-loaded AMPN mats in human body for prevention of tumor recurrence after HCC surgery.
C) Tumor recurrence rate, D) average tumor volume, and E) survival time as a function of time, for
treated animals, post “subcutaneous tumor” surgery. Reprinted from 41, Copyright (2015), with
permission from Elsevier.
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The five layered implants showed the slowest in vitro release rate of loaded Oxa which
was followed by three layered implants and two layered implants. Insertion of Oxa loaded
multilayered membranes into the cavity, formed as a result of “subcutaneous tumor”
removal, substantially slowed the rate of tumor reoccurrence and it increased the survival
rate of the rodents compared to control group. Interestingly, tumor growth suppression
capacity was shown to have a direct relation with in vitro release rate of Oxa, as the five
layered implants showed the highest inhibition of tumor growth. Furthermore, in
orthotopic HCC models wrapping of AMPN mats (loaded with OxCy) around the left
liver lobe following partial hepatectomy revealed appearance of normal liver tissue
without visible tumor reoccurrence in comparison to control groups, which was further
confirmed by histopathological observations of liver samples. Similarly, the same group
successfully fabricated other multilayered PLA electrospun mats loaded with cisplatin or
Oxa/DCA that prevented local liver cancer or cervical cancer reoccurrence in mice
models, respectively.37, 39 Last but not least, to allow loading of hydrophilic drugs into
PLA-based fibers, this polymer has been mixed with more hydrophilic polymers and
subsequently electrospun to make fibers with improved hydrophilicity. For instance,
cisplatin loaded mucoadhesive nanofibers made out of a mixture of PLA and polyethylene
oxide (PEO) were fabricated to abrogate cervical/vaginal cancer in mice.38 Owing to the
hydrophilicity properties of PEO these nanofibers showed good in vivo vaginal retention
and upon implantation into the vagina of mice, cisplatin concentration was found to be
much higher in vagina/cervix region that in the non-target organs, in contrast to the case
of IV cisplatin. However, these nanofibers did not show superiority over IV cisplatin in
treating vaginal tumors. Consequently, in a separate study the same group co-loaded the
PLA/PEO nanofibers with cisplatin and curcumin (cis-cur) to prevent cervical cancer
reoccurrence after surgery.34 After resection of subcutaneous vaginal tumors drug loaded
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fibers were implanted at the site of tumor resection and it was shown that these fibers
were better capable of preventing local cervical cancer reoccurrence when compared to
IV drugs, which was further supported by histological analysis showing large area of
necrosis induced by cis-cur/fibers only 4 days after tumor resection. Along similar lines,
Xia et al., successfully enwrapped GEM into electrospun fibers via microsol
electrospinning technology to form a stable core–shell fibrous structure.140 The shell
section of the fibers was made out of PLA and the core section contained hyaluronic acid
(HA). The GEM release rate can be adjusted by altering the thickness of the hyaluronan‐
sol inner fiber and the quantity of loaded GEM, and the release can be sustained for as
long as three weeks. In vitro assays show that these electrospun fibers effectively inhibit
pancreatic cancer cells and promote apoptosis. In vivo studies show that the fibrous
membranes are better for inhibiting the growth of residual tumors than that of integrated
tumors. Furthermore, immunohistochemistry results show that GEM‐loaded fibers
promote a higher cell apoptosis rate than does systemically injected GEM in residual
tumors. In addition, the local delivery of GEM with fibers significantly reduces liver
toxicity.
As highlighted in the beginning of this section, PLGA has also been used in fabricating
anti-cancer fibrous DDSs. For example, Ranganath et al., fabricated submicron (F2) and
nanoscale (F3) discs from PLGA(50:50) electrospun fibers loaded with PTX and used
them for inhibiting growth of glioblastoma in a mouse model.141 Consequently, F3
nanofibrous discs demonstrated a greater drug release rate in vitro and in vivo, in
comparison to counterparts including F2 submicron fibrous discs and PTX-loaded PLGA
microspheres entrapped in sodium alginate beads. As a result, F3 discs showed higher
drug availability and subsequently enhanced diffusion rate as well as diffusion distance
in the mouse brain tissue that is crucial considering that glioblastoma multiforme (GBM)
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typically reoccurs within 2 cm of the resection site. Moreover, F3 discs were capable of
inhibiting the tumor at its early stages of tumor growth as a consequence of high local
drug concentration, which is critical to slow down the reoccurrence rate of glioma in postsurgical chemotherapy. In another study carried out by Tseng et al., PLGA nanofibrous
membranes were loaded with combination of drugs including BCNU, irinotecan and
cisplatin to treat malignant glioma in tumor-bearing rats.142 Consequently, in rats treated
with drug loaded fibers (BIC/PLGA), a substantially higher concentration of drugs was
observed in brain tissue than in the blood throughout 8 weeks of study. Rats treated with
BIC/PLGA membranes experienced a much lower tumor volume after 16 days, when
compared to that in rats which received blank PLGA membranes. Furthermore, in the
BIC/PLGA treated group a much longer median survival time was achieved (~60 days)
in comparison to the group treated with non-drug loaded (blank) membranes (~22 days).
PCL
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Due to specific rheological and viscoelastic properties of PCL this polymer and its
copolymers have been successfully utilized in electrospinning to bring about fibrous
mats.143 Similar to PLA and PLGA, PCL fibers were also utilized as drug carriers for
local delivery of anti-cancer drugs to tumor site. For instance, Chen et al., made
nanofibers from combination of PCL and gelatin (PG), that contained DOX-loaded coreshell nanoparticles of Cu9S5-mesoporous SiO2 (Cu9S5@mSiO2) and used them for
synergistic chemo- and photothermal therapy of hepatoma tumors in mice (Figure 17).144

Figure 1-7. A nanofibrous PCL-based composite for synergistic chemo- and photothermal tumor
therapy. A) Schematic showing preparation of composite fibers as well as their subsequent
implantation procedure for dual therapy of tumors. B) Tumor volume as a function of time after
different treatments. C) Images of mice with tumors and photograph of corresponding excised
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tumors after 11 days of treatments. D) Mean tumor weights after 11 days of treatments.
Reproduced from 144 with permission of The Royal Society of Chemistry.

In vitro DOX release in PBS (phosphate-based buffer) revealed that these fibrous
membranes possessed pH responsive release owing to intrinsic properties of
Cu9S5@mSiO2 nanoparticles, also, it was shown that after 5 min laser irradiation the
temperature of Cu9S5@mSiO2 PG fibers dramatically increased from 21 ºC to 54.6 ºC.
Additionally, in vivo results showed that DOX-loaded Cu9S5@mSiO2 PG composite
fibers under laser irradiation had a more efficient tumor suppression effect once compared
against single photothermal therapy of tumors by Cu9S5@mSiO2 PG fibers or with single
chemotherapy by Dox loaded Cu9S5@mSiO2 PG fibers. In another study the same group
fabricated similar PG nanofibers instead loaded them with DOX-containing
NaGdF4:Yb/Er@NaGdF4:Yb@mSiO2-PEG core-shell nanoparticles (upconverting
nanoparticles; UCNPs) and indomethacin (anti-inflammatory drug) to abrogate hepatoma
tumors in mice.35 This composite fiber not only was aimed for controlled-release of DOX
but also enabled upconversion fluorescence/magnetic resonance dual-modality imaging
via NaGdF4:Yb/Er@NaGdF4:Yb incorporated into composite fibers. In vivo anti-tumor
efficacy showed that composite fibers containing DOX-loaded UCNPs and indomethacin
had the highest tumor inhibition rate (96%) when compared to simple DOX-loaded fibers
(61.8%). Moreover, owing to presence of indomethacin in composite fibers, they caused
complete healing of surgical wound. At last, in an attempt to further prolong the drug
release of PCL nanofibers, researchers fabricated cisplatin-loaded superhydrophobic
electrospun nanofibers from mixture of PCL and Poly(caprolactone-co-glycerolmonostearate) (PGC-C18) for prevention of local cancer reoccurrence post resection in
mice model with lung carcinoma.145 Owing to hydrophobicity of these nanofibers they
have shown a sustained release of drug over 90 days. Further, in vivo evaluation showed
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that these fibers were capable of significantly increasing median reoccurrence-free
survival rate to more than 23 days compared to the group treated with intraperitoneal
injection of cisplatin which all died before day 16 due to cancer recurrence.

Gelatin
Owing to superior biocompatibility and biodegradability of gelatin, this polymer was
extensively utilized to fabricate electrospun fibers (either alone or as a blend component)
for various biomedical applications including drug delivery.123, 146 For instance, Yang et
al., fabricated core-shell fibers, in which the core was comprised of polyvinyl alcohol
(PVA) containing folate-decorated micelles (FM) of poly(ε-caprolactone)-poly(ethylene
glycol) loaded with DOX (for active targeting of solid tumors), and the shell contained
genipin crosslinked gelatin (Figure 1-8).131

Figure 1-8. Core-shell micelle-loaded nanofibers for efficient cancer therapy. A) Schematic
representation of multi-axial fibers and their corresponding in vivo performance. B) Biodistribution
(for different time points) in different organs of mice after receiving different treatments. C) Tumor
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volume and D) survival rate of treated tumor-bearing mice as a function of time. Reprinted with
permission from 131, Copyright (2015) American Chemical Society.

These fibers showed delayed in vitro release of DOX when compared with micelles alone,
and further in vivo studies in mice with breast cancer revealed that DOX accumulation
in tumors for FM (IV administrated) and FM-nanofiber groups (implanted near the tumor)
were significantly higher than that in DOX treated (IV administrated) group. Moreover,
during 21 days of treatment, groups treated with FM-nanofiber showed comparable tumor
growth suppression in comparison to the groups that received four times injection of DOX
or M or FM. Lastly, FM-nanofiber treated group experienced a higher survival rate when
compared to other groups, owing to lower systemic drug exposure caused by local
delivery of DOX using the nanofibers.

1.3.1.1.3. 3D printed implants
3D printing is known as a process whereby three dimensional solid objects of any shape
are constructed from a computer-aided design (CAD) model via layer-by-layer deposition
of materials onto a computer-controlled built platform.119, 147 Technically, 3D printing
encompasses various technologies such as inkjet printing, microextrusion printing, laserassisted printing, stereolithography and fused deposition modeling (FDM), and they all
offer significant advantages over traditional fabrication methods as they endow reliability,
reproducibility and flexibility in design (geometrically complex shapes).147-149 In the
context of cancer studies 3D printing has been used to recreate the 3D microenvironment
of tumors by printing a variety of hydrogels and this aspect of 3D printing will not be
reviewed here.150-152 Herein, we solely focus on bipolymeric anti-cancer drug eluting
implants fabricated using 3D printing technologies.
3D printed DDSs are commonly fabricated via microextrusion or FDM printing.153
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Microextrusion printing involves continuous extrusion of biomaterials (in the form of
solution/paste) from a temperature-controlled micro-extrusion head to a building
platform, using pneumatic pressure or piston-assisted system, for layer-by-layer
fabrication of 3D constructs.119,

154

FDM deploys preformed filaments fed into a

temperature-controlled extruder where they are heated and subsequently the semi-molten
thermoplastic is deposited onto a platform in a layer by layer process.155-156 Such printing
is directly affected by processing parameters such as nozzle diameter and temperature,
feed rate and print head speed.157-158 Interlayer bonding significantly affects the final
properties of the printed product and consequently solidification procedures should be
carefully controlled to avoid separation of subsequent layers. The major disadvantages of
extrusion and FDM printing include: slow printing speed, nozzle clogging and interlayer
debonding.159 Even so, these methods have been successfully practiced on biopolymers
such as PCL and PLGA to fabricate implantable anti-cancer DDSs.

PLGA and PCL
Owing to the thermoplastic nature of PCL and PLGA in conjunction with their favorable
biocompatibility and biodegradability, they have been utilized to create 3D printed DDSs
for cancer therapy. For example, most recently extrusion printing was used to fabricate a
3D patch made from a mixture of PLGA (lactide:glycolide = 85:15) and PCL loaded with
5-FU for growth suppression of pancreatic cancer (Figure 1-9).29 The patches were
printed with three different pore shapes and geometries (latticed, slant and triangular) in
different thicknesses and it was found that these features can greatly affect the drug
release profile by altering the surface area:volume ratio (S:V) of the structure.
Implantation of drug-loaded patches (P100;100 mg 5-FU and P150;150 mg 5-FU)
underneath a pancreatic cancer tumor in mice, resulted in a substantial decrease in tumor
36 | P a g e

size when compared to non-drug loaded patch (P0) groups.

Figure 1-9. 3D printed patch for local delivery of 5-FU for pancreatic growth suspension. A)
Schematic showing sample preparation procedure. B) Schematic and photograph of printed
patches with different geometries. C) Relative tumor size as a function of time in mice after
implantation of drug loaded patches. D) Photographs of excised tumors and the patches 4 weeks
after implantation. Reprinted from 29, Copyright (2016), with permission from Elsevier.

In another study, Sun and his colleagues fabricated a PCL scaffold using a FDM printer
and coated the structure with a mixture of chitosan, chitosan-modified montmorillonite
clay and β-tricalcium phosphate (β-TCP) which was subsequently coated with DOX
solution (DESCLAYMR_DOX) to inhibit growth of breast tumors in mice .30 These drug
eluting implants showed a significant burst release of DOX in the first 24 h that was
followed by four weeks of sustained release. Further, subcutaneous implantation of
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DESCLAYMR_DOX in mice showed prolonged presence of DOX to a much larger
extent at the treatment site which resulted in higher tumor growth inhibition when
compared to subcutaneous injection of DOX (INJECTION_DOX). Also compared to
INJECTION_DOX, DESCLAYMR_DOX showed decreased multi-organ metastasis as
well as cardiotoxicity due to local delivery of DOX. In another instance, Wei et al.,
presented a facile method to prepare core-shell hydrogel fibers/scaffolds with controlled
drug delivery and designed structures for the treatment of the residual breast cancer and
prevention of local recurrence after surgery.160 Mixtures of polydopamine (PDA) and
concentrated alginate inks as the shell layer, and DOX-loaded temperature-sensitive
gelatin hydrogels as the core part were co-injected and coaxial 3D printed into core-shell
hydrogel fibers and scaffolds. Under near infrared (NIR) irradiation, PDA with excellent
photothermal effect could raise the temperature of core-shell fibers, which induced the
gel-sol transition of the core gels, and subsequently resulted in the drug release from the
loosened hydrogel network. Photothermal effects and the released therapeutic drugs could
effectively kill breast cancer cells and inhibited the growth of tumor. In addition, the in
vivo performance of the core-shell fiber scaffolds could be monitored by photoacoustic
imaging.

1.3.1.2.

Injectable in-situ forming implants

Injectable DDSs are typically made from a solution/semisolid mixture of polymer matrix
and therapeutic agents that solidify in situ upon injection into the tumor site. 10, 17, 161 The
solidification mechanism will differ based on the type of biopolymer used, however, the
existing injectable DDSs can be generally categorized accordingly161-163: (I) in situ
precipitation, wherein the polymer precipitates from a solution state as a consequence of
solvent removal 164-165, sol-gel transition in response to temperature change42-43, 45 or pH
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change44,

166

; (II) in situ crosslinking, wherein the polymer chains undergo

physical/chemical cross-linking upon injection as a result of covalent bonding
170

55, 57, 167-

, or non-covalent bonding of polymeric chains.52-53, 56 The injectable implants hold

great advantages over preformed implants including elimination of invasive surgical
intervention and their ability to fill any cavity, into which they are injected.171-173 Some
of the disadvantages of these implants are the complicated and sometimes toxic
crosslinking chemistry required as well as the fairly long gelation time upon injection.161
Nevertheless, recently injectable DDSs, developed from a broad range of biopolymers,
have been extensively used to inhibit the growth of malignant tumors or prevent their
recurrence in preclinical and clinical studies.174

Polyethylene glycol (PEG)
PEG is a FDA-approved synthetic hydrophilic polymer that has various structures
including linear and branched (multi-arm or star-shaped).175 Aside from its desirable
properties such as good biocompatibility and non-immunogenity, this polymer is capable
of being chemically modified with various functional groups (via replacement of two
hydroxyl groups in its repeating unit) to provide certain functionalities.176-177
Consequently, PEG and its copolymers have been frequently used to bring about
injectable DDSs based on either in situ precipitation or in situ crosslinking mechanisms.
PEG-based injectable hydrogels established via in situ precipitation are often thermogelling hydrogels that have been synthesized via copolymerization of PEG with other
polymers to allow sol-gel transition of the hydrogel upon changes in temperature. For
instance, DOX-loaded nanoparticles made from copolymer of poly(ε-caprolactone-co1,4,8,trioxa[4.6]spiro-9-undecanone)-poly(ethylene
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glycol)-poly(ε-caprolactone-co-

1,4,8, trioxa[4.6]spiro-9-undecanone) (PECT) have formed the macroscale hydrogel upon
thermo-sensitive self-aggregation of PECT/DOX nanoparticles at 37 °C in aqueous media
(Figure 1-10).43

Figure 1-10. Injectable thermosensitive nanoparticle-assembled hydrogel for peritumoral
chemotherapy. A) Schematic showing design concept and in vivo mechanism of action of the
hydrogels. B) Images of sol-gel transition of hydrogels at 37 °C. C) Tumor volume change and D)
percentage of survival, as a function of time, for treated animals. Reprinted with permission from
, Copyright (2016) American Chemical Society.

43

Peritumoral injection of PECT/DOX hydrogel into the breast tumors of mice showed a
much higher intratumoural concentration of DOX when compared to other organs, which
in turn led to greater suppression of tumor growth. In addition, survival rate increased in
animals treated with PECT/DOX hydrogel compared to ones who received IV injection
of DOX or PECT/DOX NPs, which was largely due to the fact that hydrogels were
capable of locally releasing DOX within the tumor area, preventing distribution of DOX
to other organs. Researchers developed another thermo-sensitive hydrogel from MPEGb-(PCL-PLLA) diblock copolymer loaded with 5-FU that underwent an instantaneous
sol-gel transition at body temperature.178 Intratumoral injection of this system into
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melanoma tumors in mice showed higher tumor suppression effect and subsequent
necrosis of tumor tissue which was comparable to that of mice who received three
intratumoral injections of free 5-FU, each at equivalent concentrations to that of one
hydrogel injection. Similarly, Phan et al., synthesized a thermo-sensitive triblock
copolymer

of

poly(ε-caprolactone-co-lactide)-b-poly(ethylene

glycol)-b-poly(ε-

caprolactone-co-lactide) (PCLA-PEG-PCLA) that was used to develop an injectable
hydrogel containing nanoparticles of montmorillonite loaded with Gemcitabine (MMTGEM).179 Interestingly, the targeted injection of this composite hydrogel into a pancreatic
tumor (in mice) led to enhanced anti-tumor efficacy when compared to control group of
intratumorally injected GEM solution at equivalent concentrations.
Triblock copolymers of PLGA and PEG (PLGA-PEG-PLGA) are specifically attractive
thermo-responsive systems on account of their biodegradability and acceptable safety
profile and they showed to undergo sol-gel transition at physiological temperature (37
°C).180 As a result, this copolymer has been exploited as delivery systems for anti-cancer
drug delivery purposes.181-182 As an example, incorporation of DOX into this thermo-gel
did not interfere with its sol-gel transition (except at high concentration of DOX; 4 mg/ml)
and after injection of this drug loaded hydrogel in the vicinity of a sarcoma-tumor in mice,
significant suppression of tumor growth as well as strong apoptosis of tumor cells were
achieved.

183

Similarly, Zhang et al., used the same DOX loaded PLGA-PEG-PLGA

thermo-gel and injected it into hepatic-tumor in mice.184 Interestingly, similar anti-tumor
efficacy was observed in this case and toxicity studies revealed that these drug loaded
hydrogels caused mild lesions in major organ tissues (heart, liver, spleen lung and kidney)
when compared with DOX control group. The same gel was also loaded with PTX, also
known as OncoGel, and used as palliative therapy in pre-clinical in vivo studies in rats
with metastatic spinal tumors,185 mice with breast carcinoma
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186

and porcine model for

future application in non-resectable pancreatic ductal adenocarcinoma.187

Most

importantly, a phase I clinical trial on patients with superficially accessible advanced solid
tumors and a phase 2a clinical study on patients with inoperable esophageal cancer
(OncoGel used in adjuvant to radiotherapy), showed that OncoGel administered
intralesionally was well tolerated, retained its position at the site of injection and caused
low systemic concentration of PTX.188-189 Other types of PEG-based thermo-gelling
copolymers include triblock copolymer of poly(ethyleneglycol)-poly(ε-caprolactone)poly(ethyleneglycol) (PEG-PCL-PEG, PECE) and triblock copolymer of poly(γ-ethyl-Lglutamate)-poly(ethylene glycol)-poly(γ-ethyl-L-glutamate) (PELG-PEG-PELG). Both
these copolymers form a gel quickly after being exposed to body temperature and they
have been employed for local delivery of anti-cancer drugs in animal models.190-191 For
instance, Lei et al., loaded PECE with PTX and injected it at the original tumor site in
4T1 breast cancer -bearing mice, with the intention of preventing locoregional recurrence
of primary tumor after resection.49 As a result, recurrence of the tumor was significantly
inhibited by administration of PTX-loaded PECE hydrogels (9.1%) compared with
systemic (77.8%) or local (75%) administration of PTX at an equivalent concentration.
In addition, this hydrogel accelerated post-operative wound healing at the surgical
incision site, indicating its superior biocompatibility. In another work, Cheng et al.,
loaded PELG-PEG-PELG thermo-gels with PTX and used it for local delivery of PTX to
liver carcinoma in mice models.192 Interestingly, it was shown that by adjusting the length
of each block in the copolymer a different sol-gel transition temperature could be
achieved. Injection of PTX loaded PELG-PEG-PELG hydrogel beside the tumor revealed
enhanced tumor growth suppression when compared to equivalent amounts of free PTX
and higher anti-tumor activity that was confirmed by TUNEL staining of apoptotic cells.
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As it was highlighted at the beginning of this section PEG can also be used to bring about
injectable hydrogels based on in situ crosslinking. This normally involves
functionalization of PEG with a variety of desirable functional groups, which are either
mixed with a secondary polymer to facilitate the cross-linking, or can be used alone to
enable radical/photo cross-linking of the PEG chains.193-194 For instance, Wang et al., used
polydopamine nanoparticles (PDANPs) to cross-link thiol-terminated four-arm PEG (via
thiol-ene reaction) and form a hydrogel that showed sensitivity towards NIR irradiation,
owing to the presence of polydopamine (Figure 1-11).170 This feature was further used
for controlled release of the drug as well as photothermal therapy of tumors. Upon
intratumoral injection of 7-ethyl-10-hydroxycamptothecin (SN38) loaded gel into a lung
cancer mouse model, it was found that PDA-SN38/PEG gel with NIR radiation had
greater anti-tumor activity when compared with the PDANP-SN38 group, due to
synergistic interactions of the chemo- and photothermal therapy. In addition, these gels
caused no detectable pathological change in major organs indicating their minimal
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systemic toxicity.

Figure 1-11. Injectable polydopamine nanoparticle-knotted PEG hydrogel for on demand chemophotothermal therapy of tumors. A) Schematics showing preparation PDA/PEG hydrogel and
subsequent SN38 release mechanism from the hydrogel upon NIR irradiation. B) Tumor volume
change plot for different treated groups. C) Photograph of excised tumors and D) their
corresponding average weight. Reprinted with permission from 170, Copyright (2017) American
Chemical Society.

In another study, a heparin functionalized four-arm PEG hydrogel was synthesized which
was further processed post-synthesis into injectable microparticle aggregates.51 Owing to
the presence of heparin in these hydrogel microparticles they have shown high affinity
44 | P a g e

towards DOX especially at higher concentrations, leading to slow in vitro release of this
drug in PBS. Moreover, local injection of the DOX-loaded hydrogel microparticles into
established human orthotopic breast tumors in mice showed significant reduction in tumor
burden as well as breast cancer metastasis when compared to IV bolus-treated animals.
Li et al., used acylhydrazone bonds to form a pH-sensitive injectable hydrogel from a
mixture of dibenzaldehyde-terminated PEG (DF-PEG) and polyaspartylhydrazide
(PAHy).44 In vitro, these hydrogels showed faster release of DOX in a buffer solution
with acidic pH compared to a neutral pH due to cleavage of acylhydrazone bonds in acidic
conditions. Furthermore, intratumoral injection of DOX-loaded hydrogel in fibrosarcoma
tumor bearing mice showed a superior antitumor activity compared to control groups as
well as negligible toxicity in vivo.
Guest-host interactions have also been implemented to make PEG-based injectable
hydrogels based on in situ crosslinking mechanism. For example, Kuang and his
coworkers synthesized two types of nucleobase-terminated PEG (adenine and thymine)
that upon mixing with α-cyclodextrin (α-CD) formed an injectable hydrogel based on
guest-host interactions.52 Additionally, intratumoral injection of DOX loaded hydrogel
into a cervical cancer mouse model revealed that this hydrogel substantially restricted
the tumor growth and caused no significant fluctuation in body weight (compared to
control groups) which was assumed to be a consequence of slow and longer local release
of DOX from this hydrogel. Similarly, the concept of guest-host interaction was used by
another group to make an injectable biocompatible hydrogel by developing a mixture of
methoxy polyethylene glycol (MPEG) conjugated with arginine-functionalized poly(Llysine) Dendron and α-CD (MPEG-PLLD-Arg), for delivery of MMP-9 short hairpin
RNA plasmid (pMMP-9).54 In vitro, these hydrogels were capable of sustained release of
pMMP-9 and after intratumoral injection of drug-loaded hydrogels in nasopharyngeal
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carcinoma tumor-bearing mice, it was shown that MPEG-PLLD-Arg/pMMP-9 hydrogels
enhanced retention of pMMP-9 in the tumor compared to standard pMMP-9-loaded
Polyethylenimine (PEI-25K/pMMP-9). Moreover, one time injection of this new
hydrogel had equivalent anti-tumor efficiency to seven injections of a conventional PEI25K/pMMP-9 that totalled the plasmid concentration in the hydrogel.
Wu et al., designed another injectable hydrogel based on Schiff-base interaction of
aldehyde-functionalized four-arm PEG (PFA) and 4-arm poly(ethylene glycol)-b-poly(Llysine) (PPLL) for co-delivery of metformin (ME) and 5-FU.57 In vitro drug release and
degradation studies showed that this hydrogel released both ME and 5-FU in a pHsensitive manner. Moreover, a single subcutaneous injection of the drug loaded hydrogel
(ME and 5-FU) beside the tumors of BALB/c mice bearing colon adenocarcinomas led
to significant anti-tumor activity compared to that of single and combination bolus drug
doses, and this was a result of p53-mediated G1 arrest and apoptosis of tumor cells caused
by synergistic therapeutic effect of ME and 5-FU. Additionally, histological assessment
of major organs in mice that were treated with blank (non-drug loaded) hydrogel revealed
their excellent biocompatibility. And lastly, a photo-crosslinkable hydrogel made from
polyethylene glycol dimethacrylate (PEG-DMA) was used for delivery of temozolomideloaded polymeric micelles (M-TMZ) to brain tumors in mice.169 Drug-loaded hydrogel
was intracranially injected into a human glioblastoma bearing xenograft mouse model
and subsequently photo-crosslinked in situ. It was shown that the unloaded hydrogel did
not cause any apoptosis in the brain of the mice, while the drug loaded hydrogel markedly
decreased the tumor weight when compared to all the other control groups. Furthermore,
histological analysis of tumors (retrieved seven days post-treatment) using CD34 and
Ki67 staining, revealed that mice treated with in situ cross-linked drug-loaded hydrogel
showed no sign of cancer proliferating cells at the center of tumor but were present at the
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periphery.

Pluronic F-127 (poloxamer 407)
Triblock copolymers of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene
oxide) (PEO-PPO-PEO) have been of great interest in drug delivery due to their gelation
phenomenon,195-200 however among them pluronic F127 is reported to be the least toxic
one and it also showed inhibitory effect against P-glycoprotein, a major player in the
multidrug-resistant phenotype in cancer.162, 201-202 As a result, this polymer has gained
much interest as DDS against malignant tumors.203-209 For instance, three different types
of thermo-sensitive F-127 hydrogels were developed with either paclitaxel (PTX) in the
form of molecules (MOs), nanocrystals (NCs) and microcrystals (MCs).42 Interestingly,
in vitro erosion and release studies showed very small release of PTX from PTX-NCsGel and PTX-MCs-Gel whilst PTX-MOs-Gel showed the highest amount of release after
14 days in PBS which was in direct correlation with their corresponding erosion rates. In
addition, it was shown that PTX-MCs-Gel possessed the highest intratumoral drug
concentration followed by PTX-NCs-Gel and PTX-MOs-Gel, respectively. Lastly, PTXNCs-Gel showed the highest anti-tumor efficacy against breast tumor xenografts in mice
when compared with PTX-MCs-Gel and PTX-MOs-Gel, which was assumed to be a
consequence of sustained release of drug from PTX-NCs-Gel. In a separate study, Chen
et al., attempted to improve the mechanical properties of pluronic F-127 by
copolymerzing it with hexamethylene diisocyanate (HDI-PF127) and subsequently
mixing it with hyaluronic acid (HDI-PF127/HA).45 Hence, the mentioned hydrogel
showed a sol-gel transition at 37 °C and after intratumoral injection of DOX-loaded gels
in breast tumor-bearing mice, it was shown that DOX-loaded HDI-PF127/HA gel
exhibited the highest tumor growth inhibition compared to DOX-loaded PF127/HA gel
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due to its slower degradation rate and controlled DOX release. Finally, Guo et al.,
synthesized linoleic acid (CLA)-couple poloxamer (CLA-c-P) thermo-sensitive hydrogel
to benefit pro-drug activity of CLA and further increase stability of the hydrogel.48
Injection of PTX-loaded CLA-c-P hydrogel beside breast cancer tumor in mice model led
to significant suppression of tumor growth when compared with control groups, as a result
of the synergistic effect of CLA in conjugation with PTX. Moreover, significant reduction
in expression of cell cycle signaling proteins (Cyclin A, Cyclin B, Cyclin D3 and CDK2)
in combination with considerable increase in expression level of pro-apoptic protein
caspase 3 verified cancer cell death in vivo.

Collagen
Collagen one of the most abundant proteins in the human body, has been extensively
explored for biomedical applications.210 Collagen can undergo self-assembly to form
injectable fibrous hydrogel based on non-covalent bonding.211 Consequently, collagen
has gained attention as an injectable DDS for a variety of cancers. For example, a collagen
peptide modified dendrimer attached to DOX via a hydrazone bond (CP-Dox-den) was
synthesized and embedded in collagen gel. 212 Subsequent injection of this gel underneath
a breast cancer tumor (in mice) led to prolonged suppression of tumor growth.
Additionally, CP-Dox-den/Col gel was even capable of suppressing metastasis in tumorbearing mice, as a result of sustained release of DOX from the gel over the period of the
experiment. Peng et al., designed another injectable hydrogel from a mixture of collagen
and Polyethylenimine (PEI) containing ld1-targeted siRNA for gastric cancer
inhibition.213 Consequently, collagen/PEI-siRNA gels showed slower and sustained
release of siRNA owing to better stability of these gels compared to collagen-siRNA gels.
Additionally, in vivo anti-cancer studies using a gastric cancer xenograft mouse model
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revealed that collagen/PEI-siRNA gel inhibited tumor growth to a greater degree
compared with collagen-siRNA gels or siRNA/medium, which was further confirmed by
immunostaining of treated tumor cells with cell-cycle antibodies (cyclin D1 and P21) and
cell proliferation antigen (PCNA). Most recently, researchers developed an injectable
hydrogel from a mixture of collagen and gold nanoparticles (AuNPs) containing a
photosensitizer (PS) for non-invasive combinational photodynamic therapy (PDT) and
photothermal therapy (PTT) of breast cancer in mice (Figure 1-12).56

Figure 1-12. Collagen-based injectable hybrid hydrogel for synergistic photothermal therapy (PTT)
and photodynamic therapy (PDT) of breast cancer tumor in mice model. A) Schematic
representation of injectable hybrid hydrogel, containing gold nanoparticles (Au NPs) and
photosensitizer (PS), and its corresponding in vivo anti-tumor mechanism. B) Tumor growth
graphs of mice treated with different treatments. C) Tumor recurrence in different groups.
Reprinted from 56, Copyright (2017), with permission from Elsevier.
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This hydrogel was formed due to ionic interactions of negatively charged [AuCl4]- ions
with positively charged collagen. Intratumoral injection of this hydrogel into tumorbearing animals followed by irradiation using laser light resulted in up to an 80%
elimination rate of tumors. In addition, the dual therapy caused suppression of tumor
recurrence for a longer period of time when compared to monotherapies, denoting
superior synergistic anti-cancer effect of photodynamic therapy and photo thermal
therapy.
Cisplatin/Epinephrine (CDDP/epi) gel is also an injectable hydrogel based on collagen
matrix and it was exploited in several clinical studies in patients with esophageal
cancer,214

adenocarcinomas,215 squamous cell carcinomas

216

and hepatocellular

Carcinoma.217 For instance, Monga et al., injected the CDDP/epi gel intratumorally (using
endoscopy) in nine patients with esophageal cancer and it was found that this treatment
restored swallowing in 8 of nine patients, highlighting its palliative-therapy potential. 214

Chitosan
Chitosan is a cationic linear polysaccharide composed of randomly distributed β-(1-4)linked D-glucosamine and N-acetyl-D-glucosamine units, and on account of its intrinsic
properties such as, biocompatibility, biodegradability, penetration enhancer (opening
epithelial tight-junction) and wound healing promoter, has received great deal of attention
in medical and pharmaceutical applications.218-219 Injectable chitosan-based hydrogels are
generally made by neutralization of chitosan amine groups that eliminates the repulsive
inter-chain electrostatic forces and allows development of extensive hydrogen bonding
and hydrophobic interactions between chains, which eventually leads to formation of
hydrated gel-like precipitate.220 Furthermore, it was shown that pH sensitive chitosan gels
can be transformed into thermally sensitive gels by addition of polyol salts such as β50 | P a g e

glycerophosphate (GP).221
Injectable chitosan-based gels have shown great promise in local delivery of anti-cancer
drugs. For instance, a thermo-sensitive injectable hydrogel containing chitosan and βglycerophosphate (C/GP) loaded with liposomal doxorubicin (LipDOX) was developed
and showed pH-dependent release of DOX in in vitro settings.222 In vivo results from
intratumoral injection of this gel into liver tumor-bearing mice showed that
LipDOX+C/GP had a better anti-tumor effect and less systemic cytotoxicity when
compared with DOX+C/GP gels, due to more sustained release of DOX from
LipDOX+C/GP which caused a larger therapeutic window. In another study, Hsiao et al.,
synthesized a chitosan derivative, which contained self-doped acid substituted polyaniline
(PANI) side chain (NMPA-CS) that was capable of self-assembling into a micellar
hydrogel upon local pH change (sol-gel transition at pH of 7).166 Interestingly, exposing
NMPA-CS solution to NIR laser showed rapid increase in its temperature (to 54 °C)
within 5 min of exposure and possessed excellent photostability. Subsequently,
subcutaneous injection of this gel into the right flank of mice showed mild foreign-body
reaction with slow degradation. Additionally, intratumoral injection of NMPA-CS in liver
cancer-bearing mice followed by NIR radiation (5 min every 4 days) led to effective
suppression of tumor growth and maintained no sign of tumor progression for the duration
of study, as a consequence of successful photothermal therapy of these tumors. Shi and
coworkers also made an injectable pH-sensitive hydrogel resulting from Schiff-base
interaction of succinated chitosan (S-chi) and oxidized alginate (O-alg).167 This hydrogel
showed faster in vitro release of DOX at lower pH in PBS and subsequent intratumoral
injection of DOX loaded hydrogel (DOX-OS) in a xenograft mouse model of breast
cancer resulted in greater and longer inhibition of tumor growth when compared to the
DOX-treated control group.
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Hyaluronic acid
Hyaluronic acid (HA) is a biocompatible, biodegradable non-sulfated glycosaminoglycan
which has been largely used over the years for drug delivery purposes.223 Injectable
hyaluronic acid-based hydrogels can be formed using various methods, including Schiffbase reaction and covalent crosslinking with secondary agents.224 For instance, an
injectable hydrogel based on physical cross-linking of hyaluronic acid/adipic acid
dihydrazide (HA-ADH) and hyaluronic acid aldehyde (HA-CHO) was developed and
subsequently loaded with two types of paclitaxel, namely microparticulate paxlitaxel
(PTX) and 14 nm micelle form of PTX (Taxol).225 Consequently, in vitro PTX-gel
showed slower release of paclitaxel compared to Taxol-gel as a result of larger particle
size of PTX. In addition, treatment of ovarian cancer in a xenograft mouse model with
these hydrogels revealed significant reduction in tumor burden compared to control
group, however no significant difference between tumor burden of mice treated with
PTX-gel or Taxol-gel was observed, which was assumed to be a result of limited
dissolution of PTX. Cho et al., developed a similar hydrogel and loaded them with
platinum incorporated HA nanoparticles (PtNPs) and upon injection of this gel into the
peritoneal cavity of ovarian cancer -bearing mice found that PtNP/gel and PtNP were not
capable of inhibiting tumor growth and proliferation at later time points due to protumorigenic effect of HA in the DDS.55 In a different study, Ueda et al., designed an
injectable hydrogel from interferon-alpha (IFN-α)-incorporated hyaluronic acid-tyramine
(HA-Tyr) through oxidative coupling of Tyr with hydrogen peroxide (H2O2) and
horseradish peroxide (HRP).

226-227

The IFN-α-incorporated HA-Tyr gel was further

combined with sorafenib (a small molecule tyrosine kinase inhibitor) for synergistic anticancer effect in a renal carcinoma xenograft mouse model. It was found that IFN-α52 | P a g e

incorporated HA-Tyr gel+sorafenib caused the highest inhibition of tumor growth, which
was further confirmed by the ratio of apoptotic cells and Ki-67-positive cells in the treated
tumors. This synergistic effect was attributed to induction of apoptosis in conjugation
with suppression of angiogenesis by IFN-α-incoporated HA-Tyr gel+sorafenib hydrogel.

Alginate
Alginate a naturally occurring anionic polysaccharide has been extensively studied in
tissue engineering and drug delivery avenues on account of its ideal biocompatibility and
adjustable gelation properties.228-229 Alginate-based injectable hydrogels can be made by
exploiting a variety of chemistries including non-covalent bonding such as ionic bonds,
schiff-base interactions and acylhydrazone Bonds.229 Ionic cross-linking of alginate
chains with divalent cations such as Ca2+ provides a facile route to development of
injectable formulations of this polymer. For instance most recently, Wang et al.,
developed an injectable alginate-calcium hydrogel with immobilized acetylated G5-NH2
PAMAM dendrimer-encapsulated platinum nanoparticles (DAcEPts) in its matrix for
non-invasive photothermal ablation of tumors.53 This hydrogel was capable of being
degraded on-demand upon addition of a chelator (diethylene triamine pentacetic acidDTPA). Intratumoral injection of DAcEPts containing hydrogel (H/DAcEPts) in lung
cancer -bearing immunocompromised mice followed by NIR irradiation led to significant
decrease in tumor volume compared to controls after 30 days of treatment. Interestingly,
in the DAcEPts treated group, tumor-site temperature did not stay stable due to leakage
of these nanoparticles out of the tumor tissue, however, the H/DAcEPts treated group
showed maintenance of temperature at 47 °C after each NIR irradiation. Additionally,
after two intratumoral injections of the DTPA chelator (at day 9 and day 12) the liberated
DAcEPts nanoparticles leached form the tumor tissue, which in turn resulted in an
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attenuated efficiency of the hydrogel in terms of tumor growth suppression.

Poly(organophosphazene)
Poly(organophosphazene) is an inorganic/organic hybrid polymer that has immense
potential for biomedical applications as a result of its hydrolytic degradability and nontoxic degradation products.230-231 Furthermore, this hydrogel undergoes a sol-gel
transition in psychological temperature that makes it a suitable candidate for anti-cancer
injectable DDSs.

For example, Al-Abd et al., loaded the poly(organophosphazene)

thermogel with DOX for local delivery of this drug to human gastric tumor xenografts in
mice.232 Interestingly, it was observed that DOX loaded gel (POL) had 40% and 90%
sustained drug release over 5 weeks in vitro and in vivo, respectively. In vivo results
suggested that POL had similar efficacy in suppressing tumor growth as DOX loaded
solution (SOL), however POL showed dramatically decreased systemic toxicity
compared to SOL leading to higher survival rates of animals after 28 days of treatment.
In a different study, Zhang et al., synthesized poly(organophosphazene) nanocapsules
loaded with superparamagnetic iron-oxide nanoparticle that transformed to a hydrogel
(SPION-NHs) upon exposure to body temperature and it was further used for magnetic
hyperthermia (MHT) and long-term magnetic resonance imaging (MRI).50 Intratumoral
injection of SPION-NHs in human brain cancer tumor xenograft in mice showed higher
retention of SPION nanoparticles in the tumor tissue compared with that in the group
treated with PEGylated SPIONs solution. Moreover, it was shown that treatment cycles
of multiple MHT using SPION-NHs has a direct effect on tumor regression as mice
treated with one or two cycles of MHT demonstrated resumed tumor growth after 5 days
of treatment, however, mice treated with four cycles of MHT showed significant tumor
eradication. Finally, long-term MRI monitoring of tumors injected with SPION-NHs
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showed dissipation of SPIONs from the tumor site as a result of apoptosis of tumor cells.
Similarly, the same group loaded the SPION-NHs hydrogel with tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) (T/S-NHs) to synergistically abrogate tumors
by multiple MHT and anti-cancer potential of TRAIL.233 Accordingly, it was shown that
chemical structure of poly(organophosphazene) (PPZ) had a direct effect on in vitro
degradation and subsequent release of TRAIL and SPIONs from the hydrogel, as nonionic
side group on PPZ (indicated as T/S-NHs-1) led to fastest degradation rate as well as
fastest SPIONs and TRAIL release, while, hydrogel made from PPZ with ionic side
groups (indicated as T/S-NHs-2 and T/S-NHs-3) showed much slower degradation rate
and consequently slower TRAIL and SPIONs release. Additionally, intratumoral
injection of T/S-NHs in a glioblastoma tumor xenograft in mice revealed that tumor
growth was significantly inhibited in animals that received T/S-NHs-2 with two cycles of
MHT as a result of combinational therapy.

PLGA
PLGA, an FDA approved thermoplastic biopolymer, has also been deployed to generate
injectable DDSs for cancer treatment because of its quick in-situ precipitation in aqueous
environment. For instance, Chen et al., incorporated the iron(III) oxide (Fe3O4)
nanoparticles into a PLGA solution for magnetic-hyperthermia regression of tumors.165
Intratumoral injection of this solution in a breast cancer xenograft mouse model followed
by only single magnetic ablation showed complete disappearance of the tumor after 3
days and without reoccurrence even after 1 month. The same group also developed
another injectable DDS based on PLGA, which MoS2 nanosheets and DOX were
incorporated into the implant for synergistic photothermal and chemotherapy of tumors
(Figure 1-13). 164 Therefore, this implant showed controlled release of DOX in pH- and
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NIR- responsive manner. Furthermore, intratumoral injection of this composite in a breast
cancer tumor xenograft mouse model followed by only one time NIR irradiation (5 min)
led to disappearance of tumor after 7 days and no tumor recurrence was observed within
2 months from the treatment. Lastly, mice treated with PMD+NIR had 100 % of survival
rate over a period of 50 days, which indicated high efficiency of this local synergistic
treatment.
Figure 1-13. Multifunctional PLGA/MoS2/DOX (PMD) oleosol as injectable implant for synergistic

chemo- and hyperthermia tumor therapy. A) Schematic illustration showing in vitro phase
transformation of oleosol, oleosol microstructure, and in vivo dual mechanism of tumor therapy
triggered by NIR irradiation. B) In vivo thermal images of PMD implanted mice after continuous
NIR irradiation for different durations. C) Tumor volume change in mice with different
treatments. D) Survival rate of mice following various treatments. Reprinted from 164, Copyright
(2015), with permission from Wiley-VCH.

56 | P a g e

Table 1-1. Summary of biopolymeric anti-tumor implantable DDSs.

Type of
implant
Casted foam

Type of
biopolymer(s)
Silk

Therapeutic
approach
Chemotherapy
(vincristine +
DOX)

Casted film

Silk

Chemotherapy
(DOX)

MDA-MB-231
breast cancer
mice

Casted gel

Gelatin

BGC-823
gastric cancer
mice

Casted gel

Gelatin

Chemotherapy
(Tet + PTX
loaded in PEGb-PCL NPs )
Chemotherapy
(CDDP loaded
in gelatin/poly
acrylic acid
NPs)

Casted gel

Dextran
Aldehyde +
PAMAM

MDA-MB-231
breast cancer
mice

Casted gel

Dextran
Aldehyde +
PAMAM

Chemotherapy +
Gene therapy
(Dark gold NPs
modified with 5FU and anti
MRP1 DNA
oligonucleotide)
Chemotherapy+
Gene therapy+
Photothermal
therapy (siRNA
loaded in gold
nanospheres and
avastin loaded
in gold
nanorods)

Casted
cylinder

PLA+ PLGA

Chemotherapy
(DOX loaded in
RGD-PPCD
NPs)
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In vivo model
Kelly
neuroblastoma
mice

Results
Significantly
slowed tumor
growth and
prolonged
survival time
Reducing
primary tumor
growth as well
as metastatic
spread
~ 80% reduction
in tumor volume
and weight

Ref
.
26

24

22

Significant
inhibition of
tumor growth,
increased
median survival
time and
survival rate,
enhanced drug
diffusion into
tumor tissue
90% tumor
reduction
following 80%
MRP1 silencing

28

CRC
colon cancer
mice

Complete tumor
remission for
170 days after
tumor resection,
more than 90%
tumor shrinkage
with no tumor
resection

69

C6
Brain cancer
mice

Drug long term
residence in
tumor (45 days),
highest tumor
inhibitory rate
(~61%)
compared to

75

H22 liver
cancer
mice

68

Casted
cylinder

PLGA

Gene therapy
(siRNA)

Panc 1
Pancreatic
cancer
mice

Casted
cylinder

PLGA

Gene therapy
(siRNA) +
systemic
Chemotherapy
(GEM or
FOLFIRINOX)

Pancreatic
ductal
adenocarcinom
a (PDAC)
Phase I and II
clinical trials

Casted thin
layer

PLGA

Chemotherapy
(PTX)

PDAC
mice

Casted
needleshaped
conical
implant

PCL

Chemotherapy
(5-FU)

Breast cancer
mice

Casted wafer

PCPP-SA

Anti-neoplastic
agent (3-BrPA
or DCA)

9L
Gliosarcoma
rat

Casted wafer

PCPP-SA

Adjuvant
chemotherapy
(BCNU) +
radiation
therapy

Glioma
Phase III
clinical trial
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control group
(~11%)
Retarded tumor
growth,
considerably
prolonged the
median survival
time (~100
days)
From 12
patients non
showed tumor
progression,
tmuor marker
CA 19-9 was
decreased in 70
% of patients,
18 months
survival was
38.5%
Up to 12-fold
increase in
suppression of
tumor growth,
28 days increase
in median
survival time
Higher regional
drug
concentration,
enhanced tumor
growth
inhibition
Increased
survival time
(120 days),
increased
survival rate
(~25% for 3BrPA loaded
samples and
15% for DCA
loaded samples)
Significant
increase in
survival time
(13.9 months)
and 1-year
survival rates
(59.2%)

94

95

31

107

110

Casted film

PGC-C18

Adjuvant
chemotherapy
(PTX)

CS-1
Leukemia
mice

Electrospun
nanofiber

PLA

Chemotherapy
(DOX)

EMT6
Liver cancer
mice

Electrospun
nanofiber

PLA

Anti-neoplastic
agent (DCA)

U14
Cervical
cancer
mice

Electrospun
asymmetric
multilayer
nanofibers

PLA

Adjuvant
chemotherapy
(Oxa or OxCy)

H22
Liver cancer
mice

Electrospun
nanofiber

PLGA

Chemotherapy
(BCNU+
irinotecan +
cisplatin)

C6
Glioma
rat

Electrospun
nanofiber

PCL+ Gelatin

H22
Liver cancer
mice

Electrospun
nanofiber

PCL+ Gelatin

Chemotherapy
(DOX loaded in
Cu9S5@mSiO2
NPs) +
Photothermal
therapy
Chemotherapy
(DOX loaded in
UCNPS) + Antiinflammatory
drug
(indomethaci)
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H22
Liver cancer
mice

Much lower
recurrence rate
(17%) compared
to IV PTX
treated group
(89%), longer
median overall
survival (81
days)
Significant
inhibition of
tumor growth,
increased
median survival
time (38 days)
Dramatic
shrinkage of
tumor volume
(96%), 89%
necrosis in
tumor tissue
Tumor
recurrence was
significantly
retarded,
survival time
was markedly
prolonged (40
days)
Much lower
tumor volume
after 16 days,
longer median
survival time,
higher survival
rate
95% mean
tumor
inhibition, no
negative effect
on non-target
organs
fluorescence/ma
gnetic resonance
dual-model
imaging
,Highest tumor
inhibition rate
(96%), complete
healing of
surgical wound

73

33

137

41

142

144

35

Electrospun
core-shell
nanofibers

Gelatin (shell)
+ PVA (core)

Chemotherapy
(core containing
DOX loaded in
FM micelles)

4T1
Breast cancer
mice

3D printed
patch

PLGA+ PCL

Chemotherapy
(5-FU)

Mia-Paca-2
Pancreatic
cancer
mice

3D printed
scaffold

PCL

Chemotherapy
(DOX loaded in
a clay matrix
coating)

MDA-MB-231
Breast cancer
mice

Injectable
thermosensitive gel

PECT
copolymer

Chemotherapy
(DOX)

Bcap-37
Breast cancer
mice

Injectable
thermosensitive gel

PLGA-PEGPLGA
copolymer

Chemotherapy
(DOX)

H22
Liver cancer
mice

Injectable
thermosensitive gel

PECE
copolymer

Adjuvant
Chemotherapy
(PTX)

4T1
Breast cancer
mice
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Delayed in vitro
release of DOX,
low systemic
drug exposure to
normal tissues,
Highest tumor
growth
inhibition rate,
Highest survival
rate (~30%) and
prolonged
survival time
(42 days)
Significant
decrease in
tumor volume
after 30 days
(~90%), much
lower systemic
toxicity
Higher and
prolonged
release of
DOXin the
treatment area,
higher tumor
growth
inhibition, lower
systemic
toxicity
Much higher
intratumoral
concentration of
DOX, Tumor
growth
inhibition
efficiency of
75%, 100%
survival rate for
29 days
Significant
inhibition of
tumor growth,
Highest necrosis
of tumor area

131

Lowest
locoregional
tumor
recurrence rate
(9.1%), Largest
median overall

49

29

30

43

184

survival (67
days), Lowest
lung metastases
rate (54.6%)
Injectable
thermosensitive gel

PELG-PEGPELG
copolymer

Chemotherapy
(PTX)

HepG2
Liver cancer
mice

Injectable insitu
crosslinkable
gel

4-arm-PEGSH + PDA
NPs

Chemotherapy
(SN-38)+
Photothermal
therapy

PC-9
Lung cancer
mice

Injectable insitu
crosslinkable
gel

Heparinmodified PEG

Chemotherapy
(DOX)

MDA-MB-231
Breast cancer
mice

Injectable insitu
crosslinkable
gel

nucleobaseterminated
PEG + α-CD

Chemotherapy
(DOX)

U14
Cervical
cancer
mice

Injectable insitu
crosslinkable
gel

PEG-DMA
(in-

Chemotherapy
(M-TMZ)

U87MG
Glioblastoma
mice

Injectable
thermosensitive gel

HDIPF127+HA

Chemotherapy
(DOX)

MCF-7
Breast cancer
mice
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Major
suppression of
tumor
progression,
Highest antitumor efficacy,
Low systemic
toxicity
No foreign body
reaction,
Complete
inhibition of
tumor growth,
Minimal
systemic
toxicity
High affinity
towards DOX,
Significant
reduction in
tumor burden,
Substantial
reduction in
brain, liver and
bone metastasis
Significantly
restricted the
tumor growth,
No fluctuation
in body weight
Drastic decrease
in tumor weight,
High apoptosis
at the centre of
the tumor
Caused no
chronic
inflammation,
Up to 70%
decrease in
tumor volume,
High survival
percentage
(~90%) after 28
days

192

170

51

52

169

234

Injectable insitu
crosslinkable
gel

Collagen+ PEI

Gene therapy
(siRNA)

SGC-7901
Gastric cancer
mice

Injectable insitu
crosslinkable
gel

Collagen

Photothermal
therapy
(Au NPs)+
Photodynamic
therapy
(TMPyP)

MCF-7
Breast cancer
mice

Injectable
thermosensitive gel

Chitosan+ GP

Chemotherapy
(LipDOX)

SMMC-7721
Liver cancer
mice

Injectable insitu
crosslinkable
gel

Succinated
chitosan+
Oxidized
alginate

Chemotherapy
(DOX)

MDA-MB-231
Breast cancer
mice

Injectable insitu
crosslinkable
gel

HA-ADH +
HA-CHO

Chemotheray
(PTX)

SKOV-3
Ovarian cancer
mice
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Highest
inhibitory effect
of tumor
growth,
Significant
down regulation
of cyclin D1,
Significant
increase in P21
expression,
Remarkable
decrease in
PCNA
expression
Tumor
regression (up to
80%) and
inhibition of
tumor growth,
Remarkable
inhibition of
tumor
recurrence (only
1 mouse among
6 animals)
Inhibition of
tumor growth
and further
shrinkage of
tumor volume
(0.6 fold),
Improved
survival rate
(87.5 %)
Complete
suppression of
tumor growth
over 17 days,
Elevated level
of tumor cell
apoptosis
Increase in
intraperitoneal
retention of
PTX, Low
efficiency in
decreasing
tumor burden
due to limited
dissolution of
PTX

213

56

222

167

225

Injectable insitu
crosslinkable
gel

HA-ADH +
HA-CHO

Chemotherapy
(platinum NPs)

SKOV-3
Ovarian cancer
mice

Injectable insitu
crosslinkable
gel

Alginate

Photothermal
therapy (Pt NPs
encapsulated in
PAMAM
dendrimer)

PC-9
Lung cancer
mice

Injectable
thermosensitive gel

poly(organoph
osphazene)

Magnetic
hyperthermia
(superparamagn
etic iron oxide
NPs)

U-87 MG
Brain cancer
mice

Injectable
thermosensitive gel

poly(organoph
osphazene)

Magnetic
hyperthermia
(superparamagn
etic iron oxide
NPs) + Gene
therapy
(TRAIL)

U-87 MG
Brain cancer
mice

Injectable
oleosol

PLGA

Chemotherapy
(DOX)+
Photothermal
therapy (MoS2
nanosheest)

4T1
Breast cancer
mice
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Inferior antitumor efficacy
compared to
injected
cisplatin, Slight
increase in
tumor burden
due to protumorigenic
effect of HA.
Efficient
suppression of
tumor growth,
Remarkable
increase in
apoptotic tumor
cells
Significant
eradiation of
tumor by four
cycles of
Magnetic
hyperthermia,
Only 2 mice
(out of 5) had
small recurrence
of tumor at day
22
Significant
inhibition of
tumor growth
(V/Vinitia =1.6)
by
combinational
therapy for two
cycles, 100%
survival rate

Complete
ablation of
tumor mass after
7 days of
treatment,
Complete
healing of
injection scar,
100% survival
rate for 50 days

55

53

50

233

164

1.3.2. Conclusion
Despite a steady decrease in cancer mortality incidents over last few decades, the current
standards of care in cancer treatment encounter major obstacles in efficiently treating the
disease. Therefore, bio-polymeric implantable DDSs have been designed to overcome
hurdles faced by conventional therapies, by means of local delivery of therapeutic agents
directly to the tumor site and consequently they have shown immense promise in treating
malignant tumors (or preventing the tumor recurrence) in animal models as well as some
clinical cases. Not only do these DDSs possess intriguing properties (such as
biocompatibility, biodegradability and trackability) but they are also capable of delivering
a variety of anti-cancer therapeutic agents while exerting precise spatiotemporal control
over their release. A variety of biopolymers were employed for fabrication of such DDSs,
however natural hydrogels such alginate seems to have better biocompatibility and allow
for a variety of chemical modifications to their structure. Moreover, among all fabricated
geometries, coaxial structures with biopolymer-drug affinity features has never been
studied for the purpose of cancer drug delivery. Consequently, in this thesis we aim to
make coaxial hydrogel structures for cancer drug delivery, where the core section of these
structures is comprised of dopamine-modified alginate along with chemotherapeutic
drugs to confer affinity-controlled release, while a methacrylated-alginate is used as the
shell composition to provide the controlled diffusion barrier. To fabricate these coaxial
hydrogel structures we have specifically used two different fabrication technologies
including (i) wet-spinning: as it facilitates high throughput and low cost production of
coaxial fibers, (ii) 3D-printing: as it allows fast prdoction of patches with highly
complicated geometries.
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1.3.3. Thesis Objectives
This thesis aims to develop coaxial hydrogel structures with drug-affinity features to
locally deliver therapeutics to cancer tumors. To this end, it was hypothesized that
employment of dopamine-modified alginate in the core along with chemotherapeutic
agents would confer affinity-controlled release, while employment of methacrylatedalginate as the shell would provide a diffusion barrier for controlled release of the drugs.
Consequently, dopamine-modified alginate and methacrylate-alginate were successfully
synthesized and characterized using various techniques such as Fourier-transform
infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (H NMR).
Accordingly, rheological properties of the solutions made from synthesized polymers
were assessed, and subsequently coaxial hydrogel fibers were made using a wet-spinning
technoque. Two different chemotherapeutic drugs (Gemcitabine and Doxorubicin) where
loaded in the core section of these coaxial fibers, either separately or simulataneously
together. As a result, specific interactions of these two drugs with dopamine-modified
alginate (core element) were assessed using zeta-potential measurements. Microstructural
morphology (scanning electron microscopy; SEM), mechanical properties (both in static
and dynamic conditions), swelling behaviour, and degradation of the fibers were
evaluated. In vitro drug relese from the fibers were examined, and then they have been
tested in vitro on two pancreatic cancer cell lines. Also, in vivo peformance of these drugloaded coaxial hydrogel fibers were assessed in mice with subcutanous pancreatic cancer
tumors.

Multimodal cancer therapies, such as chemo-photothermal therapy, are yet another
therapeutic aspect that has been explored using biopolymeric local drug delivery systems
to achieve a high tumor-synergistic therapy . Particularly, use of these systems for chemo65 | P a g e

photothermal therapy implies that not only these systems must allow sustained release of
the drug, but also they should generate heat instigated by an external stimuli.
Consequently, with the aim of establishing a suitable implantable platform for multimodal
chemo-photothermal cancer therapy, for the first time a coaxial composite hydrogel fiber
was fabricated using a wet-spinning method. Particularly, the core-section of these fibers
(chemo-compartment)

contained

dopamine-modified

alginate

along

with

a

chemotherapeutic drug (Doxorubicin), while their shell section (phothothermal
compartment) was composed of UV-crosslinkable methacrylate-modified algine together
with Cu2−xSe Nanoparticles. It was hypothesized that specific biopolymeric composition
of these fibers along with their corresponding core-shell geometry would allow controlled
release of Doxorubicin (loaded in the core), while the Cu2−xSe nanoparticles (loaded in
the shell) would facilitate heat generation upon near infra-red (NIR) laser irradiation.
Accordingly, various physiochemical properties of the composite fibers was assessed
including their microstructural morphology (scanning electron microscopy; SEM),
elemental composition (Energy-dispersive X-ray spectroscopy; EDX), chemical
composition and crystalline phase (Fourier-transform infrared spectroscopy; FTIR, X-ray
diffractrometry; XRD), nanoparticle content (thermogravimetric analysis), mechanical
properties (both in static and dynamic conditions), and their swelling behaviour.
Furthermore, in vitro Doxorubicin release from the fibers was assessed. Also, the
photothermal effect of the fibers upon NIR laser irradiation was assessed. Next, the fibers
were tested in vitro agaisnt breast cancer cells, in presence or absence of NIR laser. Lastly,
the fibers were tested in vivo in mice with subcutaneous breast cancer tumors to evaluate
their synergistic chemo-photothermal therapy.

Various fabrication technologies were employed to facilitate the making of biopolymeric
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drug delivery systems, while each imposed their own set of advantages and
disadvantages. Among them 3D printing technologies offer considerable advantages
including reproducibility, and ability to design geometrically complex shapes. In
addition, 3D printing is compatible with a variety of biopolymers including hydrogels
such as alginate. As a result, with the purpose of fabricating a suitable platform for
prolonged delivery of Gemcitabine (a chemotherapeutic drug), a novel 3D printed coaxial
hydrogel patch was developed. Particularly, the core-section of these patches contained
dopamine-modified alginate methacrylate loaded with Gemcitabine, while their shell
section was solely comprised of alginate methacrylate. Subsequently, these patches were
further modified with CaCO3 cross linker and a PLA coating to facilitate prolonged
release of the drug. Accordingly, different properties of the fabricated patches were
characterized including their microstructural morphology (scanning electron microscopy;
SEM), mechanical properties (in both static and dynamic conditions), and their swelling
behaviour. In vitro Gemcitabine release from different types of 3D printed coaxial patches
was assessed. Lastly, to assess the therapeutic effect of Gemcitabine-loaded 3D printed
coaxial patches they were tested in vitro against two pancreatic cancer cell lines.
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Chapter 2
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biofibers: making of a robust and efficacious depot for cancer drug delivery. Journal of
Materials Chemistry B, 2020.
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2. Coaxial mussel-inspired biofibers: Making of a robust
and efficacious depot for cancer drug delivery

2.1.

Introduction

Despite remarkable improvements in cancer treatments resulting in extended survival,
this disease still remains one of the major causes of death worldwide 174. Although current
standards of care that involve the use of chemotherapy provide encouraging results, they
still cause severe systemic toxicity and also fail in preventing recurrence of the disease 4,
235

. Tremendous progress has been made in design of bio-polymeric implantable drug

delivery systems for cancer treatment

236

, among which hydrogels have emerged as

promising platforms owing to their inherent biocompatibility, tunable physical properties
and controllable degradability

237-238

. Hydrogels are water-swollen hydrophilic polymer

networks, held together by physical and/or chemical cross-links, and have been
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successfully used as depots to protect and facilitate controlled release of drugs at the target
sites 239-240. Controlled drug release profiles attainable with these systems are dictated by
factors such as porosity, network swelling/degradation, the size of the molecule to be
released and drug-polymer interactions 13, 238.
Nevertheless, methods for incorporation of drugs into hydrogels generally fall into three
categories: (I) physical encapsulation, where drugs are simply entrapped within the crosslinked polymer network; (II) covalent conjugation, where drugs are covalently bound to
the polymer network; and (III) affinity binding, where hydrophobic, ionic, or hydrogen
bonding are utilized to retain drugs within the hydrogel network

241

. Though, physical

encapsulation renders a simplistic approach for designing drug loaded hydrogels, these
systems often face uncontrolled drug diffusion out of the bulk hydrogel immediately after
formation (burst release)

242

. On the other hand, covalent conjugation of drugs to the

hydrogel network yields a much slower drug release profile, where release is facilitated
by cleavage of the covalent linkage or by complete hydrogel degradation 243. However,
this strategy often involves chemical modification of drugs which not only can impact
their FDA approval but could also alter their biological activity

244

. Along those lines,

affinity-based drug delivery has emerged as an alternative to achieve controlled release
of small-molecule drugs, without compromising their activity

245

. Affinity-controlled

release is usually achieved by immobilizing a drug-binding ligand within a hydrogel
matrix. Based on the type of drug molecule, a variety of ligands have been explored for
affinity-controlled release, this includes heparin-like moieties, binding peptides,
cyclodextrins, and thiols

246-248

. Recently, inspired by marine mussels, researchers have

utilized 3, 4-dihydroxyphenylalanine (DOPA) to confer affinity-controlled release to
hydrogels 249-252. The catechol group of dopamine is shown to be capable of adhering to
drug molecules by using a variety of mechanisms including hydrogen bonds, π-π
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interactions, cation-π interactions and dynamic covalent bonds 253-255. For instance, Han
et al., took advantage of interaction of polydopamine component with the proteins, via
interaction with amine or thiol groups of the proteins, to achieve sustained release of
epidermal growth factor from polyacrylamide-clay-polydopamine hydrogel

251

. In

another study, Wang et al., developed a polydopamine nanoparticle-knotted
poly(ethylene

glycol)

hydrogel

which

successfully

released

the

7-ethyl-10-

hydroxycamptothecin (SN38- a chemotherapeutic drug) in a controlled manner, mainly
due to strong π−π stacking interaction

249

. Nevertheless, in the context of hydrogels for

cancer drug delivery, dopamine has rarely been used to confer affinity-controlled release
of chemotherapeutic drugs on hydrogels.
Along the same lines, in this study, with the aim of developing a suitable hydrogel
platform for local delivery of anti-cancer drugs, the well-established wet-spinning method
was used to engineer novel coaxial biofibers. Specifically, dopamine-modified alginate
hydrogel, along with the chemotherapeutic drugs, was used as the main core component
to confer affinity-controlled release, while a methacrylated-alginate hydrogel was used as
the shell composition to provide the controlled diffusion barrier (Figure 2-1).
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Figure 2-1. Schematic illustration of coaxial mussel-inspired biofibers as 3D implantable textiles for
local delivery of anti-cancer drug

Here we investigated the use of two anti-cancer drugs, Gemcitabine (GEM) and
Doxorubicin (DOX), as these drugs are in routine clinical use solely or in combination
with other drugs, to control the progression of cancer

256

. It was demonstrated that the

proposed hierarchical structure enabled the development of biocompatible hydrogel
fibers (as indicated by both in vitro and in vivo experiments) with controlled swelling,
and enhanced mechanical properties (as indicated by both static and dynamic tension
tests), when compared to single fibers made from pure alginate. Particularly, it was
observed that these coaxial fibers were capable of releasing the two drugs in a slower
manner, when compared to single fibers made from pure alginate, which was partly
attributed to stronger interactions of drugs with dopamine-modified alginate (the core
element of coaxial fibers) as observed from zeta-potential measurements. Remarkably, it
was shown that drug-loaded fibers, particularly Doxorubicin-containing fibers, had
71 | P a g e

higher anticancer effect in vivo compared to systemic injection of equivalent dosage of
the drugs. Also, simultaneous loading of the two drugs in the coaxial fibers (DOX and
GEM) also inhibited the growth of the tumors in animal models. Overall, these
biocompatible and robust coaxial hydrogel fibers may be further used as neoadjuvant or
adjuvant therapies for controlled delivery of chemotherapeutic drugs locally to the tumor
sites with the aim of suppressing cancer growth, with reduced side effects.

2.2.

Experimental section

2.2.1. Materials
Alginic

acid

sodium

salt

from

brown

dimethylaminopropyl)-Nˊ-ethylcarbodiimide

algae

(medium

hydrochloride

viscosity),

N-(3-

(≥99.0%),

N-

hydroxysuccinimide, dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%),
methacrylic anhydride, and IRAGACURE D-2959 were purchased from Sigma Aldrich.
Calcium chloride (CaCl2) and sodium hydroxide (NaOH) were purchased from ChemSupply. Doxorubicin hydrochloride and Gemcitabine hydrochloride were purchased from
Focus Bioscience. Simulated body fluid (SBF) was prepared as explained before. 19 D2O
(100% - CIL) was supplied by Novachem. The MIA-PaCa-2 human pancreatic
adenocarcinoma cell was kindly supplied by Gillian Lehrbach from the Garvan Institute
of Medical Research (Aust). The PANC-1 human pancreatic adenocarcinoma cell line
was purchased from ATCC. The CellTiter 96® Aqueous One Solution Cell Proliferation
Assay (MTS) was from purchased from Promega, Australia. DMEM-High glucose media
and foetal calf serum (FCS) were purchased from Invitrogen, USA. Trypsin/EDTA was
purchased from Life Technologies, Australia.
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2.2.2. Synthesis and characterization of alginate-dopamine
Alginate-dopamine with different substitution degrees was synthesized via carbodiimide
chemistry.257 Briefly, 1 g of alginic acid (5 mmol in terms of repeating unit) was dissolved
in 100 ml of 0.1 M MES buffer with pH of 5.6. EDC and NHS were separately dissolved
in 2 ml of MES buffer (1.25 and 2.5 mmol for 25% and 50%, respectively) and
subsequently added to the alginic acid solution. while the reaction were allowed to
continue for 30 min. Dopamine hydrochloride (at equal concentration to EDC and NHS)
was separately dissolved in 2 ml of MES buffer and added to the mixture subsequently.
The reaction were allowed to happen for 1 hr under nitrogen flushing. Afterwards the
solution was dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD) for 7 days
against acidic water (pH of 6) and subsequently precipitated in ethanol. The precipitated
polymers were next lyophilized using a freeze-dryer. Incorporation of dopamine into
alginate was further confirmed using FTIR (Shimadzu IRPrestige-21 infrared
spectrometer) and HNMR (Bruker 400 MHz) spectroscopy.

2.2.3. Synthesis and characterization of alginate-methacrylate
Alginate-methacrylate was synthesized by using methacrylic anhydride.258 Briefly, 3 g of
alginic acid was dissolved in 300 ml of distilled water (1% w/v) to which 24 ml of
methacrylic anhydride (8% v/v) was added and the pH was maintained at 8 for 6 hrs using
5.0 M NaOH solution. Afterwards, the solution was dialyzed (spectra/ por membrane
tubing; MWCO 12–14 kD) for 7 days and precipitated in ethanol followed by freezedrying. Grafting of methacrylate groups onto the alginate backbone was further confirmed
using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR (Bruker 400
MHz) spectroscopy.
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2.2.4. Rheology
All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm,
DYMAX BlueWave 75).

2.2.5. Fabrication of dye loaded fibers
After synthesis of alginate-dopamine and alginate-methacrylate, we have fabricated the
dye-loaded (fluorescein sodium salt) fibers to evaluate the effect of dopamine grafting on
subsequent release and encapsulation of the dye. Accordingly, 3% (w/v) of pure alginate,
alginate-dopamine 25% and alginate-dopamine 50%, were separately dissolved in
distilled water. Next 2 mM of fluorescein sodium salt were added to each solution to
prepare the spinning mixtures. The single and core-shell fibers were fabricated using a
coagulation bath of H2O/Ethanol (4:1) containing 2% CaCl2 (w/v). The single fibers were
fabricated by simply extruding the dye-containing solutions (50 ml/hr) into the
coagulation bath using a blunt needle (gauge 19). On the other hand, the core-shell fibers
were fabricated using a novel coaxial spinneret with two input ports.259 Alginatedopamine/alginate-methacrylate solution (75/25 w/w, 3% w/v, containing 0.05%
IRAGACURE D-2959) containing the dye (2 mM) was extruded (50 ml/hr) through the
centre outlet nozzle (gauge 19) into the coagulation bath, while alginate-methacrylate
solution (3% w/v, containing 0.05% IRAGACURE D-2959) was simultaneously being
extruded (50 ml/hr) as the sheath of the fiber (gauge 15). Right after exiting the
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coagulation bath, the core-shell fiber were irradiated with UV light (365 nm, DYMAX
BlueWave 75) as they were being collected on the rotating drum. To measure the dye
release from the fibers, 30 cm of fibers were immersed in 1 ml of SBF solution and the
supernatant was collected at certain time points and replaced with fresh SBF. Eventually
these supernatant were tested using UV spectrometer (Shimadzu, UV-1800) and the
unknown concentrations were revealed using a calibration curve achieved previously.

2.2.6. Fabrication of drug loaded fibers
Drug loaded fibers were fabricated in the same manner as dye loaded ones with minor
differences. Single alginate drug-loaded fibers were fabricated by initially dissolving the
drug in distilled water (2 mM for DOX or 50 mM for GEM), next alginate was dissolved
in the mixture at a 3% (w/v) concentration. Subsequently, the prepared mixture was
extruded into the coagulation bath using a blunt needle. For core-shell fibers, the drugs (2
mM for DOX or 50 mM for GEM) were first dissolved in distilled water, to which 3%
(w/v) of alginate-dopamine/alginate-methacrylate mixture (75/25% w/w) and 0.05%
(w/v) IRAGACURE D-2959 were added (this solution was used as the core input).
Separately, alginate-methacrylate was dissolved in distilled water (3% w/v) and 0.05%
(w/v) IRAGACURE D-2959 was added to this mixture (this solution was used as the core
input). These two solutions were simultaneously extruded through the coaxial nozzle into
the coagulation bath and the fibers were subsequently irradiated with UV light (365 nm,
DYMAX BlueWave 75) as they were collecting on the rotating drum. For dual-loaded
fibers, the core constituent was loaded with 2 mM of DOX while the shell constituent was
loaded with 50 mM of GEM. Of note, for the sole purpose of drug release studies, we
have fabricated another type of core-shell fibers which is indicated as CS •. In these fibers
the core only contained (3% w/v) alginate-methacrylate + 0.05% (w/v) IRAGACURE D75 | P a g e

2959 + the drugs (2 mM for DOX or 50 mM for GEM), while the shell only contained
(3% w/v) alginate-methacrylate + 0.05% (w/v) IRAGACURE D-2959.

2.2.7. Characterization of fibers
The morphology of fibers were examined using a JSM-6490LV SEM and Leica M205A
microscope. For SEM imaging (in dry or wet state), the fibers were cut into small pieces
and inserted into special sample holders. The sample holder containing the mounted fibers
was then immersed into liquid nitrogen for about 45 s. Next, the sample holder was then
quickly transferred to the LVSEM for examination. SEM images were taken in high
vacuum mode at 15 kV operating voltage and a spot size setting of 60. The swelling
properties of the hydrogel fibers were determined by examining their water uptake
capacity. The hydrogel fibers were incubated in simulated body fluid (SBF) at 37°C and
allowed to fully swell. The swelling ratio was calculated using the following equation:
(Ws – Wd)/Wd, where Ws represents the weight of the swollen hydrogel fibers and Wd
represents the weight of the dried hydrogel fibers at the beginning. The degradation rate
of the fibers was measured by initially freeze-drying the fibers and subsequently weighing
them (Wi). Next, the fibers were immersed in 5 ml of SBF at 37°C for in vitro degradation
testing. The SBF was replaced every three days. At predetermined time points, the
samples were removed, rinsed with distilled water, and lyophilized and weighed (Wd).
The percent mass loss was calculated using the equation (Wi-Wd)/Wi x 100. The static
mechanical properties of fibers were assessed using a mechanical tester (EZ-L tester from
Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry and wet fibers,
respectively. The dynamic mechanical properties of fibers was evaluated using a dynamic
mechanical analysis (DMA 242 E Artemis, NETZSCH). Accordingly, by using a tension
clamp the samples were exposed to a constant strain (0.1 %) of increasing frequencies in
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the range of 0.1 to 10 Hz for 30 min, subsequently storage and loss modulus were recorded
and Tan delta values were measured as a ratio of loss modulus to storage modulus.
Furthermore, hydrodynamic diameter, poly-dispersity index (PDI), and zeta potential of
various formulations were measured using a Zetasizer Nano ZS (Malvern Panalytical,
UK). Accordingly, prepolymer solutions (with similar drug/polymer ratio as in fibers)
were diluted to 100 ng mL−1 in ultrapure water for analysis of the zeta potential and
hydrodynamic diameter, and poly-dispersity index (PDI).

2.2.8. Release studies from drug loaded fibers
To measure the drug release from the fibers (either DOX or GEM), 30 cm of drug loaded
fibers were immersed in 1 ml of SBF solution and the supernatant was collected at certain
time points and replaced with fresh SBF. For measuring the DOX release, fluorescence
properties of DOX was measured (excitation 485 nm, emission 520 nm) using FLUOstar
OPTIMA microplate reader. The absorbance values were eventually converted to
concentrations using a previously achieved calibration curve for DOX. For measuring the
GEM release, a high performance liquid chromatography (HPLC, Agilent 1260 infinity)
was used. Briefly, Samples were filtered through a 0.2 μm syringe membrane filter unit
before being injected (10 μL) onto a ZORBAX Eclipse Plus column (4.6 × 100 mm, 5
μm particle size). Using an isocratic elution with a water/acetonitrile (95/5), draw and
eject speed of 200 μL/min, pressure 300 bar, Gemcitabine was detected with the UVVisible detector at 272 nm. The absorption values were converted to concentrations using
a previously observed calibration curve. The release results were plotted as mean value
of three repeated tests.
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2.2.9. In vitro cell studies
All cell lines were authenticated using short tandem repeat (STR) profiling at the Garvan
Institute of Medical Research. Cells (MIA-PaCa-2 or PANC-1) were cultured in DMEMHigh glucose media containing 10% fetal calf serum (FCS) at 37 °C, 95% humidity and
5% CO2 in a Heracell incubator (Kendro Laboratory Products, Germany). When 80%
confluence was reached, cells were detached by incubation with 5 mM trypsin/EDTA and
harvested after centrifugation in a Heraeus Megafuge 1.0 (Thermo Scientific, USA) at
1200 rpm for 5 min at RT. Cells were resuspended in media, and viable cells counted
using a hemocytometer and trypan blue staining. Cells were confirmed free of
mycoplasma contamination. MIA-Paca-2 and Panc-1 cells were seeded (8 × 104, 6 × 104,
and 4 × 104 cells/well for 24, 48, and 72 hr time points, respectively) in 24-well flat
bottomed plates in complete media (1 mL) containing 1% penicillin/streptomycin and
kept in the incubator for 24 h prior to addition of empty or drug loaded fibers (1 cm
lengths). After each time point the fibers were removed from the wells and subsequently
40 µL of MTS agent was added and allowed to react with the cells for 3 hrs. The
absorption of each solution was measured at 490 nm on a microplate reader (SPECTRA
max, PLUS). For live cell staining, at each time point the media was removed from the
wells and subsequently the cells were washed with PBS. Next 500 µL of PBS solution
(Containing 2.5 µL of Calcein AM and 1 µL of Propidium Iodide; Sigma Aldrich) was
added to the wells and the plates were incubated for 15 min, after which the staining
mixture was removed from the wells and replaced with fresh PBS. Immediately after the
IncuCyte ZOOM system (Essen BioScience, USA) at 10 × magnification, with green (live
cells) and red (dead cells) filters, was used to image the cells.
To confirm the long-term therapeutic effect on inhibition of cancer cell growth, the effect
of the medium supernatant of the drug loaded or empty fiber on the viability of the human
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pancreatic cancer cell line, MIA PaCa-2, PANC-1, and BxPC3 cell lines, was assessed
using a cell counting kit-8 method (Sigma, St. Louis, MO, USA) based on the
manufacturer’s guideline. The BxPC3 cells were cultured in DMEM (Gibco), while
PANC-1 and MIA-PaCa-2 cells were cultured in RPMI-1640 medium (Gibco)
supplemented with 10% v/v fetal bovine serum (Gibco), 100 U/mL penicillin, and 100
μg/mL streptomycin (Invitrogen) at 37 °C in 5% CO2 in a humidified incubator. Cells
were plated at a density of 3 × 103 cells per well in a 96-well culture plate and incubated
for 24 h before drug treatment. To assess the therapeutic effect of the drug released from
the fibers, the fibers (1 cm) incubated in complete culture media at 37 °C in 5% CO2 in
a humidified incubator and then the supernatant was collected at determined intervals (1, 5-, 8-, 11-, 14-, 17-, and 20-days). At day 1 after cell seeding, we changed the media to
corresponding supernatants. Cell viability at each time point was determined using a cell
counting kit-8 assay (CCK-8; Sigma Aldrich) according to the manufacturer’s guideline.

2.2.10. In vivo Studies
To confirm the in vivo effects of the CS-fibers, a subcutaneous tumor model was
established using MIA-PaCa-2 and BxPC3-Luc cells. MIA-PaCa-2 and BxPC-3-Luc cells
were harvested (2×106) and resuspended in PBS mixed with Matrigel (1:1 ratio). To
prepare the xenograft tumors were developed in 6-week-old male nude mice by injecting
MIA-PaCa-2 and BxPC-3-Luc cells subcutaneously into the right posterior flank of mice,
respectively. All mouse experiments within the guidelines of the protocol were reviewed
by the Institutional Animal Care and Use Committee of Asan Institute for Life Science
(IRB No. 2013-0939). Tumor growth was recorded twice a week in three dimensions
using a digital caliper. Tumor volume was calculated as [(length × width × height) / 2]
and reported in mm3. Tumors were grown in for 11-12 days until average tumor volume
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100mm3. Mice were randomly divided into 4 groups at day 11 or 12 after subcutaneous
cancer-cell inoculation; Group I: implanted with a drug-free CS fibers; Group II:
implanted with Gemcitabine loaded CS fibers; Group III: implanted with Doxorubicin
loaded CS fibers; and Group IV: implanted with Gemcitabine and Doxorubicin loaded
CS fibers. For MIA-PaCa-2 tumor bearing mice three extra groups were added where
equivalent dose of I) Doxorubicin or II) Gemcitabine or III) dual drugs
(Doxorubicin+Gemcitabine) in saline solution were once injected into tail vein of
animals. All experimental groups started with n=6 mice at the time of treatment initiation.
To insert the CS fibers in the mouse, CS fibers (12mg each) were cut into 5mm length.
The CS fibers were sterilized in 70% alcohol solution and then washed in the PBS solution
twice. After washing, the fibers have adhesiveness. Wetted fibers were directly attached
under the solid tumor. Tumor growth was observed over a period of 2 weeks. The
therapeutic effect and anticancer activity of local drug delivery were determined by tumor
volume and tumor weight change. Also, tumor growth was estimated using an in vivo
imaging system (IVIS) of luciferase transduced BxPC-3 cell lines. The BxPC-3-Luc cells
used in this experiment expressed a bioluminescent signal, and the correlation between
cell numbers and bioluminescent signals was confirmed before the experiment.

2.2.11. Optical imaging of the subcutaneous pancreatic tumor
Mice were intraperitoneally injected with D-luciferin (0.3 mg; Perkin Elmer Inc.). Whole
body luminescence imaging with an IVIS Spectrum (Caliper Inc., Alameda, CA) was
performed every 2 minutes until radiance values reached the maximum. The region of the
interested (ROI) level was measured with the radiance (photons/s/cm2/sr) using an
analysis program, Living Image 4.4 (Caliper Life Sciences, PerkinElmer Inc.).
Immunohistochemical staining: After sacrificing the mice at day 14, the tumors were
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removed and fixed in 4% neutral buffered paraformaldehyde and embedded in paraffin.
Paraffin blocks were cut into 4 µm sections and were reviewed histologically after
hematoxylin and eosin staining. Paraffin sections were deparaffinized and then
rehydrated. After microwave antigen retrieval, non-specific binding sites were blocked
with PBS containing 10% normal goat serum. The sections were further incubated with
the primary antibodies against Ki-67 (Dako, Glostrup, Denmark). The samples were
mounted using Prolong Gold antifade mountant with DAPI (Thermo Fisher Scientific,
Massachusetts, USA). Images were obtained using an EVOS-fluorescence microscope
(Thermo Fisher Scientific, Massachusetts, USA).

2.2.12. In vivo toxicity
Retro-orbital blood collection was performed for hematology determinations in tubes
with anticoagulants (EDTA-2 K) at day 3 and 14. Hematology determinations included
white-blood-cell (WBC) count and differential leucocyte count (neutrophils,
lymphocytes, monocytes) using an Advia 120 Hematology Analyzer (Bayer Healthcare,
Myerstown, PA, USA).

2.2.13. Statistical analysis
Statistical significance was determined using a two-way ANOVA with a Sidak post-test
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P =
0.0001. Values are reported as the average ± standard deviation.

81 | P a g e

2.3.

Results and Discussion

2.3.1. Chemical characterization of polymers
For coaxial fiber fabrication, we first synthesized alginate-dopamine (theoretical
substitution degree of 50 % - in terms of alginate repeating units) using standard
carbodiimide chemistry 260. We then synthesized alginate-methacrylate using methacrylic
anhydride

261

. Fourier-transform infrared spectroscopy (FTIR) and proton nuclear

magnetic resonance (1H NMR) were employed to investigate successful synthesis of
alginate-dopamine and alginate-methacrylate. Accordingly, FTIR spectrum of both
alginate-dopamine and alginate-methacrylate (Figure 2-S1a, supporting information)
showed the characteristic peaks of alginate associated with C-O stretching vibration (1030
cm-1), COO- symmetric and asymmetric stretching vibration (1415 and 1600 cm-1,
respectively), and –OH stretching vibrations (3325 cm-1). More specifically, alginatedopamine spectrum showed appearance of peaks at 1544 cm–1, and 1220 cm–1 assigned
to the N–H deformation and C–N stretching vibrations

262-263

. In addition, significant

reduction in intensity of COO- bands (1415 and 1600 cm-1) further indicated the
successful attachment of dopamine to the alginate back bone via carbodiimide chemistry.
Successful synthesis of alginate-dopamine was further confirmed using HNMR via
appearance of catechol protons at around 7 ppm (Figure 2-S1b-ii, supporting
information)

264

. Further, the relative integration of catechol protons (6.6-7 ppm) to

anomeric protons of the glucose ring of alginate (4.9 ppm) were used to determine the
degree of substitution which was measured to be 16 % (in terms of alginate repeating
units). It should be noted that alginate-dopamine was synthesized with the designated
degree of substitution (theoretical substitution degree of 50 %) based on preliminary
release experiments using a model dye; fluorescein sodium salt (Figure 2-S2, supporting
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information), which revealed that degree of substitution of alginate-dopamine have a
significant effect on the dye release profile and total amount of dye released.
Along similar lines, alginate-methacrylate was characterized via FTIR spectroscopy
(Figure S1a, supporting information). It exhibited –CH stretching vibration band (2980–
2850 cm−1) and the appearance of two shoulders one around 1712 cm−1 and the other at
1161 cm−1 , associated with C=O and C-O groups of the esters resulting from the grafting
of the methacrylate units.265 Additionally, HNMR (Figure 2-S1b-iii, supporting
information) also proved the grafting of methacrylate groups by appearance of double
peaks (vinyl) in the double bond region (5.5-6.5 ppm). Furthermore, the relative
integration of methyl protons (of methacrylate groups) to anomeric protons of the glucose
ring of alginate (4.9 ppm) were used to determine the degree of substitution which was
40% (in terms of alginate repeating units).

2.3.2. Rheology of polymers
To evaluate spinability of the synthesized hydrogels, their rheological properties were
investigated using a rheometer (Figure 2-2a & 2b). Accordingly, modification of alginate
with dopamine increased the viscosity of the solution (Figure 2-2a-iii) at lower shear
rates when compared to pure unmodified alginate (Figure 2-2a-iv), likely due to
noncovalent interactions including π-π stacking of dopamine moieties

251

. Also, a more

pronounced shear thinning effect was observed for alginate-dopamine samples over the
entire shear rate range, when compared to that of pure unmodified alginate. This could
possibly be associated to the attached dopamine in further hindering the entanglement of
neighbouring alginate polymeric chains.
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Figure 2-2. (a) Viscometry of 3% (w/v) solution of i) alginate-methacrylate, ii) alginate-dopamine/
alginate methacrylate (75/25 w/w), iii) alginate-dopamine, and iv) pure alginate. (b) Oscilatory
rheology of 3% (w/v) solutions (containing 0.05% (w/v) IRAGACURE D-2959) of i) alginatemethacrylate, and ii) alginate-dopamine/ alginate methacrylate (75/25 w/w). Microscopy images
showing (c & d) Top view of freshly made core-shell mussel-inspired fibers (CS) loaded with DOX
in the core (scale bars 2 mm and 1 mm, respectively).

Furthermore, modification of alginate with methacrylate groups led to a significant
decrease in viscosity of the resulting solution in comparison to pure alginate (Figure 22a-i), a phenomenon attributed to disruption of the alginate backbone by the
methacrylation chemistry 266. For coaxial fiber fabrication, effective cross-linking of the
core component is vital to assure stability of the fibers

267

. Consequently, alginate-

dopamine was physically mixed with alginate-methacrylate (75/25% w/w) to allow the
formation of a dual cross-linked core constituent by combining chemical and physical
crosslinking methods
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268

. As a result, the viscosity of the mentioned alginate-

dopamine/alginate-methacrylate solution was also assessed (Figure 2-2a-ii) and the
result showed a similar trend to that of alginate-dopamine solution (Figure 2-2a-iii), yet
with a slightly lower viscosity over the entire shear rate range, associated with small
portion of alginate-methacrylate in this solution (25% w/w). Furthermore, oscillatory
experiments (as a function of time) revealed that upon UV irradiation (365 nm for 5 sec)
the storage modulus of the alginate-methacrylate hydrogel increased significantly from
lower values (~ 1 Pa) up to 13000 Pa, indicating the formation of methacrylate bonds in
the cross-linked hydrogel (Figure 2-2b-i). Subsequently, the alginate-dopamine/alginatemethacrylate mixture showed a much lower increase in the storage modulus (levelling off
at around 3500 Pa) in correspondence with the low volume of UV cross-linkable element
in the mixture (Figure 2-2b-ii).

2.3.3. Morphology of the core-shell fibers
Next, the core-shell mussel-inspired fibers (CS) were fabricated through a custom made
coaxial nozzle based on a previously described wet-spinning method

269-270

.

Subsequently, the core-shell morphology of the CS fibers was further assessed using
optical microscopy and scanning electron microscopy (SEM) (Figure 2-2c, d & Figure
2-3). The core-shell boundaries of the Doxorubicin-loaded fibers could be clearly
observed in these images (Figure 2c-d), as indicated by higher density of red colour
(associated with DOX) in the middle region as compared to the adjacent area. The CS
fibers were then allowed to dry off and their subsequent swelling in SBF was further
investigated by recording them using a microscope camera.
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Figure 2-3. SEM images of core-shell mussel-inspired fibers (CS), (a & b) SEM image of CS fibers
at dry state. (c & d) SEM images of CS fibers fully swollen in SBF.

Accordingly, the fibers demonstrated a time-dependent swelling behaviour as it took them
almost 60 hr to completely swell. Cross-section morphology of the CS fibers, in dry and
swollen state, was also studied using scanning electron microscopy (SEM) and the results
are shown in Figure 2-3. The core-shell borders of the fibers were only detectable once
the fibers were fully swollen (Figure 2-3c&d). Remarkably, the shell showed a more
compact structure with smaller pores, as compared to the core, which was a consequence
of dual crosslinking mechanism (ionic and covalent bonds) that was imposed on alginatemethacrylate in the shell region. This pore size difference between the core and the shell
could also be attributed to limited diffusion of CaCl2 crosslinking agent into the core, as
well as, higher concentration of alginate-methacrylate in the shell. It should be mentioned
that the thickness of the shell layer can be controlled by using a larger shell nozzle.
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Of note, SEM images of single fibers made from unmodified alginate (Alg) was also
taken as a point of reference (Figure 2-S3, supporting information).
2.3.4. Swelling and degradation of the core-shell fibers
Considering the direct correlation between the drug release profile, the swelling
behaviour, and degradation of the hydrogels, we have measured the swelling ratio and
degradation rate of the fibers in SBF (Figure 2-4).

Figure 2-4. (a) Final swelling ratio of single fibers made from pure alginate (Alg), and CS fibers in
SBF. (b) In vitro degradation profiles of Alg and CS fibers in SBF as a function of time. (n = 4,
mean ± SD) (****P = 0.0001, **P ≤ 0.01)

As a result, CS fibers showed to have significantly less swelling (18.05) when compared
to Alg fibers (33.07) as shown in Figure 4a, which could be due to dual cross-linked
network in the coaxial fibers

238

. The gradual swelling behaviour of CS fibers (loaded

with DOX in the core) in SBF was also recorded over a span of 60 hr. The obtained
swelling data for CS fibers in this study were almost 20 times less than this value reported
for similar fibrous hydrogel structures

271

. In addition, the degradation rate results

revealed that CS fibers possessed a slower mass loss rate over a period of 14 days
compared to that of Alg fibers (Figure 2-4b). More specifically, after 14 days Alg fibers
experienced a 63.6 ± 9.1% of mass loss, while CS fibers showed a 43.9 ± 3.6% of mass
loss. This is possibly due to the dual cross-linked hydrogel network in the CS fibers.
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2.3.5. Mechanical properties of the core-shell fibers
Given the effect of mechanical properties on release of drugs from hydrogels272, we have
measured the tensile properties of the fibers in both static and dynamic conditions (Figure
2-S4 supporting information and Figure 2-5, respectively). Initially, mechanical
properties of the fibers were assessed using a static tension test (both in dry and wet states)
and compared them to that of Alg fibers (Figure 2-S4, supporting information). In dry
state, CS fibers showed higher modulus (2.78 ± 0.03 GPa) and tensile strength (85.44 ±
9.6 MPa) compared to those for single Alg fibers (1.26 ± 0.08 GPa and 68.5 ± 2.6 MPa,
respectively). These observations was more pronounced for the fibers in the wet state, as
CS fibers had a modulus of 0.21 ± 0.07 MPa and tensile strength of 0.64 ± 0.02 MPa,
while single Alg fibers possessed a modulus and tensile strength of 0.06 ± 0.01 MPa and
0.07 ± 0.02 MPa, respectively. This implied that the proposed core-shell structure
provides greater stability in aqueous environments, making them more practical for
biomedical applications. It is worth noting that in this study the elastic modulus of wet
CS fibers (0.21 MPa) were almost 10 times higher than that observed for fibers produced
by microfluidic systems (0.02 MPa) 273.
In order to gain a better insight into viscoelastic properties of fibers, an oscillating tension
test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz was conducted
(Figure 2-5). Remarkably, CS fibers showed a significantly higher storage modulus
(2996 ± 78.1 MPa), over the entire frequency range, when compared to that of single Alg
fibers (261.45 ± 5.4 MPa) (Figure 2-5a). For both fibers (Alg and CS) the storage
modulus values were higher than the loss modulus values, which indicated the domination
of elastic response over a viscous behaviour for the two types of samples. However, after
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measuring the damping factor (Tan δ - calculated from the ratio of E˝/Eˊ) for the fibers,
CS fibers demonstrated a significantly lower value (0.031) than that of single Alg fibers
(0.053), which was associated with higher elasticity of CS fibers over single Alg fibers
(Figure 2-5d). Consequently, the observed mechanical properties data suggested that CS
fibers possessed a more robust structure (as compared to single Alg fibers), probably due
to the dual cross-linked network (chemical and physical) arrangement. Also, the CS fibers
were robust enough to be fabricated into a woven structure (using a traditional weaving
technique) as a potential 3D implantable patch (Figure 2-S5, supporting information).

Figure 2-5. Dynamic mechanical analysis of hydrogel fibers, single fibers made from pure alginate
(Alg) or core-shell fibers (CS), by using a tension clamp. The samples were exposed to a constant
strain (0.1 %) of increasing frequencies in the range of 0.1 to 10 Hz for 30 min. (a) Storage modulus
and (b) Loss modulus of fibers at different frequencies. (c) Storage and loss modulus at the
frequency of 10 Hz. (d) Tan delta (damping factor) at the frequency of 10 Hz (n = 3, mean ± SD) (*P
= 0.05, **P ≤ 0.01).
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2.3.6. Drug release from the core-shell fibers
Next, in vitro drug release studies were carried out using two specific chemotherapeutic
drugs (GEM and DOX, as described in the section 2.2.8) and the results are shown in
Figure 2-6. Specifically, we have compared the release of drugs from core-shell musselinspired fibers (CS) to those obtained from single fibers made from unmodified alginate
(Alg), as well as core-shell fibers in which both core and shell were made entirely out of
UV-crosslinkable alginate-methacrylate (CS •). Of note, the comparison between the
normal CS fibers and the specially made CS • fibers, was for the purpose of understanding
the specific role of alginate-dopamine (in the core of CS fibers) in the obtained drug
release profiles.

Figure 2-6. In vitro drug release studies from hydrogel fibers including single fibers made from
pure alginate (Alg), core-shell mussel-inspired fibers (CS), and core-shell fibers in which both core
and shell were entirely made of UV-crosslinkable alginate-methacrylate (CS•). (a) Release profile of
Gemcitabine (GEM). (b) The first 2 hr of GEM release. (c) Release profile of Doxorubicin (DOX).
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(d) The first 10 hr of DOX release (n = 3, mean ± SD)

Consequently, Figure 2-6a&b shows the GEM release data from the above mentioned
fibers. Accordingly, CS fibers was able to slow down the release of GEM down to almost
42% when compared to that of Alg fibers (~ 93%). Of note, CS • fibers also succeeded to
slow down the release of GEM (~ 68%) in comparison to Alg fibers (~ 93), however it
seemed like CS fibers succeeded to further slowdown the release possibly due to
interactions of the drug with the dopamine moieties. Nevertheless, release of GEM from
CS fibers reached a plateau level after 10 hr. Next, release of DOX from the fibers was
evaluated (Figure 2-6c&d). Accordingly, DOX release profile from CS fibers exhibited
three distinct stages: starting with a burst release of the drug over the first 10 h (~ 24%),
followed by a slower release of the drug up to day 8 (~ 42%), and then an even slower
release rate that lasted up to day 19 (~ 46%), which was followed by a plateau region up
to day 21 (~ 49%). This was in total contrast to single Alg fibers releasing almost the
entire DOX in the first 10 h of the experiment. Of note, the Dox release profile obtained
from these CS fibers is comparable to other studies in the field 274-276.
Of note, CS • fibers also showed to slow down the release of DOX when compared to that
of Alg fibers. Accordingly, DOX release profile from these fibers exhibited two distinct
stages: starting with a burst release of the drug over the first 10 h (~ 59%), followed by a
slower release of the drug up to day 5 (~ 67%), which was followed by a by a plateau
region up to day 8 (~ 69%). Similar to Gemcitabine, the differences between the obtained
DOX release profiles of CS fibers and CS • fibers could be associated to the possible
intermolecular interactions of DOX with dopamine moiety in the CS fibers.
Consequently, to investigate this hypothesis and with the aim of scrutinizing the obtained
drug release profiles, a dynamic light scattering (DLS) analysis was conducted (Table 2S1, supporting information). Correspondingly, the measurements were carried out for
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pure unmodified alginate, as well as, dopamine-modified alginate (main component of
the core section in CS fibers), and methacrylate-modified alginate (main component of
the core section in CS

•

fibers), to better understand their interactions with the drug

molecules. The results revealed that modification of alginate with dopamine led to an
increase in hydrodynamic diameter of the polymer from 110.9 ± 0.24 nm to 192.8 ± 1.83
nm, which was attributed to addition of catechol moieties and possible aggregation of
polymeric chains due to π−π stacking of aromatic rings 277. Modification of alginate with
methacrylate groups also led to an increase in hydrodynamic diameter of the polymer to
205.7 ± 0.40. Compared to pure alginate and alginate-methacrylate, alginate-dopamine
had a higher negative zeta potential value (-33.2 ± 0.86 as compared to -28.8 ± 0.36 and
-29.9 ± 0.78, respectively), that was ascribed to acidic nature of catechol groups 278. Of
note, addition of drugs (DOX or GEM) to pure unmodified alginate or alginatemethacrylate did not cause any major change in their corresponding hydrodynamic
diameters or zeta potentials, implying the weak interactions of these drugs with pure
alginate and alginate-methacrylate, which translated into quicker release of these two
drugs from those fibers. It should also be noted that slower release of drugs from CS

•

compared to Alg fibers, could have been due to smaller porosity of these fibers indicated
from their cross-sectional SEM images (Figure 2-S6, supporting information). On the
other hand, incorporation of drugs into alginate-dopamine was associated with
remarkable changes in hydrodynamic dimeter and zeta potential of this polymer.
Specifically, hydrodynamic diameter of alginate-dopamine increased significantly from
192.8 ± 1.83 nm to 422.0 ± 0.24 and 388.0 ± 0.35 nm, after addition of DOX and GEM,
respectively. The zeta potential value of alginate-dopamine increased from -33.2 ± 0.86
mV to -37.2 ± 0.69 and -34.0 ± 0.69 mv, after addition of DOX and GEM, respectively.
The observed data suggested that both drugs could possibly had non-covalent
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hydrophobic interactions (π−π interactions) with alginate-dopamine which led to
significant increase in hydrodynamic diameter values. However, DOX seemed to also
have better ionic interactions with alginate-dopamine, as the value of zeta potential
increased significantly (-33.2 ± 0.86 mV to -37.2 ± 0.69 mV) for this drug, whereas,
addition of GEM did not generate such changes. Altogether, the obtained data showed
that alginate-dopamine had better interactions (physical or chemical) with the drugs,
when compared to pure unmodified alginate or alginate-methacrylate, a phenomenon
which was also observed in drug release studies. Also, the results confirmed that DOX
had stronger interactions with alginate-dopamine, as compared to GEM, which further
contributed to longer release profile of this drug from CS fibers. In addition, the
differences between the obtained release profiles of GEM and DOX from CS • fibers
could be attributed to larger molecular size of DOX when compared to that of GEM.

2.3.7. In vitro biocompatibility of fibers
With the aim of evaluating anti-cancer efficacy of the drug loaded CS fibers, in vitro
cellular experiments were carried out using two different human pancreatic cancer cell
lines (MIA-PaCa-2 & PANC-1) and the results are shown in Figure 2-7. The empty CS
fibers (indicated as control) were shown to be biocompatible and maintained high cell
viability for both cell lines. GEM loaded fibers were able to reduce the viability of the
MIA-PaCa-2 cells down to 26.6% ± 0.5, 72 h post treatment (Figure 2-7a). Remarkably,
DOX loaded CS fibers were able to reduce the viability of cancer cell line as early as 24
h post treatment and they showed a higher anti-cancer effect (4.2 ± 3.7) after 72 hr of
treatment (Figure 2-7b). Following the observed results we have loaded the two drugs
(GEM+DOX) simultaneously in core section of the CS fibers, indicated as dual treated,
to investigate any possible synergistic anti-cancer effect of this drug combination.
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Accordingly, the obtained results suggested that the dual loaded CS fibers were also
effective in reducing the viability of cancer cells 72 h post treatment down to 13.8 ± 1.8
(Figure 2-7c). Lastly, a live/dead staining of the corresponding cells further proved that
empty CS fibers (indicated as control) had a good level of biocompatibility after 72 hr of
treatment as implied from high density of the live cells (shown in green), whereas all
drug-containing CS fibers were capable of reducing the viable cells in correspondence

with MTS cell viability results (Figure 2-7g).

Figure 2-7. In vitro biocompatibility of fibers (1 cm) including empty CS fibers (Control),
Gemcitabine loaded CS fibers (GEM treated), Doxorubicin loaded CS fibers (DOX treated), and
dual-loaded CS fibers (GEM-, DOX-, Dual-treated). (a-c) MTS cell viability assay of MIA-PaCa-2
human pancreatic adenocarcinoma cells when treated with the fibers. (d-f) MTS cell viability assay
of PANC-1 human pancreatic adenocarcinoma cells when treated with the fibers. (g) & (h)
Corresponding live/dead cell staining of treated MIA-PaCa-2 and PANC-1 human pancreatic
adenocarcinoma cells, respectively. Values are the mean (±SEM) of quadruplicate. *P = 0.05, **P ≤
0.01, ***P = 0.001, ****P = 0.0001.
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Furthermore, in order to assess the anti-cancer effect of CS fibers on a more resilient
pancreatic cancer cell line we have tested these fibers on PANC-1 human pancreatic
cancer cell lines. The results showed a similar trend to MIA-PaCa-2 cells lines, however
herein the cells had a higher level of viability after 72 hr post treatment specially in cells
treated with GEM loaded fibers (56.6 ± 4.7) as shown in Figure 2-7d. Otherwise, cells
treated with DOX- and Dual-loaded CS fibers had 13.3 ± 2.6 and 12.6 ± 2.8, respectively
(Figure 2-7e & f). At last, live/dead staining of these cells further verified the obtained
MTS cell viability results with DOX- and Dual-loaded fibers having the least number of
viable cells 72 hr post treatment (Figure 2-7h). Of note, the difference in sensitivity to
chemotherapy is well documented for MIA-PaCa-2 and PANC-1 cells,279 and has been
attributed to differences in ERK activity 280. Moreover, the significant difference between
anti-cancer performances of GEM loaded fibers compared to DOX-containing fibers
could be a result of controlled release of DOX from the fibers and also different
mechanism of action of this drug compared to GEM

281-283

. Overall, the in vitro results

suggested that CS fibers possessed a high level of cell biocompatibility, while DOX and
dual-loaded CS fibers had superior anti-cancer efficacy when compared to GEM loaded
fibers. Moreover, in these short-term in vitro assessments, no statistical difference was
observed between the DOX- and dual-loaded fibers. This could be associated with
mechanism of action of Gemcitabine, as it requires cellular uptake and intracellular
phosphorylation.284-285 A process that is time-dependent, and also requires prolonged and
high intercellular concentration of Gemcitabine. This further validates the importance of
long-term in vitro studies to evaluate the therapeutic effect of the drug loaded CS fibers.

2.3.8. In vitro therapeutic effect of fibers
Next, with the aim of evaluating the long-term therapeutic effect of CS fibers on inhibition
of cancer cell growth, a 20 days cell counting assay (CCK-8) was conducted using three
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different human pancreatic cancer cell lines including MIA-PaCa-2, PANC-1, and
BxPC3-Luc cells (Figure 2-8).

Figure 2-8. Therapeutic effect of CS fibers on inhibition of cancer cell growth. The viability of (a)
MIA-PaCa-2, (b) PANC-1, and (c) BxPC3-Luc human pancreatic adenocarcinoma cells at the
different time points treated with Empty CS fibers (Control), Gemcitabine-loaded CS fibers (GEM
treated), Doxorubicin-loaded CS fibers (DOX treated), and dual-loaded CS fibers (GEM-, DOX-,
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Dual-treated). Values are the mean (±SEM) of quadruplicate.

Consequently, in MIA-PaCa-2 cell lines the empty CS fibers (indicated as control)
showed a high level of biocompatibility throughout the test period and did not hinder the
cancer cell growth, whilst, drug-loaded fibers were capable of slowing down the cell
growth to different degrees (Figure 2-8a). Accordingly, Dual-loaded fibers showed a
higher degree of cancer cell growth prevention which lasted for almost 14 days before the
cells became highly viable again. This was in contrast to DOX- and GEM-loaded fibers
which showed a short term inhibition of cell growth lasting only for 5 days. Regardless,
in correspondence with previous MTS cell viability results the DOX-loaded fibers had
better inhibition of cancer cell growth when compared to the GEM-loaded counterparts.
Next, PANC-1 cells were tested and similar results were obtained where Dual-loaded
fibers showed the most inhibition of cell growth that was followed DOX- and GEMloaded fibers, respectively (Figure 2-8b). At last, BxPC3-Luc cells further verified the
previous observations where Dual-loaded fibers prevented the cancer cell growth the
longest which was followed by Dox-loaded and GEM-loaded fibers (Figure 2-8c). Worth
noting that based on these results Dual-loaded fibers showed a notable synergistic anticancer effect (as compared to GEM- or DOX-loaded fibers), which was not observed in
the previous short-term MTS cell viability experiments. This further validates the
importance of long-term in vitro studies in the context of cancer drug delivery as these
chemotherapeutic drugs tends to show their therapeutic effects only after weeks of
treatment. Overall, the obtained results suggested that these drug loaded fibers can inhibit
the cancer cell growth effectively for 14 days.
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2.3.9. In vivo therapeutic effect of fibers
Next, in vivo experiments were carried out for a period of 2 weeks using a murine
subcutaneous xenograft tumor model using two pancreatic cancer cell lines including
MIA-PaCa-2, and BxPC3-Luc cancer cells (Figure 2-9 & 2-10, respectively). Following
tumor formation the drug loaded CS fibers were implanted under the tumor region,
through a small incision in the middle of the back of the mice, and after two weeks the
animals were sacrificed and their tumor size were measured.

Figure 2-9. In vivo performance of drug loaded CS fibers in MIA-PaCa-2 mice xenografts
compared to intravenous injection of same drugs at equal dose (n= 5 in each group, *P = 0.05, **P ≤
0.01, ***P = 0.001, ****P = 0.0001). (a) Schematic representation of localized therapeutic approach
with drug loaded CS fibers in mice xenograft model (MIA-PaCa-2 tumors). (b) Tumor volume at
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day 0 and day 14 after the treatment. (c) Tumor weight at day 14 after the treatment. (d) Body
weights of mice in different groups after treatment. (e) Images of hematoxylin and eosin (H&E)
staining along with KI-67 staining of pancreatic-cancer tissue (MIA-PaCa-2 tumors) sections from
treated mice. The scale bar in images with 4x, 10x, and 20x magnification is 1000 µm, 400 µm and
200 µm, respectively.

The obtained data showed that tumors treated with DOX- and dual-loaded (DOX+GEM)
CS fibers showed significant inhibition of tumor growth compared to GEM-loaded or
empty CS fibers. Accordingly, MIA-PaCa-2 tumor volume increased 79 ± 83% and 28 ±
14% in mice treated with DOX-loaded and dual-loaded CS fibers, respectively, while
mice treated with empty and GEM-loaded CS fibers experienced 323 ± 157% and 275 ±
21% increase in the tumor volume, respectively (Figure 2-9b). Moreover, slightly higher
anti-cancer efficacy of dual-loaded fibers, as compared to DOX-loaded fibers, could have
possibly been associated to synergistic effect of the two drugs

286

. Most significantly,

DOX- and dual-loaded CS fibers were able to inhibit the tumor growth to a much higher
degree when compared to injection of equal dosages of DOX and DOX+GEM (277 ±
55% and 194 ± 49% increase in the tumor volume, respectively), which was a testament
to importance of local delivery of drugs in a controlled manner. Of note, weak therapeutic
effect from GEM loaded fibers was attributed to faster release of this drug from the fibers
that prevented steady phosphorylation of GEM by cancer cells leading to its reduced
therapeutic effect 287. Also, all treated mice did not experience any significant weight loss
throughout the study, which indicated that all treatments were well tolerated and did not
cause any major toxicity (Figure 2-9d). To further evaluate the anti-cancer effect of drug
loaded CS fibers, H&E and Ki67 (proliferating cells marker) staining of tumor tissues
post-treatment were evaluated (Figure 2-9e). In correspondence with the observed
results, the DOX- and dual-loaded fibers yielded significant levels of apoptosis as
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confirmed by H&E staining of tumor tissues post-treatment, which suggests that the level
of drugs to which tumors were exposed were sufficient to shrink the tumors and prevent
their growth. Similar results were observed from Ki67 staining of the tumor tissues, as
tumors treated with empty or GEM loaded fibers showed the highest density of red
pigments (as opposed to DOX- or Dual-loaded fibers), indicating the higher population
of proliferating cells in tumors treated with these two samples. Furthermore, with the aim
of evaluating the cytotoxicity of empty or drug loaded CS fibers, various parameters in
the blood of the mice were analysed (Table 2-S2, supporting information). The
obtained results for mice treated with drug loaded or empty fibers showed no significant
difference from the haematological values (i.e. white blood cell, red blood cell,
hemoglobin, platelet, neurophil and lymphocyte count) of a normal mouse, suggesting
that CS fibers did not produce any significant changes in the haematology of mice,
implying that CS fibers may be a safe delivery platform for in vivo use.
In order to further assess the anti-cancer performance of drug-loaded CS fibers, a second
series of animal studies were conducted using murine subcutaneous xenograft tumor
model using BxCP3-Luc light-producing pancreatic cancer cell lines (Figure 2-10).
Similarly, BxCP3-Luc tumor volume increased 77 ± 53% and 47 ± 46% in mice treated
with DOX-loaded and dual-loaded CS fibers, respectively, whilst mice treated with empty
and GEM-loaded CS fibers experienced 622 ± 589% and 376 ± 138% increase in the
tumor volume, respectively (Figure 2-10b). In these tumor models after 14 days of
treatment, GEM-loaded fibers were able to slightly decrease the tumor volume when
compared to empty fibers, which was also observed in luciferase images of the growing
tumors (Figure 2-S8, supporting information). The slight difference between BxCP3Luc and MIA-PaCa-2 tumors responses to GEM-loaded fibers was associated to higher
sensitivity of BxCP3-Luc cell lines to Gemcitabine 288.
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Figure 2-10. In vivo performance of drug loaded CS fibers in BxPC3-Luc mice xenografts (n= 6 in
each group, *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 0.0001). (a) Schematic representation of
localized therapeutic approach with drug loaded CS fibers in mice xenograft model (BxPC3-Luc
tumors). (b) Tumor volume at day 0 and day 14 after the treatment. (c) Tumor weight at day 14
after the treatment. (d) Body weights of mice in different groups after treatment. (e) Images of
hematoxylin and eosin (H&E) staining along with KI-67 staining of pancreatic-cancer tissue
(BxPC3-Luc tumors) sections from treated mice. The scale bar in images with 4x, 10x, and 20x
magnification is 1000 µm, 400 µm and 200 µm, respectively.

Also, similar to MIA-PaCa-2 tumor models, in the BxCP3-Luc tumors dual-loaded fibers
failed to show any significantly higher anti-cancer efficacy, when compared to DOX101 | P a g e

loaded fibers, which could have been a result of quick release of Gemcitabine from these
fibers. Additionally, animals treated with empty or drug-loaded fibers maintained their
body weight for the whole duration of the study, which showed that these fibers did not
cause a systemic toxicity and could potentially serve as a safe in vivo treatment modality
(Figure 2-10d).Lastly, H&E and Ki67 staining of excised tumor tissue, revealed that
empty fibers did not cause apoptosis in tumor tissue and they have not interfered with
proliferation of cancerous cells, whilst DOX- and Dual-loaded fibers caused the most
apoptosis of cancer cells and left the least amount of proliferating cells (Figure 2-10e).
Overall, the in vivo findings showed that CS fibers are well tolerated in the animals and
they did not cause any major toxicity. Also, in MIA-PaCa-2 tumor models it was shown
that drug loaded fibers (especially DOX- and Dual-loaded fibers) had better anti-cancer
performance when compared to intravenous injection of the equal dosages of the drugs.
In addition, in both tumor models, it was observed that continuous and slow release of
DOX from the CS fibers can inhibit the tumor growth more effectively (DOX- and Dualloaded fibers), when compared to quick release of GEM from CS fibers. The results also
showed that dual-loaded fibers could also be effective in inhibiting the tumor growth.

2.4.

Conclusions

In this study, coaxial mussel-inspired biofibers loaded with chemotherapeutic drugs were
fabricated for the first time, where the core consisted of alginate-dopamine and the shell
contained UV cross-linkable alginate-methacrylate. This was done with a view to
improve both the drug affinity and diffusion, and facilitate high loading capacity and
controlled release to function as novel implantable drug delivery system. We propose that
the efficient intermolecular interactions between the chemotherapeutic drugs (DOX and
GEM) and catechol moieties of the DOPA in the core imparted excellent control on the
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release of DOX over a period of 21 days. These CS fibers elicited no significant undesired
toxicity as evidenced from both in vitro and in vivo experiments. DOX- and dual-loaded
(DOX+GEM) fibers achieved significant anti-cancer effect on human pancreatic cancer
cells-xenografted tumor models, while GEM loaded fibers showed minimal anti-cancer
effect at doses much higher than DOX. Most remarkably, in MIA-PaCa-2 tumor bearing
mice, Dox- and dual-loaded CS fibers were able to significantly prevent the tumor growth
(79% and 28% increase in tumor volume, respectively), when compared to intravenous
injection of equivalent dosages of the same drugs (277% and 194% increase in the tumor
volume, respectively). Enhanced inhibition of tumor growth in DOX-containing fibers
was attributed to prolonged release of the drug from these fibers, and considering the
systemic side effects of DOX, the CS fibers could be beneficial for local delivery of this
drug and subsequently reducing its cardiotoxicity. Lastly, in this study we did not observe
any significantly higher anti-cancer efficacy from dual-loaded fibers, as compared to
DOX-loaded fibers, which could be associated with quick release of GEM from the fibers.
In conclusion, this study showed that mussel-inspired coaxial biofibers, as a novel
implantable platform, provided an effective and safe strategy towards local delivery of
drug cocktails for cancer therapy.
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2.5. Supporting information
2.5.1. Analysis of dye loaded fibers
Degree of substitution of alginate-dopamine was shown to have a significant effect on the
dye release profile and total amount of dye released. Accordingly, fibers made from
alginate-dopamine 50% had the slowest release (51 µgr), followed by the fibers made
from alginate-dopamine 25% (32 µgr) and pure alginate (22 µgr), respectively (Figure
S2, supporting information). Noting, these observations were likely due to strong
intramolecular interactions of the dye and the catechol moieties in alginate-dopamine
fibers.

Figure 2-S1. Physiochemical characterization of as-synthesized polymers including, (a & b) FTIR
and HNMR spectra of i) pure alginate, ii) alginate-dopamine, and iii) alginate-methacrylate.
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Figure 2-S2. Preliminary dye release (fluorescein sodium salt, 2mM) studies from single fibers
made from pure alginate (Alg), alginate-dopamine 25% (alg-dopamine 25%), alginate-dopamine
50% (Alg-dopamine 50%) (a) Release profile of dye loaded fibers. (b) Cumulative dye released
from the fibers.
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Figure 2-S3. Morphology of single fibers made from pure alginate (Alg) using SEM imaging, (a) in
dry state, (b) in complete swollen state after 2 hr of immersion in SBF.
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Figure 2-S4. Mechanical properties of fibers following a static tensile test, pure alginate
fibers (Alg) or core-shell mussel-inspired fibers (CS), (a) Stress-strain curve for fibers in dry
state. (b & c) Tensile strength and modulus of fibers in dry state (n = 3, mean ± SD). (d)
Stress-strain curve for fibers in wet state. (e & f) Tensile strength and modulus of fibers in
wet state (n = 3, mean ± SD) (**P ≤ 0.01, ****P = 0.0001).
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Figure 2-S5. Microscopy image of woven DOX-loaded CS fibers (scale bar 2 mm).
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Figure 2-S6. Morphology of wet CS• fibers where both core and shell were made from UVcrosslinkable alginate-methacrylate (3% w/v).
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Figure 2-S7. Images of tumor bearing mice (MIA-PaCa-2) 2 days after implantation of fibers.
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Figure 2-S8. Therapeutic effect of drug loaded CS fibers in subcutaneous BxPC3-Luc tumor model.
(a) Quantitative imaging data of BxCP3-Luc tumor growth presented as mean ± SD. (b) In vivo
luciferase images of growing subcutaneous pancreatic tumors (IVIS Spectrum).
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Table 2-S1. Hydrodynamic dimeter, poly-dispersity index (PDI), and zeta potential of various
formulations (n = 5, mean ± SD).
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Table 2-S2. Hematologic parameters from MIA-PaCa-2 tumor bearing mice in various treatment
groups. Data are presented as average ± SD (n = 5). WBC: white blood cell, RBC: red blood cell,
HGB: hemoglobin, HCT: hematocrit, PLT: platelet, Neut: neutrophils, Lymp: lymphocytes, Mono:
monocytes, Luc: large unstained cells.
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Chapter 3

3. Coaxial mussel-inspired hydrogel fibers containing
Cu2−xSe Nanoparticles: Toward building an implantable
composite for local chemo-photothermal combinational
cancer therapy
3.1.

Introduction

Conventional cancer therapies involve systemic administration of drug (or drug
combinations) with the aim of inhibiting tumor growth and inducing cancer cell death.237
However, this approach is bound to certain limitations including low efficiency of
delivering drugs to their parenchymal target, which ensues undesired toxicity to healthy
tissues.289 To surmount these issues, local delivery of drugs directly to the tumor site, via
biopolymeric implants, has generated remarkable localized therapeutic effects with less
undesired casualties.236 Notably, most recently researchers have begun to explore the use
of biopolymeric implants for the delivery of multimodal cancer therapies, such as chemophotothermal therapy, with the aim of achieving synergy and therefore a high tumor
response.290-292 Particularly, use of these implants for chemo-photothermal therapy allows
for sustained release of the drug, but also the generation of heat instigated by an external
stimuli. In brief, photothermal therapy involves the use of photo-absorbing agents to
transform optical radiation to heat at the tumor site with the aim of ablating cancer cells.293

Recently, hydrogels have attracted much attention for cancer drug delivery owing to their
unique features including their tunability (both physically and chemically).236,

294

To

obtain sustained and prolonged drug release from hydrogels these polymeric carriers
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could be further functionalized with various functional moieties to facilitate drug-polymer
interactions.295 This could include usage of functional moieties such as thiols,241, 296-297
heparins (or heparin-mimetic molecules),298-301 cyclodextrins,302-304 amphiphilic
moieties192, 305-307. Inspired by marine mussels, in Chapter 2 we have used dopamine to
modify the alginate hydrogel to form dopamine-polymer conjugates, which showed
enhanced drug-polymer interactions when loaded with Doxorubicin and Gemcitabine.308
In addition, in the cotext of cancer therapy, dopamine possess peculiar properties
including NIR-responsive hyperthermia,309-311 and intrinsic anti-tumor effects.312-313
Nevertheless, controlled release of drugs from hydrogels is also affected by tortuosity of
the release path, which is detrmined by factors such as porosity and network
swelling/degradation.238 In line with this, modification of biopolymers with methacrylate
groups and their subsequent photocrosslinking has been proven as an effective way to
control physical properties of the hydrogels including their mechanical properties,
porosity, swelling behaviors, and degradation rate.314 As a result, combination of musselinspired properties with photocrosslinking capabilities in a hydrogel system might yield
a powerful platform for controlled delivery of chemotherapeutic drugs.
Within the framework of hydrogels photothermal therapy is often achieved through a
composite approach whereby photo-sensitive particles, such as gold nanopaprticles,211
graphene nanosheets,315 and MXene nanosheets290, are incporated into the hydrogel
network. Along these lines, copper selenides (Cu2–x Se) nanoparticles have emerged as
powerful photothermal agents owing to unique set of characteristics including
biodegradability, ease of chemical midifications, photoacoustic imaging, X‐ray computed
tomography (CT) imaging, and single‐photon emission computed tomography (SPECT)
imaging.316-319 Consequnetly, Cu2–xSe nanoparticles could be ideal additives for
fabricating a composite hydrogel with photothermal capabilities.
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In this chapter, with the aim of establishing a suitable implantable platform for
multimodal chemo-photothermal cancer therapy, we have fabricated for the first time a
coaxial composite hydrogel fiber using a wet-spinning method established in our
laboratory.259 Particularly, the core-section of these fibers (Chemo-compartment)
contained

dopamine-modified

alginate

along

with

a

chemotherapeutic

drug

(Doxorubicin; DOX), while their shell section (Phothothermal compartment) was
composed of UV-crosslinkable methacrylate-modified algine together with Cu2−xSe
Nanoparticles (NPs). It was hypothesized that specific biopolymeric composition of these
fibers along with their corresponding core-shell geometry would allow controlled release
of Dox (loaded in the core), while the Cu2−xSe nanoparticles (loaded in the shell) would
facilitate heat generation upon near infra-red (NIR) laser irradiation. Accordingly, a
comprehensive characterization of the physiochemical properties of the resulting fibers
were conducted which included their microstructural morphology (scanning electron
microscopy; SEM), elemental composition (Energy-dispersive X-ray spectroscopy;
EDX), chemical composition and crystalline phase (Infrared spectroscopy; FTIR. X-ray
diffractrometry; XRD), nanoparticle content (thermogravimetric analysis), tensile
properties in both static and dynamic conditions (mechanical tester and dynamic
mechanical analysis, respectively), and their swelling behaviour. The results suggested
that the fibers possessed a core-shell morphology whereby nanoparticles were dominantly
distributed in the shell section. Furthermore, it was shown that addition of DOX and
Cu2−xSe nanoparticles to the coaxial fibers led to an increase in their corresponding tensile
properties (when compared to unloaded coaxial fibers), an effect which was more
prominently observed for fibers in their wet state. In addition, the coaxial composite fibers
not only allowed controlled released of DOX in vitro over a span of 3 weeks, but they
were also capable of generating heat in a tunable manner (based on the length of the fiber)
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upon NIR irradiation, in both in vitro and in vivo conditions. Most remarkably, the coaxial
drug-loaded composite fibers in the presence of NIR radiation showed superior anticancer effect (both in vitro and in vivo) when tested against breast cancer cell lines, a
phenomenon attributed to their synergistic chemo-photothermal effect. Overall, coaxial
mussel-inspired hydrogel fibers containing Cu2−xSe nanoparticles provided a safe and
efficacious implantable platform for multimodal chemo-photothermal therapy that could
potentially be used to control the progression of cancer locally at the tumor site.

3.2.

Experimental section

3.2.1. Materials
Alginic

acid

sodium

salt

from

brown

Dimethylaminopropyl)-Nˊ-ethylcarbodiimide

algea

(medium

hydrochloride

viscosity),

N-(3-

(≥99.0%),

N-

Hydroxysuccinimide, Dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%),
Methacrylic anhydride, and IRAGACURE D-2959 were purchased from Sigma Aldrich.
Calcium chloride (CaCl2) and Sodium hydroxide (NaOH) were purchased from ChemSupply. Doxorubicin hydrochloride was purchased from Focus Bioscience. Simulated
body fluid (SBF) was prepared as explained before.19 D2O (100% - CIL) was supplied
by Novachem. Water soluble HS‐PEGylated Cu2‐xSe Nanoparticles were kindly supplied
by Dr. Zhen Li of Soochow University and they were synthesized by a previusouly
reported method.316
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3.2.2. Synthesis and characterization of alginate-dopamine
Alginate-dopamine was synthesized via carbodiimide chemistry.257 Briefly, 1 g of alginic
acid (5 mmol in terms of repeating unit) was dissolved in 100 ml of 0.1 M MES buffer
with pH of 5.6. EDC and NHS were separately dissolved in 2 ml of MES buffer (2.5
mmol) and subsequently added to the alginic acid solution. while the reaction were
allowed to continue for 30 min. Dopamine hydrochloride (at equal concentration to EDC
and NHS) was separately dissolved in 2 ml of MES buffer and added to the mixture
subsequently. The reaction were allowed to happen for 1 hr under nitrogen flushing.
Afterwards the solution was dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD)
for 7 days against acidic water (pH of 6) and subsequently precipitated in ethaol. The
precipitated polymers were next lyophilized using a freeze-dryer. Incorporation of
dopamine into alginate was further confirmed using FTIR (Shimadzu IRPrestige-21
infrared spectrometer) and HNMR (Bruker 400 MHz) spectroscopy.

3.2.3. Synthesis and characterization of alginate-methacrylate
Alginate-methacrylate was synthesized by using methacrylic anhydride.258 Briefly, 3 g of
alginic acid was dissolved in 300 ml of distilled water (1% w/v) to which 24 ml of
methacrylic anhydride (8% v/v) was added and the pH was maintained at 8 for 6 hrs using
5.0 M NaOH solution. Afterwards, the solution was dialyzed (spectra/ por membrane
tubing; MWCO 12–14 kD) for 7 days and precipitated in ethanol followed by freezedrying. Grafting of methacrylate groups onto the alginate backbone was further confirmed
using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR (Bruker 400
MHz) spectroscopy.
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3.2.4. Rheology
All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm,
DYMAX BlueWave 75).

3.2.5. Fabrication of core-shell fibers
In this study 4 different formulation of core-shell fibers were made: i) Empty core-shell
fibers (CS), ii) DOX loaded core-shell fibers (DOX-CS), iii) Cu2−xSe Nanoparticle loaded
core-shell fibers (NPs-CS), and iv) DOX and Cu2−xSe Nanoparticle loaded core-shell
fibers (NPs-DOX-CS). As mentioned in the introduction, two different solutions were
used to prepare the core-shell fibers. Accordingly, the core aqueous solution contained
3% (w/v) of alginate-dopamine/alginate-methacrylate mixture (75/25% w/w) and 0.05%
(w/v) IRAGACURE D-2959. On the other hand, the shell aqueous solution contained 3%
(w/v) of alginate-methacrylate and 0.05% (w/v) IRAGACURE D-2959. Of note, for
DOX-containing fibers the drug (2 mM) was added to the core solution, while for NPscontaining fibers the nanoparticles (1.6 mg/ml) were added to the shell solution. For fiber
fabrication a coaxial wet-spinning technique (previously established in our laboratory)
has been used.270 Briefly, those two solutions were simultaneously extruded through the
coaxial nozzle into the coagulation bath, H2O/Ethanol (4:1) containing 2% CaCl2 (w/v),
and the fibers were subsequently irradiated with UV light (365 nm, DYMAX BlueWave
119 | P a g e

75) as they were collecting on the rotating drum (10 rpm). Noting, Cu2−xSe Nanoparticles
were loaded into the shell to further facilitate their exposure to the NIR laser. Of note, in
the core solution, alginate-dopamine was physically mixed with alginate-methacrylate to
allow the formation of a dual cross-linked core constituent by combining chemical and
physical crosslinking methods.

3.2.6. Characterization of fibers
Scanning electron microscopy (SEM) observations with energy dispersive X-ray
spectroscopy (EDX) analysis were performed using a JEOL JSM-6490LV microscope
coupled with an Oxford instruments X-max 80mm2 SDD energy dispersive spectrometer.
All maps were acquired using the Oxford Instruments AZtec software suite. SEM images
were taken in high vacuum mode at 15 kV operating voltage and a spot size setting of 60.
For SEM imaging, the fibers were first allowed to completely swell in SBF, then they
were cut into small pieces and inserted into special sample holders. The sample holder
containing the mounted fibers was then immersed into liquid nitrogen for about 45 s and
immediately afterwards a razor blade was used to fracture the fibers and expose their
cross-section. Subsequently, the sample holder was then quickly transferred to the
LVSEM for examination.
Fourier transform infrared (FTIR) spectra were measured between 700 and 4000 cm–1 on
a Shimadzu IRPrestige-21 infrared spectrometer with internal beam equipped with
standard detector with mirror speed of 2.8. The spectra were obtained using attenuated
total reflection (ATR) on the fibers with resolution of 8 and number of scans of 30, on a
transmittance mode. The crystalline structures of samples were analyzed by XRD (GBC,
MtriX SSD) using Cu Kα radiation (λ = 0.154 nm), with the generator working at 40 kV
and 30 mA. The weight percentage of the nanoparticles in the fibers was obtained by
thermogravimetric analysis (TGA, Mettler Toledo-SDTA851) on 10 mg of samples with
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heating rate of 5 °C/min under a nitrogen atmosphere, between temperatures of 27°C–
900°C.
The static mechanical properties of fibers were assessed using a mechanical tester (EZ-L
tester from Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry and wet
fibers, respectively. The dynamic mechanical properties of fibers was evaluated using a
dynamic mechanical analysis (DMA 242 E Artemis, NETZSCH). Accordingly, by using
a tension clamp the samples were exposed to a constant strain (0.1 %) of increasing
frequencies in the range of 0.1 to 10 Hz for 30 min, subsequently storage and loss modulus
were recorded and Tan delta values were measured as a ratio of loss modulus to storage
modulus. Lastly, the swelling properties of the hydrogel fibers were determined by
examining their water uptake capacity. The hydrogel fibers were incubated in simulated
body fluid (SBF) at 37°C and allowed to fully swell. The swelling ratio was calculated
using the following equation: (Ws – Wd)/Wd, where Ws represents the weight of the
swollen hydrogel fibers and Wd represents the weight of the dried hydrogel fibers at the
beginning.

3.2.7. Release studies from drug loaded fibers
To measure the drug release from the fibers, 30 cm of drug loaded fibers were immersed
in 1 ml of SBF solution and the supernatant was collected at certain time points and
replaced with fresh SBF.320 For measuring the DOX release, fluorescence properties of
DOX was measured (excitation 485 nm, emission 520 nm) using FLUOstar OPTIMA
microplate reader. The absorbance values were converted to DOX concentrations using a
previously achieved calibration curve for DOX.
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3.2.8. In vitro photo-thermal effect studies
The photo-thermal effect of the fibers were evaluated in vitro by immersing either 2 cm
or 4 cm of the fibers in 1 ml of SBF solution (in a 1.5 ml eppendorf), and irradiating them
with an 808 nm laser (power density of 1.0 W·cm−2) for 600 s. The temperature change
in the solutions were monitored using an infrared camera (Micro—EPSILON/TIM160)
that was operated with thermoIMAGER TIM software.

3.2.9. In vitro cell studies
NIH-3T3 mouse fibroblast cells and 4T1 mouse breast cancer cells were cultured in the
standard cell media at 37 °C in a 5% CO2 atmosphere. 2 ×104 cells/well were seeded into
24 well plates and incubated for 24 hr in different culture medium supplemented with
10% FBS and 1% Penicillin-Streptomycin (i.e. NIH-3T3: DMEM high sugar medium
containing L-glutamine, no sodium pyruvate; 4T1: RPMI-1640 medium). Then, with the
aim of evaluating the cytotoxicity of the samples, cells were washed with PBS and
incubated with 1 cm fibers per well for 12 hr or 24 h hr at 37 °C. Following incubation,
cells were washed with PBS and subsequently 500 μL MTT (3-(4,5-Dimethylthiazol-2yl)-2,5-Diphenyltetrazolium Bromide) with a concentration of 0.5 mg/mL was added and
allowed to react with the cells for 4 h before the addition of 500 μL dimethyl sulfoxide to
dissolve the precipitates. The absorption of each solution was measured at 490 nm on a
microplate reader (Thermo, Varioskan Flash). With the purpose of live/dead imaging of
the cells, 4T1 cells were seeded in 12 well plates (2 × 105 cells per well) and incubated
with 1 cm fibers per well. Cells were then irradiated once with an 808 nm laser for 10
min, under power densities of 1.0 W·cm–2. The LIVE/DEADTM viability/cytotoxicity kit
for mammalian cells (ThermoFisher Scientific) was used to stain the live cells (green
fluorescence) and the dead cells (red fluorescence), which were subsequently imaged
using a fluorescence microscope (Leica M205 FA).
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3.2.10. In vivo tumor therapy
All animal experiments were carried out according to the protocols approved by the
Soochow University Laboratory Animal Center (Permit number: 2171075). The tumor
models used were established by subcutaneous injection of 50 μL 4T1 cell suspension
(≈5 × 106 cells) into the flank region of the right back of 6‐week‐old male BALB/c mice
(for the photothermal therapy treatment). The tumor therapy studies were carried out 10
d after the inoculation with tumor cells. Briefly, puncture needle (needle gauge 12) was
used to deliver the dry fibers adjacent to the tumor site. Five groups (n = 5) of mice were
referred as (a) tumor–bearing mice only treated with NIR laser (Control); tumor–bearing
mice irradiated with the NIR laser after injection with (b) core-shell fibers (CS), (c) DOX
loaded core-shell fibers (DOX+CS), (d) NPs loaded core-shell fibers (NPs+CS), NPs and
DOX loaded core-shell fibers (NPs+DOX+CS). The dose was either 2 cm or 4 cm of the
fiber per mice. After 24 hr post implantation, an 808 nm laser was once used for the
photothermal therapy and the power density was 1.0 W·cm−2, the irradiation time was 10
min. The tumor sizes and body weights were measured every two days, and the tumor
volume was expressed by L × W2/2, where L and W represent the length and width of the
tumor, respectively.

3.2.11. Statistical analysis
Statistical significance was determined using a two-way ANOVA with a Sidak post-test
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P =
0.0001. Values are reported as the average ± standard deviation.
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3.3.

Results and discussion

3.3.1. Rheometry
Given the role of rheology in determining the spinnability of a solution,321 rheological
evaluations of all spinning solutions were carried out (Figure 3-1). Based on the viscosity
measurements (Figure 3-1a), all solutions showed a shear thinning behaviour as their
viscosity consistently dropped by increasing the shear rate. Moreover, at the same
concentration, the core solution (alginate-dopamine/alginate-methacrylate mixture;
75/25% w/w) showed a higher viscosity when compared to that of shell solution (alginatemethacrylate). This was likely due to noncovalent interactions including π-π stacking of
dopamine moieties in alginate-dopamine that led to its higher viscosity.251

Figure 3-1. Rheometry of the spinning solutions including (a) Viscometry of 3% (w/v) solution of i)
alginate-methacrylate, ii) alginate-methacrylate + NPs, iii) alginate-dopamine/ alginate
methacrylate (75/25 w/w), and iv) alginate-dopamine/ alginate methacrylate + DOX. (b) Oscilatory
rheology of 3% (w/v) solutions (containing 0.05% (w/v) IRAGACURE D-2959) of i) alginatedopamine/ alginate methacrylate (75/25 w/w), ii) alginate-dopamine/ alginate methacrylate + DOX,
iii) alginate-methacrylate, and iv) alginate-methacrylate + NPs.

Also, methacrylation chemistry often leads to disruption of the alginate backbone

266

,

which can ultimately reduce its viscosity. Of note, addition of both DOX and NPs to their
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corresponding solutions led to a slight increase in their viscosity values, a phenomenon
that could be attributed to intermolecular interactions of these entities with their
polymeric carrier.322 To further evaluate the UV crosslinking-ability of the spinning
solutions, oscillatory experiments (as a function of time) upon UV irradiation were
conducted and the results are presented in Figure 3-1b. Accordingly, the shell solution
(with or without NPs) experienced a significant jump in its storage modulus upon
initiating the UV irradiation, an indication of UV cross-linking of alginate-methacrylate
in the solution. On the other hand, the core solution (with or without DOX) only
experienced a slight increase in its storage modulus values, a consequence of low volume
of alginate-methacrylate in this solution. Subsequently, the core and shell solutions were
used to fabricate the core-shell fibers using a coaxial wet-spinning technique, as discussed
in section 2.5.

3.3.2. Physiochemical characterization of fibers
In order to study the morphology of the resulting fibers and evaluate the dispersion of
NPs in the shell section, SEM microscopy with energy dispersive X-ray spectroscopy
(EDX) analysis was employed (Figure 3-2). Consequently, the cross-section SEM image
of the fully swollen fiber (Figure 3-2a) showed two distinctly different pore distribution,
associated with the core and shell section of these fibers. Thus, the shell section appeared
to have a less porous structure, as compared to the core section, and its thickness was
roughly around 100 µm. This was largely associated with higher concentration of
alginate-methacrylate in the shell section, as well as limited diffusion of CaCl2
crosslinking agent into the core. On the other hand, the core section showed more porosity
with a pore size distribution varying along the fibers diameter. Similarly, this could have
been a result of limited diffusion of CaCl2, along with minimized penetration of UV light
to centre of the fibers.323-325 Next, with the aim of investigating the presence of NPs in the
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fibers, EDX elemental mapping was implemented on the obtained SEM image (Figure
2b). The results showed the distribution of carbon and oxygen as the major component of
the organic fibers, whereas the inorganic Cu and Se were only observed at the edges of
the fiber associated with the Cu2−xSe nanoparticles loaded into the shell. Furthermore, Cu
and Se mapping showed the homogenous distribution of nanoparticles in the shell section
with few agglomeration sites.

Figure 3-2. (a) SEM image of the NPs-CS fibers, (b) EDX elemental mapping of the corresponding
SEM image.

Next, with the aim of scrutinizing the composition of the resulting CS fibers, FTIR and
XRD analysis were utilized (Figure 3-3). The FTIR spectra (Figure 3-3a) of both CS and
NPs-CS fibers showed characteristic peaks associated with alginate-dopamine and
alginate-methacrylate. Accordingly, the characteristic alginate peaks associated with CO stretching vibration (1030 cm-1), COO- symmetric and asymmetric stretching vibration
(1415 and 1600 cm-1, respectively), and –OH stretching vibrations (3325 cm-1) were
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observed in both spectra.326 Moreover, in both spectrums the peak at 1257 cm-1 was
associated to C-N stretching of phenyl amines in alginate-dopamine,327 and the peak at
2920 cm-1 was due to methyl group of alginate-methacrylate.328 Of note, for NPs-CS
fibers, characteristic peaks of Cu2−xSe were out of the range of our measurements (below
700 cm-1),329-330 however appearance of C-S stretching vibration (small peak at 720 cm1

) was attributed to the thiol groups in the nanoparticles.331 Also, NPs-CS fiber FTIR

spectrum showed a significant decrease in intensity of COO- peaks (at 1415 cm-1 and
1600 cm-1), and a slight shift in corresponding carboxylic acid C=O peak from 1712 cm1

to 1720 cm-1. These findings could potentially point out to a possible thioesterification

reaction between the thiol groups in the nanoparticles and the carboxylic acid groups in
alginate backbone.332

Figure 3-3. (a) FTIR and (b) XRD analysis of the CS and NPs-CS fibers.

To further investigate the presence of nanoparticles in NPs-CS fibers, XRD analysis of
the fibers was conducted (Figure 3-3b). The XRD spectrum of CS fibers did not show
any specific peak implying the amorphous nature of these fibers. On the other hand, the
NPs-CS fibers showed three sharp peaks at 2θ of approximately 26.6 ⸰, 44.7 ⸰, and 52.8 ⸰
associated to (111), (220), and (311) planes of cubic berzelianite (Cu2‐xSe, JCPDS Card
No. 06–0680), respectively.316 Lastly, with the aim of measuring the exact NPs content
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in the NPs-CS fibers, TGA analysis of the fibers were carried out (Figure 3-4).
Consequently, the CS fibers showed 3 different stages of thermal degradation: (i) the loss
of volatile products through dehydration (from room temperature to 200°C), (ii) thermal
degradation of polymeric content (200°C - 600°C), and (iii) carbonization process (above
600°C).333 The NPS-CS fibers showed a similar trend in their TGA graph, except they
created more residue at 900°C associated with Cu2‐xSe nanoparticles. The difference
between final residue content of CS and NPs-CS fibers was used to measure the NPs
content which was equal to 5% (weight %).

Figure 3-4. (a) TGA and (b) DTGA thermographs of CS and NPs-CS fibers.

3.3.3. Mechanical properties in static conditions
A static tensile test was employed to evaluate the mechanical properties of the fibers in
both dry and wet state (Figure 3-5). The results for dry fibers (Figure 3-5a,c) showed
that CS fibers possessed a modulus of 2.0 ± 0.2 GPa and a tensile strength of 81.9 ± 20.5
MPa. The obtained values for the CS fibers in dry state exceeded that of other core-shell
hydrogel fibers that were reported in the literature,334-335possibly due to doublecrosslinking (physical and chemical) mechanism in our fibers. Addition of DOX to the
fibers (DOX-CS) slightly increased the modulus and tensile strength values to 2.4 ± 0.3
GPa and 113.2 ± 4.4 MPa, respectively. In a similar manner, addition of NPs to the fibers
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(NPs-CS) further enhanced the modulus and tensile strength values to 3.1 ± 0.3 GPa and
145.5 ± 3.2 MPa, respectively. These observations along with the rheometry results,
further reinforced the idea of DOX and NPs interacting with their corresponding polymer
carriers. Ultimately, simultaneous incorporation of DOX and NPs into the fibers (NPsDOX-CS) yielded the highest modulus and tensile strength values, 3.4 ± 0.2 GPa and 210
± 1.0, comparable numbers to those obtained from other core-shell fibers reported in the
literature.336-337 Mechanical properties of the fibers in wet state were also evaluated and
the results are presented in Figure 3-5d,f. These results showed a similar trend to that of
fibers in dry state, in that NPs-DOX-CS fibers possessed a significantly higher modulus
and tensile strength values (0.4 ± 0.05 GPa and 1.6 ± 0.03 MPa, respectively) when
compared to that of CS fibers (0.15 ± 0.07 GPa and 0.26 ± 0.01 MPa, respectively). In
fact the obtained tensile values for NPs-DOX-CS fibers in wet state were greater than
those for other core-shell hydrogel fibers that were reported in the literature.338-339

Figure 3-5. Mechanical properties of fibers following a static tensile test, (a) Stress-strain curve for
fibers in dry state. (b & c) Modulus and tensile strength of fibers in dry state (n = 3, mean ± SD). (d)
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Stress-strain curve for fibers in wet state. (e & f) Modulus and tensile strength of fibers in wet state
(n = 3, mean ± SD) (*P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 0.0001).

3.3.4. Mechanical properties in dynamic conditions
With the aim of gaining a better insight into viscoelastic properties of the fibers an
oscillating tension test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz
was conducted (Figure 3-6).

Figure 3-6. Dynamic mechanical analysis of hydrogel fibers by using a tension clamp. The samples
were exposed to a constant strain (0.1 %) of increasing frequencies in the range of 0.1 to 10 Hz for
30 min. (a) Storage modulus and (b) Loss modulus of fibers at different frequencies. (c) Storage and
loss modulus at the frequency of 10 Hz. (d) Tan delta (damping factor) at the frequency of 10 Hz (n
= 3, mean ± SD) (**P ≤ 0.01, ****P = 0.0001).

Accordingly, for all fiber formulations the storage modulus values exceeded the loss
modulus values over the entire frequency range (Figure 3-6c), which indicated the
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dominance of elastic response over a viscous behaviour in all the samples. Most
significantly, NPs-DOX-CS had a remarkably higher storage modulus value (7.5 ± 0.5
GPa) when compared to that of CS fibers (0.9 ± 0.2 GPa). This in turn translated into a
significantly lower damping factor (Tan δ - calculated from the ratio of E˝/Eˊ) for NPsDOX-CS fibers (0.0065 ± 0.0007) compared to that of CS fibers (0.0315 ± 0.0021), as
shown in Figure 3-6d. These findings suggested that NPs-DOX-CS are mechanically
strong fibers (in both dry and wet conditions) with high level of elasticity, making them
ideal candidates for fabricating implantable 3D structures using textile manufacturing
techniques.340-341

3.3.5. Swelling behaviour and DOX release study
The swelling behaviour of fibers (in simulated body fluid; SBF) were assessed and the
results were presented in Figure 3-7a. Consequently, all fiber formulations showed a
large swelling ratio (> 10) befitting of their hydrogel nature,342 however NPs-DOX-CS
fibers showed a statistically significant decrease in their swelling ratio (12.4 ± 0.6) when
compared to that of CS fibers (15.5 ± 0.5). The decrease in swelling ratio of the NPsDOX-CS was in agreement with previously observed rheological and mechanical analysis
of the fibers, implying to additional interactions of NPs and DOX entities with their
corresponding polymeric carriers.
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Figure 3-7. (a) in vitro swelling ratio of the fibers upon immersion in simulated body fluid (SBF), (b)
in vitro release profile of Doxorubicin from drug loaded fibers. (**P ≤ 0.01)

Furthermore, release of DOX from the NPs-DOX-CS fibers was assessed and the results
were shown in Figure 3-7b. Consequently, DOX release profile from the fibers exhibited
three distinct stages: starting with a burst release of the drug over the first 10 h (35.9 ±
3.3%), followed by a slower release of the drug up to day 8 (57.7 ± 8.0%), and then an
even slower release rate that lasted up to day 19 (65.7 ± 4.6%), which was followed by a
plateau region up to day 21 (66.8 + 3.8%). The obtained DOX release profile further
validated the rationale behind the specific composition and structure of the fibers, as they
succeeded in prolonged release of the drug over a span of 21 days, longer than that of
other hydrogels recently reported in the literature.343-347 Also, given the possible
interactions of DOX with the core polymeric carrier (as supported by the rheological and
mechanical evaluations), one can expect even a longer DOX release profile at
concentrations higher than what was used in this study (2 mM).
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3.3.6. In vitro photo-thermal effect
With the aim of evaluating the photo-thermal conversion capability of the fibers, an initial
in vitro assessment was performed (Figure 3-8), where 4 cm of the fibers (immersed in
SBF) were irradiated with 808 nm laser (power density of 1.0 W·cm−2) for 10 min.
Accordingly, CS and DOX-CS fibers only raised the medium temperature up to 29°C and
33°C (respectively) after 10 min of laser treatment. On the other hand, under similar
circumstances, NPs-CS and NPs-DOX-CS fibers were capable of raising the medium
temperature up to 65°C and 72°C (respectively), a clear indication of photo-thermal effect
of fibers loaded with NPs. In addition, a separate set of experiments were conducted using
2 cm of the fibers (Figure 3-S2, supporting information), and the results showed a
similar trend where NPs-CS and NPs-DOX-CS were capable of increasing the
temperature up to 54°C and 61°C, respectively. These observations showed that NPscontaining fibers possessed a photo-thermal conversion capability that was directly
correlated with length of the fibers. Accordingly, a whole variety of temperature profiles
can be achieved by simply adjusting the fiber length, and this could be a distinguishing
feature of these fibers.
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Figure 3-8. In vitro photo-thermal conversion effect of 4 cm of the fibers in SBF. (a) Infrared
thermal images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for
10 min, under power densities of 1.0 W·cm–2.

3.3.7. In vitro biocompatibility
First, the biocompatibility of all fiber formulations were tested against 4T1 breast cancer
cells and the results are shown in Figure 3-9a. Based on the obtained results CS fibers
reduced the cell viability down to 71.7% ± 5.0 after 12 hr of treatment. This was followed
by a further reduction in cell viability down to 45.2% ± 1.9 after 24 hr of treatment.
Similar trend was observed for other fiber formulations, to a point where DOX-NPs-CS
fibers showed a cell viability of 45.9% ± 5.6 and 18.1% ± 0.2 after 12 and 24 hr of
treatment, respectively.
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Figure 3-9. In vitro biocompatibility evaluation of the fibers including (a) MTT cell viability assay
of 4T1 breast cancer cells, (b) MTT cell viability assay of NIH-3T3 fibroblast cells, and (c)
Live/dead staining of 4T1 cells treated with different fiber formulations in absence (- NIR) or
presence (+NIR) of laser irradiation (808 nm laser for 10 min, under power densities of 1.0 W·cm–
2

). The scale bar in microscopy images is 100 µm. Values are the mean (±SEM) of quadruplicate.
****P = 0.0001.

These results suggested that empty CS fibers possessed some level of toxicity towards the
4T1 breast cancer cell line. Consequently, with the aim of further evaluating the
biocompatibility of the samples, a second set of in vitro experiments were conducted
where fibers were tested against NIH-3T3 fibroblast cells (Figure 3-9b). As opposed to
4T1 cell line results, the NIH-3T3 cells showed viability of 95.0% ± 2.1 and 83.6% ± 2.1
after 12 and 24hr of treatment, respectively. Furthermore, NIH-3T3 cells treated with
NPs-CS fibers showed similar levels of viability (87.6% ± 5.6 and 86.2% ± 4.6 for 12 and
24 hr treatment, respectively) to that of CS fibers, indicating that addition of NPs to the
fibers did not cause any major toxicity. Additionally, DOX containing fibers (DOX-CS
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and NPs-DOX-CS) caused a significant reduction in cell viability, compared to that of
control samples, associated with antineoplastic action of the drug. These observations
showed that CS fibers possessed a high level of toxicity against the breast cancer cells,
whereas no such effect was observed when they were tested against healthy fibroblast
cells. This could be associated with anti-cancer action of dopamine in the CS fibers,
caused by dopamine-instigated oxidative DNA cleavage of cancer cells.312-313, 348-349
Lastly, the photothermal therapeutic effect of the fibers, in presence of NIR laser, was
tested against 4T1 breast cancer cells (as described in section 3.2.9) and the live/dead
confocal images of the treated cells are shown in Figure 3-9c. The results demonstrated
that 4T1 cells could not be completely killed in the absence of NIR light. In contrast, NPsDOX-CS fibers were capable of completely killing the cells upon NIR laser irradiation,
through synergistic effect of hyperthermia and chemotherapy. Overall, the obtained
results revealed that CS fibers possessed certain level of toxicity towards cancer, but not
towards healthy cells. Besides, the NPs-containing fibers (NPs-CS and NPs-DOX-CS)
were capable of killing the cells with a higher efficiency, due to their hyperthermia effect.

3.3.8. In vivo photo-thermal effect
Next, the photo-thermal conversion effect of the fibers was assessed by implanting 4 cm
of fibers subcutaneously in animal models, and subsequently exposing them to 808 nm
laser irradiation (power density of 1.0 W·cm−2) for 10 min (Figure 3-10). Consequently,
the results showed that NPs-CS and NPs-DOX-CS fibers were capable of increasing the
temperature of irradiation site up to 57°C and 65°C, respectively. Whereas, all the other
fibers (CS and DOX-CS) did not show any significant raise in their temperature when
compared to that of control samples. Furthermore, we have repeated the same experiment
with 2 cm of the fibers (Figure 3-S3, supporting information), to compare the data with
previously obtained in vitro observations. Accordingly, the fibers did not show any
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significantly different temperature profiles, indicating the length-dependence photothermal conversion effect of the fibers. Most importantly, the obtained in vivo
temperatures in this study (50 ºC to 65 ºC) were perfectly in range of previously reported
temperature for the death of tumor cells and tumor-encapsulating blood vessels.350

Figure 3-10. In vivo photo-thermal conversion effect of 4 cm of the fibers. (a) Schematic
representation of subcutaneous implantation of the fibers in mice model, (b) Infrared thermal
images and (c) corresponding temperature curves upon exposure to 808 nm NIR laser for 10 min,
under power densities of 1.0 W·cm–2.

3.3.9. In vivo tumor eradication
Lastly, in vivo experiments were carried out by implanting 4 cm of the fibers next to a
subcutaneous tumor model in mice, and subsequently irradiating them with NIR laser (as
described in section 3.2.10). Accordingly, tumor volume values were recorded throughout
the experiment (Figure 3-11a) and 24 days post-treatment the following tumor volume
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values were obtained: i) 1184.3 ± 175.3 mm3 for control, ii) 1121.4 ± 320.7 mm3 for CS,
iii) 1037.0 ± 280.0 mm3 for DOX-CS, iv) 463.2 ± 534.8 mm3 for NPs-CS, and v) 196.6
± 393.2 mm3 for NPs-DOX-CS. Among all samples, mice treated with NPs-DOX-CS
fibers showed a significantly lower tumor volume value 24 days post-treatment (as
compared to control group), indicating that these fibers inhibited the tumor growth, and
even in some cases completely eradicated the tumor as further shown in Figure 3-11c.

Figure 3-11. In vivo tumor eradication performance of different fibers in 4T1 tumor‐bearing mice
(4 cm fibers, n= 6 in each group, *P < 0.05), upon exposure to 808 nm NIR laser (power density of
1.0 W·cm−2) for 10 min, 24 hr post fibers implantation. (a) Tumor volumes, and (b) Body weights of
mice in different groups at every time point throughout the experiment. (c) Representative
photographs of mice bearing 4T1 tumors before and after treatments.

In contrast, under similar circumstances, NPs-CS fibers were only capable of preventing
the tumor growth for a short period of time (approximately 8 days), which was followed
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by a partial regrowth of the tumors. This was probably due to synergistic photothermal/chemotherapeutic effect of NPs-DOX-CS fibers which led to their prolonged
higher anti-cancer efficacy. It is assumed that the heat generated by the photothermal
therapy might have reduced the tumor interstitial fluid pressure (TIFP) by interrupting the
highly packed order of the cancer cells in the tumors, hence enhancing uptake of
macromolecular therapeutics in tumor tissue.351 Also, photothermal therapy can interrupt
the growth of fibrous or connective tissue around the tumor (desmoplasia) leading to
enhanced drug uptake.352 Regardless, all treated mice did not experience any significant
weight loss throughout the study, which indicated that all treatments were well tolerated
and did not cause any major toxicity (Figure 3-11b). Noting, Zhang et al., previously
evaluated the hemo-compatibility and bio-distribution of these copper selenide
nanoparticles in animal models, and it was shown that these nanoparticles caused minimal
toxicity to the animals.353
Furthermore, a separate set of experiments (under similar conditions) were also conducted
where animal were treated with 2 cm of the fibers, and the results were shown in Figure
S4. Correspondingly, a similar trend was observed in the treated animals where NPsDOX-CS fibers showed the highest level of tumor growth prevention (Figure 3-S4a,
supporting information). However, 2 cm of these fibers was not capable of completely
eradicating the tumor as depicted in Figure S4b. This further shed light on association
between the length of these fibers and their corresponding anti-cancer efficacy. In
conclusion, the in vivo results suggested that NPs-DOX-CS fibers could be potentially
applied as implants for preventing the tumor growth, in which their anti-cancer efficacy
can be tuned based on their length.
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3.4.

Conclusion

In this chapter, for the first time, a coaxial mussel-inspired composite fiber was fabricated
for local chemo-photothermal combinational cancer therapy. Particularly, the coresection of these fibers (Chemo-compartment) contained dopamine-modified alginate
along with a chemotherapeutic drug (Doxorubicin; DOX), while their shell section
(Phothothermal compartment) was composed of UV-crosslinkable methacrylatemodified alginate together with Cu2−xSe nanoparticles (NPs). First, successful fabrication
of the coaxial fibers was assessed through a series of physiochemical characterization
methods including SEM, EDX elemental mapping, FTIR, XRD, and TGA. We have
further shown that these fibers possessed good mechanical properties, in both static and
dynamic conditions, and they were capable of releasing DOX over a span of 21 days.
Also, NPs-containing fibers demonstrated a photo-thermal conversion capability upon
NIR laser irradiation (both in vitro and in vivo), in which the obtained temperature profiles
could be directly tuned by adjusting the length of the fibers. Noting, the fibers only start
to chemically degrade at temperatures above 200ºC (TGA test; Figure 3-4) which below
the highest achieved temperature in both in vitro (70ºC) and in vivo (65ºC) studies. As a
result, the increase in temperature during laser irradiation does not cause degradation of
the fibers. In addition, the glass transition temperature of alginic acid cross-linked with
calcium chloride is above 75°C

354-356

, and it has been shown previously that hydrogel

swelling ratio stays constant at temperatures below this.357 This implies that an increase
in temperature during laser irradiation did not interfere with the drug release profile.
Furthermore, during in vivo studies only one term of laser irradiation was used which
lasted for 10 min and this would not have a major impact on the obtained drug release
profile.
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Next, It was shown that CS fibers possessed a specific cancer cell killing capability in
vitro, as they consistently yielded low levels of viability in breast cancer cells (4T1 mouse
breast cancer cells), while not showing such effect in healthy cell lines (NIH-3T3 mouse
fibroblast cells). Besides, it was shown that NPs-DOX-CS fibers were capable of
completely eradicating the cancer cells in vitro upon NIR laser irradiation (808 nm laser
for 10 min, under power densities of 1.0 W·cm–2). Most remarkably, in vivo experiments
revealed that in presence of NIR laser, NPs-DOX-CS fibers were capable of effectively
preventing the tumor growth up to 24 days, without causing any major toxicity to the
animals. In addition, the in vivo anti-cancer efficacy of NPs-DOX-CS fibers was shown
to have a direct correlation with the length of the implanted fibers. To conclude, the
coaxial mussel-inspired composite fiber, containing DOX (in the core) and NPs (in the
shell), could be a safe and effective implant for combinational chemo-photothermal
therapy of tumors.

3.5.

Supporting information

3.5.1.

HNMR and FTIR analysis of the synthesized polymers

For coaxial fiber fabrication, we first synthesized alginate-dopamine (theoretical
substitution degree of 50 % - in terms of alginate repeating units) using standard
141 | P a g e

carbodiimide chemistry. We then synthesized alginate-methacrylate using methacrylic
anhydride. Fourier-transform infrared spectroscopy (FTIR) and proton nuclear magnetic
resonance (1H NMR) were employed to investigate successful synthesis of alginatedopamine and alginate-methacrylate. Accordingly, FTIR spectrum of both alginatedopamine and alginate-methacrylate (Figure 3-S1a, supporting information) showed
the characteristic peaks of alginate associated with C-O stretching vibration (1030 cm-1),
COO- symmetric and asymmetric stretching vibration (1415 and 1600 cm-1, respectively),
and –OH stretching vibrations (3325 cm-1). More specifically, alginate-dopamine
spectrum showed appearance of peaks at 1544 cm–1, and 1220 cm–1 assigned to the N–H
deformation and C–N stretching vibrations. In addition, significant reduction in intensity
of COO- bands (1415 and 1600 cm-1) further indicated the successful attachment of
dopamine to the alginate back bone via carbodiimide chemistry. Successful synthesis of
alginate-dopamine was further confirmed using HNMR via appearance of catechol
protons at around 7 ppm (Figure S1b-ii, supporting information). Further, the relative
integration of catechol protons (6.6-7 ppm) to anomeric protons of the glucose ring of
alginate (4.9 ppm) were used to determine the degree of substitution which was measured
to be 16 % (in terms of alginate repeating units).
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Figure 3-S1. Physiochemical characterization of as-synthesized polymers including, (a & b) FTIR
and HNMR spectra of i) pure alginate, ii) alginate-dopamine, and iii) alginate-methacrylate.
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Figure 3-S2. In vitro photo-thermal conversion effect of 2 cm of the fibers in SBF. (a) Infrared
thermal images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for
10 min, under power densities of 1.0 W·cm–2.
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Figure 3-S3. In vivo photo-thermal conversion effect of 2 cm of the fibers. (a) Infrared thermal
images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for 10 min,
under power densities of 1.0 W·cm–2.

145 | P a g e

Figure 3-S4. In vivo tumor eradication performance of different fibers in 4T1 mice xenografts (2 cm
fibers, n= 6 in each group), upon exposure to 808 nm NIR laser (power density of 1.0 W·cm−2) for
600s, 24 h post fibers implantation. (a) Tumor volumes of mice in different groups at every time
point throughout the experiment. (b) Representative photographs of mice bearing 4T1 tumors after
treatments.
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Chapter 4

4. 3D-printed coaxial hydrogel patches with mussel-inspired
elements for prolonged release of Gemcitabine
4.1.

Introduction

The therapeutic modalities for cancer are very much dependent on the type and state of
the disease, and so far a variety of treatments have been exploited in the clinic.3 More
specifically, such treatments are aimed to address one or more of the following issues
associated with cancer: (i) to shrink inoperable solid tumors to make them operable, (ii)
to prevent recurrence of a tumor after surgical resection, and (iii) to eliminate circulating
cancer cells in the peripheral blood in patients with metastasis.2 Along these lines,
systemic administration of relevant drugs has been used prevalently to resolve some of
the above-mentioned issues, and it even yielded some promising results in the clinic.240
However, as discussed in Chapter 1 (Section 1.3), systemic administration of drugs is
often linked to undesirable consequences such as high-dose requirement, poor
bioavailability, and adverse side effects.358 This started a scientific movement towards
discovering various ways where the drugs could be delivered locally to the tumor site,
with the aim of rectifying drawbacks of systemic administration.4 Consequently,
biopolymers entered the fray as candid materials to institute implantable drug delivery
systems, designed for local delivery of therapeutics to the diseased site.359 Thus, various
fabrication technologies were employed to facilitate the making of these biopolymeric
drug delivery systems, while each imposed their own set of advantages and
disadvantages.359 Among them 3D printing technologies offer considerable advantages
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including reproducibility, and ability to design geometrically complex shapes.360 In
addition, 3D printing is compatible with a variety of biopolymers ranging from
hydrophobic thermoplastic polymers (such as polycaprolactone; PCL, and polylactic
acid; PLA) to hydrophilic hydrogels (such as alginate, chitosan, and gelatine).160, 361 For
instance, Yi et al. fabricated 3D printed patches made from a mixture of PLGA
(lactide:glycolide = 85:15) and PCL loaded with Fluorouracil (5‐FU), which was aimed
for growth suppression of pancreatic cancer.29 Accordingly, it was shown that the specific
geometry (latticed, slant, or triangular) and number of layers could directly affect the
release profile of 5-FU. Moreover, these patches were capable of releasing 5-FU over a
period of 4 weeks and when tested in mice with subcutaneous MIA-PaCa-2 pancreatic
tumors they induced significant reduction in relative tumor size compared to that of empty
implanted patches. In another instance, 3D printed scaffolds made from PCL were used
for local delivery of Doxorubicin (DOX) to inhibit breast cancer tumor growth.30
Consequently, the results showed that these scaffolds were capable of releasing DOX
over a period of 14 days, and when tested in mice with subcutaneous MDA-MB-231
breast cancer tumors they were capable of inhibiting tumor growth to a higher degree with
less systemic toxicity compared to that of mice who received equivalent dosage of the
drug systemically.30 Based on the existing evidence in the literature, most of the 3D
printed cancer drug delivery systems are made from hydrophobic thermoplastic polymers,
which indicated the infancy of research in the field of 3D printed hydrogels for cancer
drug delivery.359, 362-366
In Chapter 2 we have previously investigated the application of coaxial mussel-inspired
hydrogel fibers for delivery of two chemotherapeutic drugs (Gemcitabine and
Doxorubicin) and the in vitro release studies showed that these coaxial fibers were
capable of releasing Doxorubicin over a period of 21 days.367 However, they did not yield
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a sustained release of Gemcitabine (GEM) as they released the entire loading in a 10 hr
time span. The quick release of Gemcitabine from those fibers, as compared to
Doxorubicin, was associated with its smaller molecular size. Along similar lines, it is
suggested that controlling a hydrogel swelling behaviour could decrease its pore size
distribution, which can mediate a slower drug release rate from the gel.342 One of the
common approaches to control the swelling of hydrogels is to implement crosslink agents
that allow physical or chemical crosslinking of the polymeric chains.368 For instance,
alginate-based hydrogels have been shown to undergo ionic crosslinking with calcium
carbonate (CaCO3), which directly affected their pore size distribution in a concentrationbased manner.369 Another approach to control the swelling of hydrogels is to subject them
to a hydrophobic polymeric coating that could spatially confine the hydrogel
boundaries.370 For instance, drug-loaded alginate disks were successfully coated with
PCL, which subsequently led to a reduced swelling of the disks and instigated a slower
release of the drug.371
In this chapter, with the purpose of fabricating a suitable platform for prolonged delivery
of Gemcitabine (a chemotherapeutic drug), we have 3D printed a novel coaxial hydrogel
patch. Particularly, the core-section of these patches contained dopamine-modified
alginate methacrylate loaded with Gemcitabine, while their shell section was solely
comprised of alginate methacrylate. Subsequently, these patches were further modified
with CaCO3 cross linker and a PLA coating to facilitate prolonged release of the drug.
Accordingly, different properties of the fabricated patches were characterized including
their microstructural morphology (scanning electron microscopy; SEM), tensile
properties in both static and dynamic conditions (mechanical tester and dynamic
mechanical analysis, respectively), and their swelling behaviour. The results showed that
addition of CaCO3 to the formula enhanced the mechanical properties of the patches and
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significantly reduced their swelling ratio as compared to that for patches without CaCO3.
Furthermore, addition of PLA coating to CaCO3-containing patches has further reduced
their swelling ratio, which then significantly slowed down the release of Gemcitabine, to
a point where 4 layered patches were capable of releasing Gemcitabine over a period of
7 days in vitro. Moreover, PLA coated CaCO3-containing patches showed a good level
of biocompatibility when tested in vitro against two pancreatic cancer cell lines (MIAPaCa-2 and Panc-1). Lastly, a 14 days cell counting assay (CCK-8) was conducted using
MIA-PaCa-2 cells to measure long term therapeutic effect of GEM-loaded patches, and
the results showed that 3 layers- and 4 layers structures were successful in inhibiting the
cancer cell growth for the entire duration of study. Overall, our proposed approach for
achieving a sustained release of Gemcitabine from 3D-printed hydrogel patches has been
shown to be effective, and with future development, these patches might become useful
as neo-adjuvant or adjuvant therapies in cancer patients.

4.2.

Experimental section

4.2.1. Materials
Alginic

acid

sodium

salt

from

brown

dimethylaminopropyl)-Nˊ-ethylcarbodiimide

algea

(medium

hydrochloride

viscosity),

N-(3-

(≥99.0%),

N-

hydroxysuccinimide, dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%),
methacrylic anhydride, calcium carbonate (CaCO3; <50µm size), d-(+)-gluconic acid δlactone (GDL), and IRAGACURE D-2959 were purchased from Sigma Aldrich. Sodium
hydroxide (NaOH), ethanol (96%), and chloroform were purchased from Chem-Supply.
Poly(DL-lactide) (PURASORB PDL 20) was purchased from Corbion. Gemcitabine
hydrochloride was purchased from Focus Bioscience. Simulated body fluid (SBF) was
prepared as explained before.19 D2O (100% - CIL) was supplied by Novachem.
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4.2.2. Synthesis and characterization of alginate-methacrylate
Alginate-methacrylate was synthesized using methacrylic anhydride as described
previously.258, 261 Briefly, 3 g of alginic acid was dissolved in 300 ml of distilled water
(1% w/v) to which 24 ml of methacrylic anhydride (8% v/v) was added and the pH was
maintained at 8 for 6 hrs using 5.0 M NaOH solution. Afterwards, the solution was
dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD) for 7 days and precipitated
in ethanol followed by freeze-drying. Successful attachment of methacrylate groups onto
the alginate backbone was further confirmed using FTIR (Shimadzu IRPrestige-21
infrared spectrometer) and HNMR (Bruker 400 MHz) spectroscopy.

4.2.3. Synthesis and characterization of alginate-methacrylate-dopamine
Alginate-methacrylate-dopamine was synthesized using carbodiimide chemistry.257
Briefly, 1 g of alginate-methacrylate (5 mmol in terms of repeating unit) was dissolved in
100 ml of 0.1 M MES buffer with pH of 5.6. EDC and NHS were separately dissolved in
2 ml of MES buffer (2.5 mmol) and subsequently added to the alginate methacrylate
solution. while the reaction were allowed to continue for 30 min. Dopamine
hydrochloride (at equal concentration to EDC and NHS) was separately dissolved in 2 ml
of MES buffer and added to the mixture subsequently. The reaction were allowed to
happen for 1 hr under nitrogen flushing. Afterwards the solution was dialyzed (spectra/
por membrane tubing; MWCO 12–14 kD) for 7 days against acidic water (pH of 6) and
subsequently precipitated in ethaol. The precipitated polymers were next lyophilized
using a freeze-dryer. Incorporation of dopamine into alginate-methacrylate was further
confirmed using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR
(Bruker 400 MHz) spectroscopy.
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4.2.4. Rheology
All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm,
DYMAX BlueWave 75).

4.2.5. 3D printing of coaxial hydrogel structures
In this study 2 different formulations of core-shell structures were made: i) without
CaCO3 (-CaCO3), ii) with CaCO3 (+CaCO3). Two different solutions were used to prepare
the core-shell structures. Accordingly, the core aqueous solution contained 6% (w/v) of
alginate-methacrylate-dopamine and 0.05% (w/v) IRAGACURE D-2959. On the other
hand, the shell aqueous solution contained 6% (w/v) of alginate-methacrylate and 0.05%
(w/v) IRAGACURE D-2959. Of note, for structures with CaCO3, 144 mM of CaCO3 and
36 mM of GDL were added to both core and shell solutions, based on previously reported
values.369 Also, for GEM-containing patches Gemcitabine hydrochloride (50 mM) was
added to the core solution. Structures in different geometries (Figure 4-S1, supporting
information) were printed via a GeSiM BioScaffolder (Model 3.1) using a coxial nozzle
with a core diameter of 400 µm and a shell diameter of 800 µm. The print parameters as
input to the proprietary GeSiM software are listed in table 1. A UV light (365 nm,
DYMAX BlueWave 75) was used to facilitate photo-crosslinking of the structures for
both patches and strands.
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Table 4-1. Parameters used for fabrication of the printed structures.

4.2.6. PLA coating of 3D printed patches
The previously 3D printed patches containing CaCO3 were allowed to dry overnight in
room temperature, and subsequently dip coated into a 15% (w/v) solution of Poly(DLlactide) in chloroform followed by overnight drying at room temperature. The dried
coated patches were used for further processing.

4.2.7. Characterization of printed structures
The morphology of 3D printed patches were investigated using Leica M205A
stereomicroscope. Scanning electron microscopy (SEM) observations were performed
using a JEOL JSM-6490LV microscope. SEM images were taken in high vacuum mode
at 15 kV operating voltage and a spot size setting of 60. For SEM imaging, the patches
were first allowed to completely swell in SBF, then they were cut in half using a razor
blade to expose their cross-section and subsequently inserted into special sample holders.
The sample holder containing the mounted structure was then immersed into liquid
nitrogen for about 45 s. The sample holder was then quickly transferred to the LVSEM
for examination. The static tensile properties of strands were assessed using a mechanical
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tester (EZ-L tester from Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry
and wet strands, respectively. The dynamic mechanical properties of strands was
evaluated using a dynamic mechanical analysis (DMA 242 E Artemis, NETZSCH).
Accordingly, by using a tension clamp the samples were exposed to a constant strain (0.1
%) of increasing frequencies in the range of 0.1 to 10 Hz for 30 min, subsequently storage
and loss modulus were recorded and Tan delta (damping factor) values were measured as
a ratio of loss modulus to storage modulus. The static compressive properties of the
patches in wet state were assessed using a mechanical tester (EZ-L tester from Shimadzu)
at 10 mm.min-1 via a 50 N load cell. Lastly, the swelling properties of the hydrogel
patches were determined by examining their water uptake capacity. The hydrogel patches
were incubated in simulated body fluid (SBF) at 37°C and allowed to fully swell. The
swelling ratio was calculated using the following equation: (Ws – Wd)/Wd, where Ws
represents the weight of the swollen hydrogel patches and Wd represents the weight of
the dried hydrogel patches at the beginning.

4.2.8. Release studies from drug loaded patches
To measure the Gemcitabine release from the patches, each patch was immersed in 5 ml
of SBF solution. The supernatant was collected at certain time points and replaced with
fresh SBF. For quantifying the Gemcitabine release, a high performance liquid
chromatography (HPLC, Agilent 1260 infinity) was used. Briefly, Samples were filtered
through a 0.2 μm syringe membrane filter unit before being injected (10 μL) onto a
ZORBAX Eclipse Plus column (4.6 × 100 mm, 5 μm particle size). Using an isocratic
elution with a water/acetonitrile (95/5), draw and eject speed of 200 μL/min, pressure 300
bar, Gemcitabine was detected with the UV-Visible detector at 272 nm. The absorption
values were converted to concentrations using a previously observed calibration curve.
The release results were plotted as mean value of three repeated tests.
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4.2.9. In vitro cell studies
All cell lines were authenticated using short tandem repeat (STR) profiling at the Garvan
Institute of Medical Research. Cells (MIA-PaCa-2 or PANC-1 cells obtained from
ATCC) were cultured in DMEM-High glucose media containing 10% fetal calf serum
(FCS) at 37 °C, 95% humidity and 5% CO2 in a Heracell incubator (Kendro Laboratory
Products, Germany). When 80% confluence was reached, cells were detached by
incubation with 5 mM trypsin/EDTA and harvested after centrifugation in a Heraeus
Megafuge 1.0 (Thermo Scientific, USA) at 1200 rpm for 5 min at RT. Cells were
resuspended in media, and viable cells counted using a hemocytometer and trypan blue
staining. Cells were confirmed free of mycoplasma contamination. MIA-Paca-2 and
Panc-1 cells were seeded 4 × 104 cells/well in 24-well flat bottomed plates in complete
media (1 mL) containing 1% penicillin/streptomycin and kept in the incubator for 24 hr
prior to addition of empty or drug loaded patches. After 72 hr the patches were removed
from the wells and subsequently 40 µL of MTS agent was added and allowed to react
with the cells for 3 hrs. The absorption of each solution was measured at 490 nm on a
microplate reader (SPECTRA max, PLUS). For live cell staining, at 72 hr time point the
media was removed from the wells and subsequently the cells were washed with PBS.
Next 500 µL of PBS solution (Containing 2.5 µL of Calcein AM and 1 µL of Propidium
Iodide; Sigma Aldrich) was added to the wells and the plates were incubated for 15 min,
after which the staining mixture was removed from the wells and replaced with fresh PBS.
Immediately after the IncuCyte ZOOM system (Essen BioScience, USA) at 10 ×
magnification, with green (live cells) and red (dead cells) filters, was used to image the
cells.
To confirm the long-term therapeutic effect on inhibition of cancer cell growth, the effect
of the medium supernatant of the drug loaded or empty patches on the viability of the
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human pancreatic cancer cell line, MIA-PaCa-2 cell line, was assessed using a cell
counting kit-8 method (Sigma, St. Louis, MO, USA) based on manufacturer’s guideline.
MIA-PaCa-2 cells were cultured in RPMI-1640 medium (Gibco) supplemented with 10%
v/v fetal bovine serum (Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin
(Invitrogen) at 37 °C in 5% CO2 in a humidified incubator. Cells were plated at a density
of 3 × 103 cells per well in a 96-well culture plate and incubated for 24 hr before drug
treatment. To assess the therapeutic effect of the drug released from the patches, the
patches incubated in complete culture media at 37 °C in 5% CO2 in a humidified
incubator and then the supernatant was collected at determined intervals. At day 1 after
cell seeding, we changed the media to corresponding supernatants. Cell viability at each
time point was determined using a cell counting kit-8 assay (CCK-8; Sigma Aldrich)
according to the manufacturer’s guideline.

4.2.10. Statistical analysis
Statistical significance was determined using a two-way ANOVA with a Sidak post-test
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P =
0.0001. Values are reported as the average ± standard deviation.

4.3.

Results and discussion

4.3.1. Chemical characterization of the synthesized polymers
Initially the chemical structure of the synthesized polymers were assessed using Fourier
Transform Infrared (FTIR) and Proton nuclear magnetic resonance (HNMR)
spectroscopies and results are shown in Figure 4-1. Accordingly, the FTIR spectra of
both alginate-methacrylate and alginate-methacrylate-dopamine (Figure 1a) showed the
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characteristic peaks of alginate at 1035 cm-1, 1408 cm-1, 1606 cm-1, and 3350 cm-1
associated with C-O stretching vibration, COO- symmetric and asymmetric stretching
vibration, and –OH stretching vibrations, respectively.372 More specifically, both spectra
also showed two more peaks at 1165 cm-1, and 1712 cm-1 attributed to C=O and C-O
groups of the esters resulting from the grafting of the methacrylate units.265

Figure 4-1. Chemical characterization of as-synthesized polymers including, (a) FTIR and (b & c)
HNMR spectra of i) alginate-methacrylate, and ii) alginate-methacrylate-dopamine.

Additionally, alginate-methacrylate-dopamine spectrum showed appearance of three new
peaks (due to attachment of dopamine) at 1210 cm-1, 1470 cm-1 and 2850-2950 cm-1
assigned to C–N stretching vibrations, N–H deformation, and C-H stretching vibrations,
respectively.262-263 Also, HNMR analysis of alginate-methacrylate (Figure 4-1b) proved
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the grafting of methacrylate groups by appearance of double peaks (vinyl) in the double
bond region (5.5-6.5 ppm).265 Furthermore, the relative integration of methyl protons (of
methacrylate groups) to anomeric protons of the glucose ring of alginate (4.9 ppm) were
used to determine the degree of substitution which was 42% (in terms of alginate
repeating units). In a similar manner, HNMR analysis of alginate-methacrylate-dopamine
(Figure 4-1c) showed the mentioned double peaks in the double bond region (5.5-6.5
ppm) associated with methacrylate groups, along with appearance of catechol protons at
around 7 ppm associated to the dopamine. 264 Further, the relative integration of catechol
protons (6.6-7 ppm) to anomeric protons of the glucose ring of alginate (4.9 ppm) were
used to determine the degree of substitution which was measured to be 18 % (in terms of
alginate repeating units). Overall, these results suggested that alginate-methacrylate and
alginate-methacrylate-dopamine were successfully synthesized.

4.3.2. Rheometry
Considering the essential role of polymer rheology in subsequent properties of the 3D
printed structure,373 viscoelastic properties of all printing solutions were assessed using a
rheometer and the results are shown in Figure 4-2.

Figure 4-2. Rheometry of printing solutions including (a) Viscometry of 6% (w/v) solution of i)
alginate-methacrylate, ii) alginate-methacrylate-dopamine, iii) alginate-methacrylate + CaCO3, and
iv) alginate-methacrylate-dopamine + CaCO3. (b) Oscilatory rheology of 6% (w/v) solutions
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(containing 0.05% (w/v) IRAGACURE D-2959) of i) alginate-methacrylate-dopamine, ii) alginatemethacrylate-dopamine + CaCO3, iii) alginate-methacrylate, and iv) alginate-methacrylate +
CaCO3.

Accordingly, both alginate-methacrylate (Figure 4-2a i) and alginate-methacrylatedopamine (Figure 4-2a ii) solutions demonstrated shear thinning behaviour as their
viscosities gradually decreased with increase in the shear rate, yet alginate-methacrylatedopamine solution showed a higher viscosity throughout the measurement range which
was speculated to be a result of noncovalent interactions of dopamine moieties among
each other.374 Most remarkably, after addition of CaCO3 the viscosity of both alginatemethacrylate (Figure 4-2a iii) and alginate-methacrylate-dopamine (Figure 4-2a iv)
solutions increased significantly due to ionic interaction between Ca2+ ions and alginate
backbone, however alginate-methacrylate-dopamine solution showed a higher level of
increase in its viscosity which was assumed to be due to catechol-ion interactions through
formation of a bis-complex.375 Moreover, both alginate-methacrylate and alginatemethacrylate-dopamine solutions containing CaCO3 (Figure 4-2a iii & 4-2a iv), showed
a more pronounced shear-thinning behaviour when compared to their counterparts
without CaCO3 (Figure 4-2a i & 4-2a ii). This is due to disruption of calcium-alginate
egg-box model and calcium-dopamine bis-complex upon increasing the shear-rate.376 To
further evaluate the UV crosslinking-ability of the 3D printing solutions, oscillatory
experiments (as a function of time) upon UV irradiation were conducted and the results
are shown in Figure 4-2b. Accordingly, both alginate-methacryate (Figure 4-2b iii) and
alginate-methacrylate-dopamine (Figure 4-2b i) solutions experienced a significant jump
in their storage modulus upon initiating the UV irradiation, an indication of UV crosslinking of both solutions. Of note, alginate-methacrylate-dopamine experienced a slightly
lower storage modulus after UV irradiation when compared to that of alginatemethacrylate, which could be attributed to the effect of dopamine moieties in the polymer
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absorbing part of the UV rays.377 Also, addition of CaCO3 to alginate-methacrylate
(Figure 4-2b iv) and alginate-methacrylate-dopamine (Figure 4-2b ii) solutions caused
a slight increase in their corresponding storage modulus associated with presence of ionic
bonds in the formulations. Overall it was shown that all solutions had shear-thinning
behaviours were UV-crosslinkable, making them suitable for extrusion printing.

4.3.3. Morphological analysis of 3D printed patches
With the aim of studying the morphology of the 3D printed patches light microscopy and
scanning electron microscopy were implemented and the results were shown in Figure
4-3 and Figure 4-S2 (Supporting information). First, we have evaluated the
morphology of 3D printed structure in the absence of CaCO3 cross linker (Figure 4-3a,c).
Accordingly, it was shown these patches possessed intricate structures with well-ordered
dimensions, and their cross-section SEM images revealed their perfectly circular coaxial
microstructure where the shell thickness in range of 70-84 µm. Of interest, the shell
showed a less porous structure as compared to that of the core, probably due to absorption
of a portion of UV light by the dopamine moiety in the core which hindered their further
chemical cross-linking (as it was observed in rheology studies of section 4.3.2). Next, we
have examined the morphology of 3D printed patches that contained CaCO3 cross linker
(Figure 4-3d,f). The results showed that these patches contained opaque structures with
rough edges due high viscosity of their precursor solutions (as discussed in section 4.3.2)
and their cross-section SEM images further revealed their almost circular coaxial
microstructure with occasional CaCO3 agglomerates, where the shell thickness was in
range of 120-145 µm. Lastly, the morphology of PLA coated 3D printed patches
containing CaCO3 cross linker were examined and the results were shown in Figure 4S2 (Supporting information). Correspondingly, the PLA coating was hard to detect from
the light microscopy image, however their cross-section SEM images clearly showed the
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PLA coating around a single strand of the structure with a thickness in range of 50-90
µm. Of note, the coaxial structure was hard to observe in these structures as the PLA
coating avoided full swelling of the hydrogel components. Also, the partial deformation
of the encapsulated 3D printed structure in this SEM image was a result of cutting
procedure to expose their cross-section for imaging purposes. Overall, the results showed
that addition of CaCO3 cross linker to the patches caused changes to the microstructure
of the patches due to interactions between Ca2+ and alginate backbone. Also, it was shown
that PLA coating did not have any negative effect on the microstructure of the patches.

Figure 4-3. (a) Light microscopy and (b & c) SEM images of 3D printed coaxial patches without
CaCO3. (d) Light microscopy and (e & f) SEM images of 3D printed coaxial patches with CaCO3.
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4.3.4. Mechanical properties of the 3D printed patches
To further assess the effect of CaCO3 cross linker addition on the subsequent mechanical
properties of the fabricated structures we have specifically printed single coaxial strands
(as described in section 4.2.5 and shown in Figure 4-S1a, supporting information) and
applied them to either static or dynamic tensile stress. Thus, measurements in static state
were carried out for strands in both dry and wet state and the results were shown in Figure
4-S3, supporting information. Correspondingly, in dry state no significant difference
was observed in tensile strength values of the strands without CaCO3 (30.3 ± 3.3 MPa)
and the ones with CaCO3 (29.3 ± 2.4 MPa). However, strands with CaCO3 had a higher
modulus values (1.1 ± 0.1 GPa) when compared to that of strands without CaCO3 (0.7 ±
0.05 GPa). In wet state a significant difference was observed in both tensile strength and
modulus values of the strands with CaCO3 (0.096 ± 0.002 MPa and 0.17 ± 0.02 MPa,
respectively) as compared to those of strands without CaCO3 (0.05 ± 0.005 MPa and
0.025 ± 0.007 MPa, respectively). The obtained results suggested that addition of CaCO3
cross linker has led to improvements in mechanical properties of the strands especially in
wet state, and the corresponding values were comparable to that of other printed hydrogel
strands in the literature.378-379
To gain a better insight into dynamic mechanical properties of the strands an oscillating
tension test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz was conducted
(Figure 4-4). The obtained results showed that for both formulations (with or without
CaCO3) storage modulus values were significantly higher than loss modulus values over
the entire frequency range, indicating the prominence of elastic behaviour over viscous
behaviour in all the formulations (Figure 4-4c). Moreover, as shown in Figure 4-4a
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strands with CaCO3 showed a significantly higher storage modulus (8159.5 ± 182.7 MPa)
over the entire frequency range when compared to that of strands without CaCO3 (2233.0
± 119.3 MPa). As a result, strands with CaCO3 showed to have a significantly lower
damping factor (0.0295 ± 0.0007) in comparison to that of strands without CaCO3 (0.051
± 0.007) (Figure 4-4d). Overall, the measurements in dynamic conditions showed that
strands with CaCO3 had a more elastic response to oscillating stress when compared to
strands without CaCO3, which was further attributed to calcium-alginate and calciumdopamine interactions that were previously observed in rheology measurements. Lastly,
given the superior tensile properties of structures with CaCO3, a static compression test
was applied to 2-, 3-, and 4-layered 3D printed patches that were made from the same
formulation and the results were shown in Figure 4-S4, supporting information.
Consequently, a common trend was observed where the strength of the patches increased

in accordance with their number of layers, as the 4-layers structures showed to withstand
the most amount of compression force amongst others.
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Figure 4-4. Dynamic mechanical analysis of 3D printed coaxial strands by using a tension clamp.
The samples were exposed to a constant strain (0.1 %) of increasing frequencies in the range of 0.1
to 10 Hz for 30 min. (a) Storage modulus and (b) Loss modulus of strands at different frequencies.
(c) Storage and loss modulus at the frequency of 10 Hz. (d) Tan delta (damping factor) at the
frequency of 10 Hz (n = 3, mean ± SD) (*P = 0.05, ****P = 0.0001).

4.3.5. Gemcitabine release studies
Next in vitro release of Gemcitabine from three different formulations of 3D printed
patches (without CaCO3, with CaCO3, and PLA coated with CaCO3) were assessed as
described in section 4.2.8 and the results were shown in Figure 4-5.
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Figure 4-5. In vitro Gemcitabine release studies from various 3D printed coaxial patches including
(a-b) patches without CaCO3, (c-d) patches with CaCO3, and (e-f) PLA coated patches with CaCO3.
(n = 3, mean ± SD)

Accordingly, Patches without CaCO3 (Figure 4-5a,b) showed a burst release of the drug
in the first 2 hr of the experiment where 78.8 ± 0.2%, 71.9 ± 0.5%, and 62.5 ± 2.6% of
the drug was released from 2-, 3-, and 4-layers structures, respectively. However, all these
patches reached a plateau level at the 4 hr of the release and they failed to yield a sustained
release of the drug. Subsequently, patches with CaCO3 (Figure 4-5c,d) were tested and
they collectively showed a slower release profiles compared to obtained results from the
patches without CaCO3. Patches with CaCO3 still showed a burst release of the drug in
the first 2 hr of the experiment where 50.1 ± 1.0%, 37.5 ± 2.4%, and 25.9 ± 2.0% of the
drug was released from 2-, 3-, and 4-layers structures, respectively. Yet, these patches
also failed to provide a sustained release of Gemcitabine as their release profiles reached
a plateau level at the 6 hr of the release. Next, PLA coated patches containing CaCO3
(Figure 4-5e,f) were tested and they collectively showed a slower release profiles
compared to obtained results from the patches with only CaCO3. Correspondingly, these
patches have released Gemcitabine in a peculiar manner over two different stages: (i)
initially Gemcitabine was released with a faster rate in the first 10 hr of the experiment
where 29.3 ± 0.9%, 25.7 ± 0.7%, and 24.0 ± 0.07 of the drug was released from 2-, 3-,
and 4-layers structures, respectively. (ii) This was followed by a slower release of the
drug which lasted 3 days (40.0%), 4 days (36.0%), and 7 days (30.0%) for 2-, 3-, and 4layers structures, respectively. The obtained results suggested that PLA coated patches
containing CaCO3 had the slowest Gemcitabine release profile and specifically 4-layers
structures were capable of releasing the drug over a period of 7 days, which was longer
than that from other hydrogels reported in the literature.19, 274, 380-384 Furthermore, with the
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aim of further investigating the obtained release profiles, the swelling ratio values of the
tested patches were measured and the results were shown in Figure 4-5a. Accordingly,
addition of CaCO3 has significantly reduced the swelling ratio of the patches from 42.9 ±
1.0 to 17.9 ± 0.6, which was attributed to calcium-alginate and calcium-dopamine
interactions. Moreover, addition of a PLA coating to CaCO3-contaning patches further
reduced their swelling ration down to 1.2 ± 0.5, which was due to hydrophobic nature of
the PLA coating which hindered fast penetration of water into the structures and
subsequently prevented them from reaching their maximum swelling. Overall, based on
the obtained results, PLA coated patches containing CaCO3 were chosen for further in
vitro cell studies.

4.3.6. In vitro biocompatibility of the 3D printed patches
With the purpose of evaluating the biocompatibility of the PLA coated patches containing
CaCO3, they have been tested in vitro on two human pancreatic cancer cell lines (MIAPaCa-2 & PANC-1) for a period of 72 hr and the results were shown in Figure 4-6.
Accordingly, when empty patches, indicated as “– GEM”, were tested against both cell
lines and they showed to have > 80% viability (Figure 6a & c), which was further
confirmed with the live/dead imaging of the treated cells (Figure 6b & d). However, when
Gemcitabine loaded patches, indicated as “+ GEM”, were tested against both cell lines
they caused a significantly low viability in the cells (< 6%) (Figure 4-6a & c), which was
evident from low density of viable cells in the corresponding live/dead images taken from
treated cells (Figure 4-6b & d). Overall, these results showed that empty patches did not
cause any significant toxicity to the cells, but long term therapeutic effect of these drug
loaded patches is essential to evaluate their potential in preventing the cancer cell growth.
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Figure 4-6. In vitro biocompatibility of PLA coated 3D printed coaxial patches containing CaCO3
either without Gemcitabine (- GEM), or loaded with Gemcitabine (+ GEM). (a) MTS cell viability
assay of PANC-1 human pancreatic adenocarcinoma cells when treated with the patches for 72 hr.
(b) Corresponding live/dead cell staining of treated PANC-1 human pancreatic adenocarcinoma
cells. (c) MTS cell viability assay of MIA-PaCa-2 human pancreatic adenocarcinoma cells when
treated with the patches for 72 hr. (d) Corresponding live/dead cell staining of treated MIA-PaCa-2
human pancreatic adenocarcinoma cells. Values are the mean (±SEM) of quadruplicate. ****P =
0.0001.
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4.3.7. In vitro therapeutic effect of the 3D printed patches
Next, the long term therapeutic effect of Gemcitabine loaded patches (PLA coated patches
containing CaCO3) were examined in vitro by testing them against MIA-PaCa-2
pancreatic cancer cells and the results were shown in Figure 4-7.

Figure 4-7. Therapeutic effect of PLA coated 3D printed coaxial patches containing CaCO3, with
Gemcitabine (+ GEM) or without Gemcitabine (control), on inhibition of MIA-PaCa-2 pancreatic
cancer cell growth. Values are the mean (±SEM) of quadruplicate. D in the figure legend denotes
days of treatment. ****P = 0.0001.

Four different patches were tested for this purpose including Gemcitabine loaded 2-, 3-,
and 4-layers patches, as well as empty 4 layers patches which were used as a control.
Consequently, the results showed that empty 4 layers patches showed some level of
toxicity to the cells for the first 24 hr of testing (cell viability dropped to almost 40%),
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which then the cells recovered from in the following days to a point where totally viable
cells were remained at the end of the 14th day. Most significantly, Gemcitabine loaded 2
layers patches were only capable of inhibiting cancer cell growth for 8 days, whereas 3
layers and 4 layers patches succeeded to prevent the cancer cell growth up to 10 days
before the cells started to increase again. More specifically, after 14 days cells treated
with Gemcitabine loaded 2-layers structures fully regained their viability, whereas cells
treated with Gemcitabine loaded 3- and 4-layers patches had a viability of 72 ± 10%, and
61 ± 9% at day 14th of the experiment. The obtained data showed that by adjusting the
number of layers in the drug loaded patches one can control the duration of their
therapeutic effect. Overall, the results suggested that PLA coated-3D printed patches with
CaCO3 were suitable for long-term delivery of Gemcitabine for preventing MIA-PaCa-2
pancreatic cancer cell growth.

4.4.

Conclusion

In this study, for the first time, 3D printed coaxial hydrogel patches were fabricated for
prolonged release of Gemcitabine. Specifically, the core-section of these patches
contained alginate-methacrylate-dopamine loaded with Gemcitabine, while their shell
section was solely comprised of alginate-methacrylate. Consequently, with the aim of
enhancing the Gemcitabine release profile, the patches were first modified with CaCO3
cross linker in both core and shell. Subsequently, characterization of these patches
showed that addition of CaCO3 led to significant improvements in their mechanical
properties (in both static and dynamic conditions) and swelling behaviour when compared
to those of original hydrogel patches. However, patches containing CaCO3 failed to yield
a prolonged release of Gemcitabine in vitro, as they released the entire drug in the first
10 hr of the experiment. As a result, the effect of addition of a PLA coating to these
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patches on their subsequent drug release profile was studied. Remarkably, addition of a
PLA coating led to significant reduction in swelling of the hydrogel patches, which in
turn translated into a prolonged release of the drug in vitro over a span of 7 days. The
PLA coated patches showed good level of biocompatibility in vitro when tested against
two pancreatic cancer cell lines (MIA-PaCa-2 & PANC-1). Moreover, in a 14 days in
vitro experiment against MIA-PaCa-2 cells, the 3- and 4-layers PLA coated drug loaded
patches succeeded to prevent the growth of cancer cells over the entire testing period. Of
note, in vivo studies of these drug loaded patches are essential to further confirm their
efficacy for inhibiting the tumor growth. In conclusion, these PLA coated 3D printed
patches might be used as biocompatible implants for local delivery of Gemcitabine to
diseased site, to either shrink the tumor or to prevent the tumor recurrence after resection.
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4.5.

Supporting information

Figure 4-S1. Design of 3D printed coaxial structures including (a) strands, (b) patches.

171 | P a g e

Figure 4-S2. Light microscopy and SEM images of PLA coated 3D printed coaxial patches
containing CaCO3.
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Figure 4-S4. Mechanical properties of 3D printed coaxial strands following a static tensile test, (a-c)
Stress-strain curve, tensile strength, and modulus of strands in dry state (n = 3, mean ± SD). (d-f)
Stress-strain curve, tensile strength, and modulus of strands in wet state (n = 3, mean ± SD). (*P =
0.05, **P ≤ 0.01).
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Figure 4-S5. Static compression testing of 3D printed coaxial patches containing CaCO3.
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Figure 4-S6. (a) Swelling ratio of different 3D printed coaxial patches in simulated body fluid
(SBF). (b) Mass of PLA coating on the 3D printed coaxial patches containing CaCO3, showing no
significant difference between 2-, 3-, or 4-layers structures.

175 | P a g e

Chapter 5

5. CONCLUSION AND FUTURE WORK
5.1.

Conclusion

The main objective of this thesis was to develop coaxial hydrogel structures to be utilized
as implants for controlled local delivery of therapeutics to human tumors. To this end, it
was hypothesized that a coaxial structure comprised of (i) a core containing dopaminemodified alginate hydrogel along with chemotherapeutic drugs would confer affinitycontrolled drug release, while (ii) a shell containg methacrylated-alginate hydrogel would
provide a drug diffusion barrier. Consequently, in Chapter 2, a wet-spinning technique
was employed to fabricated the coaxial hydrogel fibers (with the above mentioned
composition), as it allows for cost-effective and high throughput production of fibers. The
results showed that the coaxial fibers possessed superior physical properties (mechanical,
swelling, and degradation) over single fibers that were made from pure unmodified
alginate. Remarkably, in vitro release studies showed that the coaxial fibers were capable
of releasing Doxorubicin over a period of 21 days, however they released Gemcitabine
over a span of 10 hr. Zeta-potential measurements were carried out to further scrutenize
the obtained drug release profiles, and the results showed that dopamine-modified
alginate (the core element of the coaxial fibers) had stronger interactions with
Doxorubicin when compared to Gemcitabine as indicated from obtained hydrodynamic
diameter and zeta potential values. Subsequently, drug-loaded coaxial fibers were tested
in vitro against two pancreatic cancer cell lines (MIA-PaCa-2 & PANC-1), and the results
revealed that Doxorubicin-containing fibers had higher anti-cancer efficacy (compared to
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empty or Gemcitabine-loaded fibers) probably due to slow release of this drug from the
fibers. Most significantly, in vivo evaluations in mice with subcutaneous pancreatic
cancer tumors (MIA-PaCa-2 & BxCP3-Luc cell lines) revealed that Doxorubicincontaining coaxial fibers were able to significantly prevent the tumor growth with
minimal toxicity when compared to intravenous injection of equivalent dosages of the
same drugs. The obtained results in Chapter 2 showed that the proposed coaxial hydrogel
fibers were capable of prolonged release of Doxorubicin, which in turn translated into
optimal anti-cancer effect from Doxorubicin-containing fibers when tested both in vitro
and in vivo.

Given the obtained results in Chapter 2, the proposed coaxial hydrogel fibers were
implemented for chemo-photothermal combinational cancer therapy. Particularly, the
core-section of these fibers (chemo-compartment) contained dopamine-modified alginate
along with Doxorubicin, while their shell section (phothothermal compartment) was
composed of UV-crosslinkable methacrylate-modified algine together with Cu2−xSe
Nanoparticles (NPs). It was hypothesized that specific biopolymeric composition of these
fibers along with their corresponding core-shell geometry would allow controlled release
of Doxorubicin (loaded in the core), while the Cu2−xSe nanoparticles (loaded in the shell)
would facilitate heat generation upon near infra-red (NIR) laser irradiation. Subsequently,
the results showed that the coaxial composite fibers allowed controlled released of
Doxorubicin in vitro over a span of 3 weeks, and they were also capable of generating
heat in a tunable manner (based on the length of the fiber) upon NIR irradiation, in both
in vitro and in vivo conditions. Most remarkably, the coaxial drug-loaded composite fibers
in the presence of NIR radiation showed superior anti-cancer effect (both in vitro and in
vivo) when tested against breast cancer cell lines, a phenomenon attributed to their
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synergistic chemo-photothermal effect. Overall, the obtained results in Chapter 3 showed
that the proposed coxial hydrogel fibers could also be used as a platform for multi-modal
cancer therapy, as indicated from their optimal anti-cancer effect both in vitro and in vivo.

Considering the obtained results in Chapter 2, the proposed composition of coaxial
hydrogel structures came up short in releasing Gemcitabine in a prolonged manner.
Consequently, with the purpose of developing a suitable platform for controlled release
of Gemcitabine, Chapter 4 focused on using a 3D printing method was used to fabricate
coaxial hydrogel patches, as this fabrication method offers considerable advantages
including reproducibility, and ability to design geometrically complex shapes.
Particularly, the core-section of these patches contained dopamine-modified alginate
methacrylate loaded with Gemcitabine, while their shell section was solely comprised of
alginate methacrylate. Subsequently, these patches were further modified with CaCO3
cross linker and a PLA coating to facilitate prolonged release of the drug. Accordingly,
the results showed that addition of CaCO3 to the formula enhanced the mechanical
properties of the patches and significantly reduced their swelling ratio as compared to that
for patches without CaCO3. Furthermore, addition of PLA coating to CaCO3-containing
patches has further reduced their swelling ratio, which then significantly slowed down the
release of Gemcitabine, to a point where 4 layered patches were capable of releasing
Gemcitabine over a period of 7 days in vitro. Most significantly, when Gemcitabine
loaded patches (PLA coated patches containing CaCO3) were tested in vitro against MIAPaCa-2 pancreatic cancer cells, it was shown that 3- and 4-layers patches were capable of
inhibiting cancer cell growth for a period of 14 days. In conclusion, the 3D printed coaxial
hydrogel patches were capable of prolonged release of Gemcitabine only after further
modifications with CaCO3 crosslinker and an extra PLA coating around the patches to
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inhibit Gemcitabine burst release.

5.2.

Recommendations for Future Work

In this thesis a variety of coaxial hydrogel structures have been fabricated for cancer drug
delivery, using either wet-spinning or 3D printing techniques. In Chapter 2 and Chapter
3, wet-spun coaxial hydrogel fibers were used as platforms for local chemotherapy and
chemo-photothermal therapy, respectively. In Chapter 4, 3D printed coaxial hydrogel
patches were used as a platforms for local chemotherapy. Overall, in this thesis local
delivery of Doxorubicin and Gemcitabine (chemotherapeutic drugs) was successfully
achieved and it was further accompanied by in vitro and in vivo evidences. However,
similar to any other body of work, there are still avenues yet to be explored in future
works which could not be undertaken in this thesis.

•

Wet-spun coaxial fibers could be made from alginate of high molecular weight, which
will substantially improve the drug release profiles. Also, instead of alginate, other
biopolymers such as chitosan could be used to fabricate the fibers. In fact, both
dopamine-modification and methacrylation is reported for chitosan hydrogels.

•

Application of two different biopolymeric hydrogels for core and the shell could be
beneficial. For instance, two oppositely charged hydrogels such as alginate and
chitosan could be used for such purpose which would subsequently lead to formation
of more mechanically robust fibers as a consequence of their ionic interactions.

•

Other crosslinking agents should be implemented in the wet-spinning coagulation
bath, considering that dopamine-modified polymer may establish further crosslinking
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upon exposure to oxidizing agents such as sodium periodate or ammonium persulfate.
These oxidizing agents can facilitate attachment of dopamine moieties on the polymer
back bone which could act as secondary cross-linking mechanism.
•

The biopolymeric hydrogel of the core can be modified with other functional groups
to allow further interactions with the drug, for instance thiols.

•

The intrinsic anti-cancer effect of coaxial fibers (as was observed in Chapter 3) should
be further tested against other cancer cell lines to have more conclusive evidences.

•

The 3D-printed patches in chapter 4 must be tested for biodegradation both in vitro
and in vivo.

•

The 3D-printed structures must be tested in vivo to prove their effect on inhibiting
cancer tumor growth.
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